Document:

Exhibit 4.2

      

    

    EXECUTION VERSION

    

    

    DEPOSIT AGREEMENT

    

    

    among

    

    

    HEARTLAND FINANCIAL USA, INC.,

    

    

    BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., as Depositary,

    

    

    and

    

    

    THE HOLDERS FROM TIME TO TIME OF

    

    

    THE DEPOSITARY RECEIPTS DESCRIBED HEREIN

    

    

    Dated as of June 26, 2020

    

    

    
      
        

    

    
    TABLE OF CONTENTS

    

    

    	
            ARTICLE I DEFINED TERMS

          	
            1

          
	
            Section 1.1

          	
            Definitions.

          	
            1

          
	 	 
	
            ARTICLE II FORM OF RECEIPTS, DEPOSIT OF SERIES E PREFERRED STOCK, EXECUTION AND DELIVERY, TRANSFER, SURRENDER AND REDEMPTION OF RECEIPTS

          	
            3

          
	
            Section 2.1

          	
            Form and Transfer of Receipts.

          	
            3

          
	
            Section 2.2

          	
            Deposit of Series E Preferred Stock; Execution and Delivery of Receipts in Respect Thereof.

          	
            4

          
	
            Section 2.3

          	
            Registration of Transfer of Receipts.

          	
            4

          
	
            Section 2.4

          	
            Split-ups and Combinations of Receipts; Surrender of Receipts and Withdrawal of Series E Preferred Stock.

          	
            4

          
	
            Section 2.5

          	
            Limitations on Execution and Delivery, Transfer, Surrender and Exchange of Receipts.

          	
            5

          
	
            Section 2.6

          	
            Lost Receipts, etc.

          	
            6

          
	
            Section 2.7

          	
            Cancellation and Destruction of Surrendered Receipts.

          	
            6

          
	
            Section 2.8

          	
            Redemption of Series E Preferred Stock.

          	
            6

          
	
            Section 2.9

          	
            Bank Accounts.

          	
            7

          
	
            Section 2.10

          	
            Receipts Issuable in Global Registered Form.

          	
            7

          
	 	 
	
            ARTICLE III CERTAIN OBLIGATIONS OF HOLDERS OF RECEIPTS AND THE CORPORATION

          	
            8

          
	
            Section 3.1

          	
            Filing Proofs, Certificates and Other Information.

          	
            8

          
	
            Section 3.2

          	
            Payment of Taxes or Other Governmental Charges.

          	
            8

          
	
            Section 3.3

          	
            Warranty as to Series E Preferred Stock.

          	
            9

          
	
            Section 3.4

          	
            Warranty as to Depositary Shares.

          	
            9

          
	 	 
	
            ARTICLE IV THE DEPOSITED SECURITIES; NOTICES

          	
            9

          
	
            Section 4.1

          	
            Cash Distributions.

          	
            9

          
	
            Section 4.2

          	
            Distributions Other than Cash, Rights, Preferences or Privileges.

          	
            9

          
	
            Section 4.3

          	
            Subscription Rights, Preferences or Privileges.

          	
            10

          
	
            Section 4.4

          	
            Notice of Dividends, etc.; Fixing Record Date for Holders of Receipts.

          	
            10

          
	
            Section 4.5

          	
            Voting Rights.

          	
            11

          
	
            Section 4.6

          	
            Changes Affecting Deposited Securities and Reclassifications, Recapitalizations, etc.

          	
            11

          
	
            Section 4.7

          	
            Delivery of Reports.

          	
            11

          
	
            Section 4.8

          	
            Lists of Receipt Holders.

          	
            11

          
	
            Section 4.9

          	
            Withholding.

          	
            12

          
	 	 
	
            ARTICLE V THE DEPOSITARY, THE DEPOSITARY’S AGENTS, THE REGISTRAR AND THE CORPORATION

          	
            12

          
	
            Section 5.1

          	
            Appointment of the Depositary.

          	
            12

          
	
            Section 5.2

          	
            Maintenance of Offices, Agencies and Transfer Books by the Depositary; Registrar.

          	
            12

          
	
            Section 5.3

          	
            Prevention of or Delay in Performance by the Depositary, the Depositary’s Agents, the Registrar or the Corporation.

          	
            13

          
	
            Section 5.4

          	
            Obligations of the Depositary, the Depositary’s Agents, the Registrar, the Transfer Agent and the Corporation.

          	
            13

          
	
            Section 5.5

          	
            Resignation and Removal of the Depositary; Appointment of Successor Depositary.

          	
            16

          
	
            Section 5.6

          	
            Corporate Notices and Reports.

          	
            16

          
	
            Section 5.7

          	
            Indemnification by the Corporation.

          	
            17

          
	
            Section 5.8

          	
            Fees, Charges and Expenses.

          	
            17

          
	 	 
	
            ARTICLE VI AMENDMENT AND TERMINATION

          	
            17

          
	
            Section 6.1

          	
            Amendment.

          	
            17

          
	
            Section 6.2

          	
            Termination.

          	
            18

          
	 	 
	
            ARTICLE VII MISCELLANEOUS

          	
            18

          
	
            Section 7.1

          	
            Counterparts.

          	
            18

          
	
            Section 7.2

          	
            Exclusive Benefit of Parties.

          	
            18

          
	
            Section 7.3

          	
            Invalidity of Provisions.

          	
            18

          
	
            Section 7.4

          	
            Notices.

          	
            19

          

    

    

    
      i

      
        

    

    	
            Section 7.5

          	
            Depositary’s Agents.

          	
            19

            

          
	
            Section 7.6

          	
            Appointment of Registrar, Dividend Disbursing Agent and Redemption Agent in Respect of the Series E Preferred Stock.

          	
            20

          
	
            Section 7.7

          	
            Holders of Receipts Are Parties.

          	
            20

          
	
            Section 7.8

          	
            Governing Law.

          	
            20

          
	
            Section 7.9

          	
            Inspection of Deposit Agreement.

          	
            20

          
	
            Section 7.10

          	
            Headings.

          	
            20

          
	
            Section 7.11

          	
            Force Majeure.

          	
            20

          
	
            Section 7.12

          	
            Further Assurances

          	
            20

          
	
            Section 7.13

          	
            Confidentiality.

          	
            21

          

    

    

    EXHIBITS

     

    

    	
            Exhibit A

          	
            Form of Depositary Receipt

          

    

    

    
      ii

      
        

    

    
    
      DEPOSIT AGREEMENT dated as June 26, 2020, among (i) Heartland Financial USA, Inc., a Delaware corporation, (ii) Broadridge Corporate Issuer Solutions, Inc., a Pennsylvania corporation, and (iii) the Holders from time to time of the Receipts
        described herein.

       

      

      WHEREAS, it is desired to provide, as hereinafter set forth in this Deposit Agreement, for the deposit of shares of Series E Preferred Stock of the Corporation from time to time with the Depositary for the purposes set forth in this Deposit
        Agreement and for the issuance hereunder of Receipts evidencing Depositary Shares in respect of the Series E Preferred Stock so deposited; and

       

      

      WHEREAS, the Receipts are to be substantially in the form of Exhibit A attached hereto, with appropriate insertions, modifications and omissions, as hereinafter provided in this Deposit Agreement;

       

      

      NOW, THEREFORE, in consideration of the premises, the parties hereto agree as follows:

       

      

      ARTICLE I

        DEFINED TERMS

       

      

      Section 1.1       Definitions.

       

      

      The following definitions shall for all purposes, unless otherwise indicated, apply to the respective terms used in this Deposit Agreement:

       

      

      “Affiliate” shall mean, with respect to any Person, any Person directly or indirectly controlling, controlled by, or under common control with, such other Person. For the purpose of this definition, “controlling,” “controlled by” or
        “under common control with,” mean the ownership, direct or indirect, of the power to direct or cause the direction of the operation or management and policies of a Person, whether through the ownership or control of voting interests, by contract or
        otherwise.

       

      

      “Broadridge” shall mean Broadridge Corporate Issuer Solutions, Inc., a Pennsylvania corporation.

       

      

      “Certificate of Designations” shall mean the Certificate of Designations filed by the Corporation with the Secretary of State of the State of Delaware creating the Series E Preferred Stock.

       

      

      “Corporation” shall mean Heartland Financial USA, Inc., a Delaware corporation, and its successors.

       

      

      “Deposit Agreement” shall mean this Deposit Agreement, as amended or supplemented from time to time in accordance with the terms hereof.

       

      

      “Depositary” shall mean Broadridge, and any successor Depositary hereunder.

       

      

      “Depositary Shares” shall mean the depositary shares, each representing 1/400th of one share of the Series E Preferred Stock, evidenced by a Receipt.

       

      

      “Depositary’s Agent” shall mean an agent appointed by the Depositary pursuant to Section 7.5.

       

      

      “Depositary’s Office” shall mean the office of the Depositary at which at any particular time its depositary receipt business shall be administered, which at the date of this Deposit Agreement is located at 51 Mercedes Way, Edgewood, NY
        11717.

       

      

      “DTC” shall mean The Depository Trust Company, together with its successors and assigns.

       

      

      “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

       

      

      “Exchange Event” shall mean with respect to any Global Registered Receipt:

       

      

      
        1

        
          

      

      (1) (A) the Global Receipt Depository which is the Holder of such Global Registered Receipt notifies the Corporation that it is no longer willing or able to properly discharge its responsibilities under any Letter of Representations or that it
        is no longer eligible or in good standing under the Exchange Act and (B) the Corporation has not appointed a qualified successor Global Receipt Depository within 90 calendar days after the Corporation received such notice, or

      

      

      (2) the Corporation in its sole discretion notifies the Depositary in writing that the Receipts or portion thereof issued or issuable in the form of one or more Global Registered Receipts shall no longer be represented by such Global Registered
        Receipt.

      

      

      “Global Receipt Depository” shall mean, with respect to any Receipt issued hereunder, DTC or such other entity designated as Global Receipt Depository by the Corporation in or pursuant to this Deposit Agreement, which entity must be, to
        the extent required by any applicable law or regulation, a clearing agency registered under the Exchange Act.

      

      

      “Global Registered Receipt” shall mean a global registered Receipt registered in the name of a nominee of DTC.

      

      

      “Letter of Representations” shall mean any applicable agreement among the Corporation, the Depositary and a Global Receipt Depository with respect to such Global Receipt Depository’s rights and obligations with respect to any Global
        Registered Receipt, as the same may be amended, supplemented, restated or otherwise modified from time to time and any successor agreement thereto.

      

      

      “Person” shall mean any natural person, partnership, joint venture, firm, corporation, limited liability company, limited liability partnership, unincorporated association, trust or other entity, and shall include any successor (by merger
        or otherwise) of the foregoing.

      

      

      “Receipt” shall mean one of the depositary receipts issued hereunder, substantially in the form set forth as Exhibit A hereto, whether in definitive or temporary form, and evidencing a number of Depositary Shares held of record by
        a Record Holder.

      

      

      “Record Holder” or “Holder” as applied to a Receipt shall mean the Person in whose name such Receipt is registered on the books of the Depositary maintained for such purpose.

      

      

      “Redemption Date” shall have the meaning set forth in Section 2.8.

      

      

      “Redemption Price” shall mean $10,000 per share, plus the per share amount of any declared and unpaid dividends, without regard to any undeclared dividends, on the Series E Preferred Stock prior to the date fixed for redemption.

      

      

      “Registrar” shall mean the Depositary or such other successor bank or trust company which shall be appointed by the Corporation to register ownership and transfers of Receipts and the deposited Series E Preferred Stock as herein provided.
        If a successor Registrar shall be so appointed, all references herein to “the books” of or maintained by the Depositary shall be deemed, as applicable, to refer as well to the register maintained by such Registrar for such purpose.

      

      

      “Securities Act” shall mean the Securities Act of 1933, as amended.

      

      

      “Series E Preferred Stock” shall mean the shares of the Corporation’s 7.00% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E, par value $1.00 per share, with a liquidation preference of $10,000 per share.

      

      

      “Transfer Agent” shall mean the Depositary or such other successor bank or trust company which shall be appointed by the Corporation to transfer the Receipts or the deposited shares of the Series E Preferred Stock, as the case may be, as
        herein provided.

      

      

      
        2

        
          

      

      ARTICLE II

      

      FORM OF RECEIPTS, DEPOSIT OF SERIES E PREFERRED STOCK, EXECUTION AND DELIVERY,

      TRANSFER, SURRENDER AND REDEMPTION OF RECEIPTS

      

      Section 2.1       Form and Transfer of Receipts.

      

      

      The definitive Receipts shall be substantially in the form set forth in Exhibit A attached to this Deposit Agreement, with appropriate insertions, modifications and omissions, as hereinafter provided (but which do not affect the rights,
        duties, obligations or immunities of the Depositary as set forth in this Deposit Agreement) and shall be engraved or otherwise prepared so as to comply with the applicable rules of The Nasdaq Stock Market LLC. Pending the preparation of definitive
        Receipts, the Depositary, upon the order of the Corporation delivered in compliance with Section 2.2, shall be authorized and instructed to, and shall execute and deliver temporary Receipts which may be printed, lithographed, typewritten,
        mimeographed or otherwise substantially of the tenor of the definitive Receipts in lieu of which they are issued and with such appropriate insertions, omissions, substitutions and other variations (but which do not affect the rights, duties,
        obligations or immunities of the Depositary as set forth in this Deposit Agreement), with the Corporation’s prior approval, as the Persons executing such Receipts may reasonably determine necessary, as evidenced by their execution of such Receipts.
        If temporary Receipts are issued, the Corporation and the Depositary will cause definitive Receipts to be prepared without unreasonable delay. After the preparation of definitive Receipts, the temporary Receipts shall be exchangeable for definitive
        Receipts upon surrender of the temporary Receipts at an office described in Section 2.3. Upon surrender for cancellation of any one or more temporary Receipts, the Depositary is hereby authorized and instructed to, and shall execute and
        deliver in exchange therefor definitive Receipts representing the same number of Depositary Shares as represented by the surrendered temporary Receipt or Receipts registered in the name (and only in the name) of the holder of the temporary receipt;
        provided that the Depositary has been provided with all necessary information that it may request in order to execute and deliver such definitive Receipt or Receipts. Such exchange shall be made at the Corporation’s expense and without any
        charge therefor. Until so exchanged, the temporary Receipts shall in all respects be entitled to the same benefits under this Deposit Agreement, and with respect to the Series E Preferred Stock, as definitive Receipts.

      

      

      Any Receipt to be executed by the Depositary pursuant to this Deposit Agreement shall be executed by the manual or facsimile signature of a duly authorized officer of the Depositary. No Receipt shall be entitled to any benefits under this
        Deposit Agreement or be valid or obligatory for any purpose unless it shall have been executed manually or by the facsimile signature of a duly authorized officer of the Depositary or, if a Registrar for the Receipts (other than the Depositary)
        shall have been appointed, by the manual or facsimile signature of a duly authorized officer of the Depositary and countersigned by the manual or facsimile signature by a duly authorized officer of such Registrar. The Depositary shall record on its
        books each Receipt so signed and delivered as hereinafter provided.

      

      

      Receipts shall be in denominations of any number of whole Depositary Shares. All Receipts shall be dated the date of their issuance.

      

      

      Receipts may be endorsed with or have incorporated in the text thereof such legends or recitals or changes not inconsistent with the provisions of this Deposit Agreement all as may be (i) reasonably required by the Depositary and approved by the
        Corporation, (ii) required to comply with any applicable law or any regulation thereunder or with the rules and regulations of any securities exchange upon which the Series E Preferred Stock, the Depositary Shares or the Receipts may be listed or
        to conform with any usage with respect thereto, or (iii) to indicate any special limitations or restrictions to which any particular Receipt is subject (but which do not affect the rights, duties, obligations or immunities of the Depositary as set
        forth in this Deposit Agreement).

      

      

      Title to Depositary Shares evidenced by a Receipt which is properly endorsed or accompanied by a properly executed instrument of transfer, shall be transferable by delivery of such Receipt with the same effect as if such Receipt were a
        negotiable instrument; provided, however, that until transfer of any particular Receipt shall be registered on the books of the Depositary as provided in Section 2.3, the Depositary may, notwithstanding any notice to the
        contrary, treat the Record Holder thereof at such time as the absolute owner thereof for the purpose of determining the Person entitled to distributions of dividends or other distributions or to any notice provided for in this Deposit Agreement and
        for all other purposes.

      

      

      
        3

        
          

      

      Section 2.2       Deposit of Series E Preferred Stock; Execution and Delivery of Receipts in Respect Thereof.

      

       

      

      Subject to the terms and conditions of this Deposit Agreement, the Corporation may from time to time deposit shares of Series E Preferred Stock under this Deposit Agreement by delivery to the Depositary of a certificate or certificates for such
        shares of Series E Preferred Stock to be deposited, properly endorsed in the name of the Depositary (or its nominee) or accompanied, if required by the Depositary, by a duly executed instrument of transfer or endorsement including a guarantee of
        the signature thereon by a participant in a Medallion Signature Guarantee Program at the guarantee level acceptable to the Transfer Agent (a “Signature Guarantee”) in  a form reasonably satisfactory to the Depositary, together with (i) all
        such certifications as may be reasonably required by the Depositary pursuant to this Deposit Agreement, (ii) an instruction letter from the Corporation authorizing the Depositary to register such shares of the Series E Preferred Stock in book-entry
        form, each in form satisfactory to the Depositary, and (iii) a written order of the Corporation directing the Depositary to execute and deliver to, or upon the written order of, the Person or Persons stated in such order a Receipt or Receipts
        evidencing in the aggregate the number of Depositary Shares representing such deposited shares of Series E Preferred Stock.

       

      

      The shares of Series E Preferred Stock that are deposited pursuant to this Deposit Agreement shall be held by the Depositary at the Depositary’s Office or at such other place or places as the Depositary shall determine. The Depositary shall not
        lend any shares of Series E Preferred Stock deposited hereunder.

       

      

      Upon receipt by the Depositary of a certificate or certificates for shares of Series E Preferred Stock to be deposited in accordance with the provisions of this Section 2.2, together with the other documents required as specified above,
        and upon recordation of the shares of Series E Preferred Stock on the books of the Corporation (or its duly appointed transfer agent) in the name of the Depositary (or its nominee), the Depositary, subject to the terms and conditions of this
        Deposit Agreement, shall execute and deliver to or upon the written order of the Person or Persons named in the order delivered to the Depositary referred to in the first paragraph of this Section 2.2, a Receipt or Receipts evidencing in
        the aggregate the number of Depositary Shares representing the shares of Series E Preferred Stock so deposited and registered in such name or names as may be requested by such Person or Persons. The Depositary shall execute and deliver such Receipt
        or Receipts at the Depositary’s Office or such other offices, if any, as the Depositary may designate. Delivery at other offices shall be at the risk and expense of the Person requesting such delivery.

       

      

      Section 2.3       Registration of Transfer of Receipts.

       

      

      The Corporation hereby appoints the Depositary as the Registrar and Transfer Agent for the Receipts and the Depositary hereby accepts such appointment, subject to the express terms and conditions of this Deposit Agreement (and no implied terms
        or conditions) and, as such, the Depositary shall register on its books from time to time transfers of Receipts upon any surrender thereof by the Holder in person or by duly authorized attorney, properly endorsed or accompanied by a properly
        executed instrument of transfer or endorsement, including a Signature Guarantee, together with evidence of the payment of any taxes or charges as may be required by law. Thereupon, the Depositary shall execute a new Receipt or Receipts evidencing
        the same aggregate number of Depositary Shares as those evidenced by the Receipt or Receipts surrendered and deliver such new Receipt or Receipts to or upon the order of the Person entitled thereto. With respect to the appointment of the Depositary
        as Registrar and Transfer Agent in respect of the Receipts, the Depositary, in its respective capacities under such appointments, shall be entitled to the same rights, indemnities, immunities and benefits as the Depositary hereunder as if
        explicitly named in each such provision. Any references to the Depositary herein shall, to the extent applicable, also mean the Depositary as the Transfer Agent and Registrar.

       

      

      Section 2.4       Split-ups and Combinations of Receipts; Surrender of Receipts and Withdrawal of Series E Preferred Stock.

       

      

      Upon surrender of a Receipt or Receipts at the Depositary’s Office or at such other offices as it may designate for the purpose of effecting a split-up or combination of such Receipt or Receipts, and the receipt by the Depositary of all other
        necessary information and documents, and subject to the terms and conditions of this Deposit Agreement, the Depositary shall execute a new Receipt or Receipts in the authorized denomination or denominations requested, evidencing the aggregate
        number of Depositary Shares evidenced by the Receipt or Receipts surrendered, and shall deliver such new Receipt or Receipts to or upon the order of the Holder of the Receipt or Receipts so surrendered.

       

      

      
        4

        
          

      

      Any Holder of a Receipt or Receipts may withdraw the number of whole shares of Series E Preferred Stock (and all money and other property, if any, represented thereby) by surrendering such Receipt or Receipts at the Depositary’s Office or at
        such other offices as the Depositary may designate for such withdrawals; provided, however that a Holder of a Receipt or Receipts may not withdraw such whole shares of Series E Preferred Stock (or money and other property, if any,
        represented thereby) which has previously been called for redemption. After such surrender and upon the receipt of written instructions from the Holder of such Receipt or Receipts, without unreasonable delay (provided that the Corporation
        has provided the Depositary with all necessary documentation and a sufficient amount of cash), the Depositary shall deliver to such Holder, or to the Person or Persons designated by such Holder as hereinafter provided, the number of whole shares of
        Series E Preferred Stock (and all money and other property, if any), represented by such Receipt or Receipts so surrendered for withdrawal, but Holders of such whole shares of Series E Preferred Stock will not thereafter be entitled to deposit such
        shares of Series E Preferred Stock hereunder or to receive a Receipt evidencing Depositary Shares therefor. If a Receipt delivered by the Holder to the Depositary in connection with such withdrawal shall evidence a number of Depositary Shares in
        excess of the number of Depositary Shares representing the number of whole shares of Series E Preferred Stock to be withdrawn, the Depositary shall at the same time, in addition to such number of whole shares of Series E Preferred Stock and such
        money and other property, if any, to be so withdrawn, deliver to such Holder, or subject to Section 2.3 upon the written order of such Holder, a new Receipt evidencing such excess number of Depositary Shares. Delivery of such shares of the
        Series E Preferred Stock and such money and other property being withdrawn may be made by the delivery of such certificates, documents of title and other instruments as the Depositary may deem appropriate, which, if required by the Depositary,
        shall be properly endorsed or accompanied by proper instruments of transfer.

       

      

      In no event will fractional shares of Series E Preferred Stock (or any cash payment in lieu thereof) be delivered by the Depositary. Delivery of the Series E Preferred Stock and money and other property, if any, being withdrawn may be made by
        the delivery of such certificates, documents of title and other instruments as the Depositary may deem appropriate.

       

      

      If the Series E Preferred Stock and the money and other property, if any, being withdrawn are to be delivered to a Person or Persons other than the Record Holder of the related Receipt or Receipts being surrendered for withdrawal of such Series
        E Preferred Stock, such Holder shall execute and deliver to the Depositary a written order so directing the Depositary, and the Depositary may require that the Receipt or Receipts surrendered by such Holder for withdrawal of such shares of Series E
        Preferred Stock be properly endorsed in blank or accompanied by a properly executed instrument of transfer in blank.

       

      

      Delivery of the Series E Preferred Stock and the money and other property, if any, represented by Receipts surrendered for withdrawal shall be made by the Depositary at the Depositary’s Office, except that, at the request, risk and expense of
        the Holder surrendering such Receipt or Receipts and for the account of the Holder thereof, such delivery may be made at such other place as may be designated by such Holder.

       

      

      Section 2.5       Limitations on Execution and Delivery, Transfer, Surrender and Exchange of Receipts.

       

      

      As a condition precedent to the execution and delivery, registration of transfer, split-up, combination, surrender or exchange of any Receipt, the Depositary, any of the Depositary’s Agents or the Corporation may require (i) payment to it of a
        sum sufficient for the payment (or, in the event that the Depositary or the Corporation shall have made such payment, the reimbursement to it) of any charges, taxes or expenses payable by the Holder of a Receipt pursuant to Section 5.8
        (including any such tax or charge with respect to any shares of Series E Preferred Stock being deposited or withdrawn or any charges or expense pursuant to Section 3.2 and Section 5.7), (ii) the production of evidence satisfactory
        to it as to the identity and genuineness of any signature (which evidence may include a Signature Guarantee) and any other reasonable evidence of authority that may be required by the Depositary, and (iii) compliance with such additional
        requirements, if any, as the Depositary or the Corporation may reasonably establish consistent with the provisions of this Deposit Agreement and/or applicable law.

       

      

      The deposit of shares of Series E Preferred Stock may be refused, the delivery of Receipts against such shares of Series E Preferred Stock may be suspended, the registration of transfer of Receipts may be refused and the registration of
        transfer, surrender or exchange of outstanding Receipts may be suspended (i) during any period when the register of stockholders of the Corporation is closed or (ii) if any such action is deemed necessary or advisable by the Depositary, any of the
        Depositary’s Agents or the Corporation at any time or from time to time because of any requirement of law or of any government or governmental body or commission or under any provision of this Deposit Agreement.

       

      

      
        5

        
          

      

      Section 2.6       Lost Receipts, etc.

        

      

      In case any Receipt shall be mutilated, destroyed, lost or stolen, the Depositary in its discretion may execute and deliver in exchange therefore a Receipt of like form and tenor in exchange and substitution for such mutilated Receipt, or in
        lieu of and in substitution for such destroyed, lost or stolen Receipt, upon (i) the filing by the Holder thereof with the Depositary of evidence satisfactory to the Depositary of such destruction or loss or theft of such Receipt, of the
        authenticity thereof and of his or her ownership thereof and (ii) the Holder thereof furnishing the Depositary with an affidavit and an indemnity or bond satisfactory to the Depositary. Such Holder shall also comply with such other reasonable
        regulations and pay such other reasonable charges as the Depositary may prescribe and as required by Section 8-405 of the Uniform Commercial Code in effect in the State of New York.

       

      

      Section 2.7       Cancellation and Destruction of Surrendered Receipts.

       

      

      All Receipts surrendered to the Depositary or any Depositary’s Agent shall be cancelled by the Depositary. Except as prohibited by applicable law or regulation, the Depositary is authorized and directed to destroy all Receipts so cancelled.

       

      

      Section 2.8       Redemption of Series E Preferred Stock.

       

      

      Whenever the Corporation shall be permitted and shall elect to redeem shares of Series E Preferred Stock in accordance with the terms of the Certificate of Designations, it shall (unless otherwise agreed to in writing with the Depositary) give
        or cause to be given to the Depositary, not less than 30 days and not more than 60 days prior to the Redemption Date (as defined below), notice of the date of such proposed redemption of Series E Preferred Stock and of the number of such shares
        held by the Depositary to be so redeemed and the applicable Redemption Price, which notice shall be accompanied by a certificate from the Corporation stating that such redemption of shares of Series E Preferred Stock is in accordance with the
        provisions of the Certificate of Designations. On the applicable Redemption Date, provided that the Corporation shall then have paid or caused to be paid in full to the Depositary the Redemption Price of the Series E Preferred Stock to be
        redeemed, the Depositary shall redeem the number of Depositary Shares representing such shares of Series E Preferred Stock. The Depositary shall, if requested in writing and provided with all necessary information and documents, mail notice of the
        Corporation’s redemption of shares of Series E Preferred Stock and the proposed simultaneous redemption of the number of Depositary Shares representing such shares of the Series E Preferred Stock to be redeemed by first-class mail, postage prepaid,
        at the respective last addresses as they appear on the records of the Depositary or transmit by such other method approved by the Depositary (in its reasonable discretion), in either case not less than 30 days and not more than 60 days prior to the
        date fixed for redemption of such shares of Series E Preferred Stock and Depositary Shares (the “Redemption Date”), to the Record Holders of the Receipts evidencing the Depositary Shares to be so redeemed at the addresses of such Holders as
        they appear on the records of the Depositary; but neither failure to mail or transmit any such notice of redemption of Depositary Shares to one or more such Holders nor any defect in any notice of redemption of Depositary Shares to one or more such
        Holders shall affect the sufficiency of the proceedings for redemption as to the other Holders. Each such notice shall be prepared by the Corporation and shall state: (i) the Redemption Date; (ii) the number of Depositary Shares to be redeemed and,
        if less than all the Depositary Shares held by any such Holder are to be redeemed, the number of such Depositary Shares held by such Holder to be so redeemed; (iii) the applicable Redemption Price; (iv) the place or places where Receipts evidencing
        such Depositary Shares are to be surrendered for payment of the redemption price; and (v) that dividends in respect of the Series E Preferred Stock represented by such Depositary Shares to be redeemed will cease to accrue on such Redemption Date.
        In case less than all the outstanding Depositary Shares are to be redeemed, the Depositary Shares to be so redeemed shall be selected either pro rata or by lot or in such other manner as the Corporation may determine to be fair and equitable and
        permitted by DTC and the rules of any national securities exchange on which the Series E Preferred Stock is listed (which determination the Corporation will promptly notify the Depositary in writing).

       

      

      
        6

        
          

      

      Notice having been mailed or transmitted by the Depositary as aforesaid, from and after the Redemption Date (unless the Corporation shall have failed to provide the funds necessary to redeem the Series E Preferred Stock evidenced by the
        Depositary Shares called for redemption) (i) all dividends on the shares of Series E Preferred Stock so called for Redemption shall cease to accrue from and after such date, (ii) the Depositary Shares being redeemed from such proceeds shall be
        deemed no longer to be outstanding, (iii) all rights of the Holders of Receipts evidencing such Depositary Shares (except the right to receive the applicable Redemption Price) shall, to the extent of such Depositary Shares, cease and terminate, and
        (iv) upon surrender in accordance with such redemption notice of the Receipts evidencing any such Depositary Shares called for redemption (properly endorsed or assigned for transfer, if the Depositary or applicable law shall so require), such
        Depositary Shares shall be redeemed by the Depositary at a redemption price per Depositary Share equal to 1/400th of the redemption price per share of Series E
        Preferred Stock so redeemed, plus 1/400th of the per share amount of any declared and unpaid dividends, without accumulation of any undeclared dividends, on the Series E Preferred Stock to, but excluding, the Redemption Date.

       

      

      If fewer than all of the Depositary Shares evidenced by a Receipt are called for redemption, the Depositary will deliver to the Holder of such Receipt upon its surrender to the Depositary, together with the applicable Redemption Price for all of
        the Depositary Shares redeemed, a new Receipt evidencing the Depositary Shares evidenced by such prior Receipt and not called for redemption.

       

      

      Section 2.9       Bank Accounts.

       

      

      All funds received by the Depositary under this Deposit Agreement that are to be distributed or applied by the Depositary in the performance of services hereunder (the “Funds”) shall be held by the Depositary as agent for the Corporation
        and deposited in one or more bank accounts to be maintained by the Depositary in its name as agent for the Corporation. Until paid pursuant to this Deposit Agreement, the Depositary, with the prior written consent of the Corporation, may hold or
        invest the Funds through such accounts in: (i) obligations of, or guaranteed by, the United States of America, (ii) commercial paper obligations rated A-1 or P-1 or better by S&P or Moody’s, respectively, (iii) money market funds that comply
        with Rule 2a-7 of the Investment Company Act of 1940, or (iv) demand deposit accounts, short term certificates of deposit, bank repurchase agreements or bankers’ acceptances, of commercial banks with Tier 1 capital exceeding $1 billion or with an
        average rating above investment grade by S&P (LT Local Issuer Credit Rating), Moody’s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Depositary shall have no
        responsibility or liability for any diminution of the Funds that may result from any deposit or investment made by the Depositary in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or
        other third party. The Depositary may from time to time receive interest, dividends or other earnings in connection with such deposits or investments. The Depositary shall not be obligated to pay such interest, dividends or earnings to the
        Corporation, any holder or any other party.

       

      

      Section 2.10     Receipts Issuable in Global Registered Form.

       

      

      If the Corporation shall determine in a writing delivered to the Depositary that the Receipts are to be issued in whole or in part in the form of one or more Global Registered Receipts, then the Depositary shall, if instructed and provided with
        all necessary information, in accordance with the other provisions of this Deposit Agreement, execute and deliver one or more Global Registered Receipts evidencing the Receipts of such series which (i) shall represent, and shall be denominated in
        an amount equal to the aggregate principal amount of, the Receipts to be represented by such Global Registered Receipt or Receipts and (ii) shall be registered in the name of the Global Receipt Depository therefor or its nominee.

       

      

      Notwithstanding any other provision of this Deposit Agreement to the contrary, unless otherwise provided in the Global Registered Receipt, a Global Registered Receipt may only be transferred in whole and only by the applicable Global Receipt
        Depository for such Global Registered Receipt to a nominee of such Global Receipt Depository, or by a nominee of such Global Receipt Depository to such Global Receipt Depository or another nominee of such Global Receipt Depository, or by such
        Global Receipt Depository or any such nominee to a successor Global Receipt Depository for such Global Registered Receipt selected or approved by the Corporation or to a nominee of such successor Global Receipt Depository. Except as provided below,
        owners solely of beneficial interests in a Global Registered Receipt shall not be entitled to receive physical delivery of the Receipts represented by such Global Registered Receipt. Neither any such beneficial owner nor any direct or indirect
        participant of a Global Receipt Depository shall have any rights under this Deposit Agreement with respect to any Global Registered Receipt held on their behalf by a Global Receipt Depository and such Global Receipt Depository may be treated by the
        Corporation, the Depositary and any director, officer, employee or agent of the Corporation or the Depositary as the Holder of such Global Registered Receipt for all purposes whatsoever. Unless and until definitive Receipts are delivered to the
        owners of the beneficial interests in a Global Registered Receipt, (1) the applicable Global Receipt Depository will make book-entry transfers among its participants and receive and transmit all payments and distributions in respect of the Global
        Registered Receipts to such participants, in each case, in accordance with its applicable procedures and arrangements, and (2) whenever any notice, payment or other communication to the holders of Global Registered Receipts is required under this
        Deposit Agreement, the Corporation and the Depositary shall give all such notices, payments and communications specified herein to be given to such holders to the applicable Global Receipt Depository.

       

      

      
        7

        
          

      

      If an Exchange Event has occurred with respect to any Global Registered Receipt, then, in any such event, the Depositary shall, upon receipt of a written order from the Corporation authorizing and directing the Depositary to execute and deliver
        individual definitive registered Receipts in exchange for such Global Registered Receipt, shall execute and deliver, individual definitive registered Receipts, in authorized denominations and of like tenor and terms in an aggregate principal amount
        equal to the principal amount of the Global Registered Receipt in exchange for such Global Registered Receipt. The Depositary shall have no duties, obligations or liability under this paragraph unless and until such order has been received by the
        Depositary.

       

      

      Definitive registered Receipts issued in exchange for a Global Registered Receipt pursuant to this Section 2.10 shall be registered in such names and in such authorized denominations as the Global Receipt Depository for such Global
        Registered Receipt, pursuant to instructions from its participants, shall instruct the Depositary in writing. The Depositary shall deliver such Receipts to the Persons in whose names such Receipts are so registered.

       

      

      Notwithstanding anything to the contrary in this Deposit Agreement, should the Corporation determine that the Receipts should be issued as a Global Registered Receipt, the parties hereto shall comply with the terms of any Letter of
        Representations.

       

      

      ARTICLE III

        CERTAIN OBLIGATIONS OF HOLDERS OF RECEIPTS AND THE CORPORATION

       

      

      Section 3.1       Filing Proofs, Certificates and Other Information.

       

      

      Any Holder of a Receipt may be required from time to time to file such proof of residence, or other matters or other information, to execute such certificates and to make such representations and warranties as the Depositary or the Corporation
        may reasonably deem necessary or proper. The Depositary or the Corporation may withhold the delivery, or delay the registration of transfer or redemption, of any Receipt or the withdrawal of shares of Series E Preferred Stock represented by the
        Depositary Shares and evidenced by a Receipt or withhold or delay the distribution of any dividend or other distribution or the sale of any rights or of the proceeds thereof until such proof or other information is filed or such certificates are
        executed or such representations and warranties are made.

       

      

      Section 3.2       Payment of Taxes or Other Governmental Charges.

       

      

      Holders of Receipts shall be obligated to make payments to the Depositary, of certain charges and expenses, as provided in Section 5.8. Registration of transfer of any Receipt or any withdrawal of shares of Series E Preferred Stock and
        all money or other property, if any, represented by the Depositary Shares evidenced by such Receipt may be refused until any such payment due is made, and any dividends, interest payments or other distributions may be withheld or any part of or all
        the Series E Preferred Stock or other property represented by the Depositary Shares evidenced by such Receipt and not theretofore sold may be sold for the account of the Holder thereof (after attempting by reasonable means to notify such Holder
        prior to such sale), and such dividends, interest payments or other distributions or the proceeds of any such sale may be applied to any payment of such charges or expenses, with the Holder of such Receipt remaining liable for any deficiency.

       

      

      
        8

        
          

      

      Section 3.3       Warranty as to Series E Preferred Stock.

       

      

      The Corporation hereby represents and warrants that the Series E Preferred Stock, when issued, will be duly authorized, validly issued, fully paid and nonassessable. Such representation and warranty shall survive the deposit of the Series E
        Preferred Stock and the issuance of the related Receipts.

       

      

      Section 3.4       Warranty as to Depositary Shares.

       

      

      The Corporation hereby represents and warrants that the Receipts, when issued, will represent legal and valid interests in the Series E Preferred Stock. Such representation and warranty shall survive the deposit of the Series E Preferred Stock
        and the related issuance of the Receipts.

       

      

      ARTICLE IV

        THE DEPOSITED SECURITIES; NOTICES

       

      

      Section 4.1       Cash Distributions.

       

      

      Whenever the Depositary shall receive any cash dividend or other cash distribution on the Series E Preferred Stock, the Depositary shall, subject to Section 3.1 and Section 3.2, and if received, upon the written instructions from
        the Corporation, distribute to Record Holders of Receipts on the record date fixed pursuant to Section 4.4 such amounts of such dividend or distribution as are, as nearly as practicable, in proportion to the respective numbers of Depositary
        Shares evidenced by the Receipts held by such Holders; provided, however, that in case the Corporation or the Depositary shall be required to withhold and shall withhold from any cash dividend or other cash distribution in respect
        of the Series E Preferred Stock an amount on account of taxes or other governmental charges, the amount made available for distribution or distributed in respect of Depositary Shares shall be reduced accordingly. In the event that the calculation
        of any such cash dividend or other cash distribution to be paid to any Record Holder on the aggregate number of Depositary Shares held by such Record Holder results in an amount that is a fraction of a cent and that fraction of a cent is equal to
        or greater than $0.005, the amount the Depositary shall distribute to such Record Holder shall be rounded up to the next highest whole cent; otherwise, such fractional amount shall be disregarded by the Depository and shall be added to and be
        treated as part of the next succeeding distribution. Each Holder of a Receipt shall provide the Depositary with its certified tax identification number on a properly completed Form W–8 or W–9, as may be applicable. Each Holder of a Receipt
        acknowledges that, in the event of non-compliance with the preceding sentence, the Internal Revenue Code of 1986, as amended, may require withholding by the Depositary of a portion of any of the distributions to be made hereunder.

       

      

      Section 4.2       Distributions Other than Cash, Rights, Preferences or Privileges.

       

      

      Whenever the Depositary shall receive any distribution other than cash, rights, preferences or privileges upon the Series E Preferred Stock, the Depositary shall, subject to Section 3.1 and Section 3.2, distribute to Record
        Holders of Receipts on the record date fixed pursuant to Section 4.4 such amounts of the securities or property received by it as are, as nearly as practicable, in proportion to the respective number of Depositary Shares evidenced by such
        Receipts held by such Holders, in any manner that the Depositary may deem equitable and practicable for accomplishing such distribution. If in the opinion of the Depositary such distribution cannot be made proportionately among such Record Holders,
        or if for any other reason (including any requirement that the Corporation or the Depositary withhold an amount on account of taxes or charges) the Depositary deems, after consultation with the Corporation, such distribution not to be feasible, the
        Depositary may, with the approval of the Corporation, adopt such method as it deems equitable and practicable for the purpose of effecting such distribution, including the sale (at public or private sale) of the securities or property thus
        received, or any part thereof, in a commercially reasonable manner. The net proceeds of any such sale shall, subject to Section 3.1 and Section 3.2, be distributed or made available for distribution, as the case may be, by the
        Depositary to Record Holders of Receipts as provided by Section 4.1 in the case of a distribution received in cash. The Corporation shall not make any distribution of securities or property (other than cash) to the Depositary and the
        Depositary shall not make any distribution of securities or property (other than cash) to the Holders of Receipts unless such securities or property have been registered under the Securities Act or the Corporation shall have provided an opinion of
        counsel, dated as of or prior to the date of such distribution, stating that such securities or property do not need to be registered under the Securities Act in connection with such distributions.

       

      

      
        9

        
          

      

      Section 4.3       Subscription Rights, Preferences or Privileges.

       

      

      If the Corporation shall at any time offer or cause to be offered to the Persons in whose names the Series E Preferred Stock is recorded on the books of the Corporation any rights, preferences or privileges to subscribe for or to purchase any
        securities or any rights, preferences or privileges of any other nature, such rights, preferences or privileges shall in each such instance be communicated to the Depositary and made available by the Depositary to the Record Holders of Receipts in
        such manner as the Corporation shall reasonably direct; provided, however, that (i) if at the time of issue or offer of any such rights, preferences or privileges the Corporation determines that it is not lawful or (after
        consultation with the Depositary) not feasible to make such rights, preferences or privileges available to Holders of Receipts by the issue of warrants or otherwise, or (ii) if and to the extent so instructed by Holders of Receipts who do not
        desire to exercise such rights, preferences or privileges, then the Corporation, in its discretion (with the acknowledgement of the Depositary, in any case where the Corporation has determined that it is not feasible to make such rights,
        preferences or privileges available), may, if applicable laws or the terms of such rights, preferences or privileges permit such transfer, sell such rights, preferences or privileges at public or private sale, at such place or places and upon such
        terms as it may deem proper. The net proceeds of any such sale shall be delivered to the Depositary and, if received, upon the written instructions of the Corporation and, subject to Section 3.1 and Section 3.2, be distributed by
        the Depositary to the Record Holders of Receipts entitled thereto as provided by Section 4.1 in the case of a distribution received in cash.

       

      

      The Corporation shall notify the Depositary whether registration under the Securities Act of the securities to which any rights, preferences or privileges relate is required in order for Holders of Receipts to be offered or sold the securities
        to which such rights, preferences or privileges relate, and the Corporation agrees with the Depositary that it will file promptly a registration statement pursuant to the Securities Act with respect to such rights, preferences or privileges and
        securities and use its best efforts and take all steps available to it to cause such registration statement to become effective sufficiently in advance of the expiration of such rights, preferences or privileges in compliance with the Securities
        Act to enable such Holders to exercise such rights, preferences or privileges. In no event shall the Depositary make available to the Holders of Receipts any right, preference or privilege to subscribe for or to purchase any securities unless and
        until such registration statement shall have become effective or the Corporation shall have provided to the Depositary an opinion of counsel stating that the offering and sale of such securities to the Holders are exempt from registration under the
        provisions of the Securities Act.

       

      

      The Corporation shall notify the Depositary whether any other action under the laws of any jurisdiction or any governmental or administrative authorization, consent or permit is required in order for such rights, preferences or privileges to be
        made available to Holders of Receipts, and the Corporation agrees with the Depositary that the Corporation will use its reasonable best efforts to take such action or obtain such authorization, consent or permit sufficiently in advance of the
        expiration of such rights, preferences or privileges to enable such Holders to exercise such rights, preferences or privileges.

       

      

      Section 4.4       Notice of Dividends, etc.; Fixing Record Date for Holders of Receipts.

       

      

      Whenever any cash dividend or other cash distribution shall become payable or any distribution other than cash shall be made, or if rights, preferences or privileges shall at any time be offered, with respect to the Series E Preferred Stock, or
        whenever the Depositary shall receive notice of any meeting at which holders of the Series E Preferred Stock are entitled to vote or of which holders of the Series E Preferred Stock are entitled to notice, or whenever the Depositary and the
        Corporation shall decide it is appropriate, the Depositary shall in each such instance fix a record date (which shall be the same date as the record date fixed by the Corporation with respect to or otherwise in accordance with the terms of the
        Series E Preferred Stock) for the determination of the Holders of Receipts who shall be entitled to receive such dividend, distribution, rights, preferences or privileges or the net proceeds of the sale thereof, or to give instructions for the
        exercise of voting rights at any such meeting, or who shall be entitled to notice of such meeting or for any other appropriate reasons.

       

      

      
        10

        
          

      

      Section 4.5       Voting Rights.

       

      

      Subject to the Certificate of Designations, upon receipt of notice from the Corporation of any meeting at which the holders of the Series E Preferred Stock are entitled to vote, the Depositary shall, if requested in writing and provided with all
        necessary information and documents, as soon as practicable thereafter, mail or transmit by such other method approved by the Depositary, in its reasonable discretion, to the Record Holders of Receipts, as determined on the record date set forth in
         Section 4.4, a notice prepared by the Corporation which shall contain (i) such information as is contained in such notice of meeting, (ii) a statement that the Holders of Receipts at the close of business on a specified record date fixed
        pursuant to Section 4.4 may, subject to any applicable restrictions, instruct the Depositary as to the exercise of the voting rights pertaining to the shares of Series E Preferred Stock represented by their respective Depositary Shares
        (including an express indication that instructions may be given to the Depositary to give a discretionary proxy to a Person designated by the Corporation), and (iii) a brief statement as to the manner in which such instructions may be given. Upon
        the written request of the Holders of Receipts on the relevant record date, the Depositary shall endeavor insofar as practicable to vote or cause to be voted, in accordance with the instructions set forth in such requests, the maximum number of
        whole shares of Series E Preferred Stock represented by the Depositary Shares evidenced by all Receipts as to which any particular voting instructions are received. The Corporation hereby agrees to take all reasonable action which may be deemed
        necessary by the Depositary in order to enable the Depositary to vote such Series E Preferred Stock or cause such Series E Preferred Stock to be voted. In the absence of specific instructions from the Holder of a Receipt, the Depositary will not
        vote (but, at its discretion, may appear at any meeting with respect to such Series E Preferred Stock unless directed to the contrary by the Holders of all the Receipts) to the extent of the Series E Preferred Stock represented by the Depositary
        Shares evidenced by such Receipt. The Depositary shall not be required to exercise any discretion in voting any shares of the Series E Preferred Stock represented by the Depositary Shares evidenced by such Receipt.

      

       

      

      Section 4.6       Changes Affecting Deposited Securities and Reclassifications, Recapitalizations, etc.

       

      

      Upon any change in par or stated value, split-up, combination or any other reclassification of the Series E Preferred Stock, subject to the Certificate of Designations, or upon any recapitalization, reorganization, merger or consolidation
        affecting the Corporation or to which it is a party, the Depositary shall, upon the written instructions of the Corporation setting forth any adjustment, (i) make such adjustments as are certified by the Corporation in the fraction of an interest
        represented by one Depositary Share in one share of Series E Preferred Stock and in the ratio of the redemption price per Depositary Share to the redemption price per share of Series E Preferred Stock, in each case as may be necessary fully to
        reflect the effects of such change in par or stated value, split-up, combination or other reclassification of the Series E Preferred Stock, or of such recapitalization, reorganization, merger or consolidation, as stated in such instructions and
        (ii) treat any securities or property (including cash) which shall be received by the Depositary in exchange for or upon conversion of or in respect of the Series E Preferred Stock as new deposited securities or property so received in exchange for
        or upon conversion or in respect of such Series E Preferred Stock. In any such case the Depositary shall, upon receipt of instructions of the Corporation, execute and deliver additional Receipts or may call for the surrender of all outstanding
        Receipts to be exchanged for new Receipts specifically describing such new deposited securities or property. Anything to the contrary herein notwithstanding, Holders of Receipts shall have the right from and after the effective date of any such
        change in par or stated value, split-up, combination or other reclassification of the Series E Preferred Stock or any such recapitalization, reorganization, merger or consolidation to surrender such Receipts to the Depositary with instructions to
        convert, exchange or surrender the Series E Preferred Stock represented thereby only into or for, as the case may be, the kind and amount of shares and other securities and property and cash into which the Series E Preferred Stock represented by
        such Receipts might have been converted or for which such Series E Preferred Stock might have been exchanged or surrendered immediately prior to the effective date of such transaction.

       

      

      Section 4.7       Delivery of Reports.

       

      

      The Depositary shall make available for inspection by Holders of Receipts at the Depositary’s Office and at such other places as it may from time to time deem advisable during normal business hours any reports and communications received from
        the Corporation, which are received by the Depositary and which the Corporation is required to furnish to the holders of the Series E Preferred Stock. In addition, the Depositary shall transmit, upon the request of the Corporation, certain notices
        and reports to the Holders of Receipts as provided in Section 5.6.

       

      

      Section 4.8       Lists of Receipt Holders.

       

      

      Reasonably promptly upon request from time to time by the Corporation, at the sole expense of the Corporation, the Registrar shall furnish to it a list, as of the most recent practicable date, of the names, addresses and holdings of Depositary
        Shares of all registered Holders of Receipts.

       

      

      
        11

        
          

      

      Section 4.9       Withholding.

       

      

      Notwithstanding any other provision of this Deposit Agreement, in the event that the Depositary determines that any distribution in property is subject to any tax or other charge that the Depositary is obligated by law to withhold, the
        Depositary may dispose of, by public or private sale, all or a portion of such property in such amounts and in such manner as the Depositary deems necessary and practicable to pay such taxes or charges, and the Depositary shall distribute the net
        proceeds of any such sale or the balance of any such property after deduction of such taxes or charges to the Holders of Receipts entitled thereto in proportion to the number of Depositary Shares held by them, respectively; provided, however,
        that in the event the Depositary determines that such distribution of property is subject to withholding tax only with respect to some but not all Holders of Receipts, the Depositary will use its best efforts (i) to sell only that portion of such
        property distributable to such holders that is required to generate sufficient proceeds to pay such withholding tax and (ii) to effect any such sale in such a manner so as to avoid affecting the rights of any other Holders of Receipts to receive
        such distribution in property.

       

      

      ARTICLE V

        THE DEPOSITARY, THE DEPOSITARY’S AGENTS, THE REGISTRAR AND THE CORPORATION

       

      

      Section 5.1       Appointment of the Depositary.

       

      

      The Corporation hereby appoints Broadridge to act as Depositary in accordance with the express terms and conditions hereof (and no implied terms or conditions), and Broadridge accepts this appointment. Depositary is engaged in an independent
        business and will perform its obligations under this Deposit Agreement as an agent of the Corporation.

       

      

      Section 5.2       Maintenance of Offices, Agencies and Transfer Books by the Depositary; Registrar.

       

      

      Upon execution of this Deposit Agreement, the Depositary shall maintain at the Depositary’s Office, facilities for the execution and delivery, registration and registration of transfer, surrender and exchange of Receipts, and at the offices of
        the Depositary’s Agents, if any, facilities for the delivery, registration of transfer, surrender and exchange of Receipts, all in accordance with the provisions of this Deposit Agreement.

       

      

      The Depositary shall keep books at the Depositary’s Office for the registration and registration of transfer of Receipts. Upon direction from the Corporation and with reasonable notice to the Depositary, the Registrar shall open its books for
        inspection by the Record Holders of Receipts; provided that any such Record Holder requesting to exercise such right shall certify to the Depositary that such inspection shall be for a proper purpose reasonably related to such Person’s
        interest as an owner of Depositary Shares evidenced by the Receipts.

       

      

      The Depositary or Registrar may close such books, at any time or from time to time, when deemed necessary or advisable by the Depositary, the Registrar, any Depositary’s Agent or the Corporation because of any requirement of law or of any
        government, governmental body or commission, stock exchange or any applicable self-regulatory body.

       

      

      If the Receipts or the Depositary Shares evidenced thereby or the Series E Preferred Stock represented by such Depositary Shares shall be listed on one or more national securities exchanges, the Depositary may, with the written approval of the
        Corporation, appoint a Registrar (acceptable to the Corporation) for registration of the Receipts or Depositary Shares in accordance with any requirements of such exchange. Such Registrar (which may be the Depositary if so permitted by the
        requirements of any such exchange) may be removed and a substitute registrar appointed by the Depositary upon the request or with the approval of the Corporation. If the Receipts, Depositary Shares or the Series E Preferred Stock are listed on one
        or more other securities exchanges, the Depositary will, at the written request and expense of the Corporation, arrange such facilities for the delivery, registration, registration of transfer, surrender and exchange of such Receipts, Depositary
        Shares or Series E Preferred Stock as may be required by law or applicable securities exchange regulation.

       

      

      
        12

        
          

      

      Section 5.3       Prevention of or Delay in Performance by the Depositary, the Depositary’s Agents, the Registrar or the Corporation.

       

      

      Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the Corporation, as the case may be, shall incur any liability to any Holder of a Receipt if by reason of any provision of any present or future law, or regulation
        thereunder, of the United States of America or of any other governmental authority or, in the case of the Depositary, the Depositary’s Agent or the Registrar, as the case may be, by reason of any provision, present or future, of the Corporation’s 
        Certificate of Incorporation, as amended (including the Certificate of Designations), or by reason of any act of God or war or other circumstance beyond the control of the relevant party, the Depositary, the Depositary’s Agent, the Registrar or the
        Corporation, as the case may be, shall be prevented or forbidden from, or subjected to any penalty on account of, doing or performing any act or thing which the terms of this Deposit Agreement provide shall be done or performed; nor shall the
        Depositary, any Depositary’s Agent, any Registrar or the Corporation, as the case may be, incur liability to any Holder of a Receipt (i) by reason of any nonperformance or delay, caused as aforesaid, in the performance of any act or thing which the
        terms of this Deposit Agreement shall provide shall or may be done or performed, or (ii) by reason of any exercise of, or failure to exercise, any discretion provided for in this Deposit Agreement except as otherwise explicitly set forth in this
        Deposit Agreement.

       

      

      Section 5.4       Obligations of the Depositary, the Depositary’s Agents, the Registrar, the Transfer Agent and the Corporation.

       

      

      Neither the Depositary nor any Depositary’s Agent nor any Registrar, any Transfer Agent nor the Corporation, as the case may be, assumes any obligation or shall be subject to any liability under this Deposit Agreement to Holders of Receipts or
        to any other Person (other than to the Corporation in accordance with the next sentence of this paragraph) other than for its gross negligence, willful misconduct, fraud or bad faith (each as finally determined by a non-appealable judgment of a
        court of competent jurisdiction). Notwithstanding anything in this Deposit Agreement to the contrary, excluding the Depositary’s gross negligence, willful misconduct, fraud or bad faith, the aggregate liability of the Depositary, any Depositary’s
        Agent or the Registrar or Transfer Agent, as the case may be, to the Corporation under this Deposit Agreement, whether in contract, tort, or otherwise, is limited to, and shall not exceed, the amounts paid hereunder by the Corporation to the
        Depositary as fees and charges, but not including reimbursable expenses; provided, however, that in the event that such liability arises as a result of misappropriation of funds by the Depositary, any of the Depositary’s Agents
        (except for such Depositary’s Agents which are not employees of the Depositary), any Registrar or any Transfer Agent, as the case may be, through fraud or willful misconduct on the part of such Person (as finally determined by a non-appealable
        judgment of a court of competent jurisdiction), such limit shall not apply and such liability hereunder shall be instead limited to the amount of such misappropriated funds or the liability resulting from such fraud or willful misconduct.

       

      

      NOTWITHSTANDING ANYTHING IN THIS DEPOSIT AGREEMENT TO THE CONTRARY, NEITHER THE DEPOSITARY, NOR THE DEPOSITARY’S AGENT NOR ANY REGISTRAR NOR THE TRANSFER AGENT NOR THE CORPORATION, AS THE CASE MAY BE, SHALL BE LIABLE
        IN ANY EVENT FOR SPECIAL, PUNITIVE, INCIDENTAL, INDIRECT OR CONSEQUENTIAL LOSSES OR DAMAGES OF ANY KIND WHATSOEVER (INCLUDING BUT NOT LIMITED TO LOST PROFITS), EVEN IF THEY HAVE BEEN ADVISED OF THE LIKELIHOOD OF SUCH LOSS OR DAMAGE AND REGARDLESS
        OF THE FORM OF ACTION.

       

      

      Neither the Depositary nor any Depositary’s Agent nor any Transfer Agent nor the Registrar nor the Corporation, as the case may be, shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect
        of the Series E Preferred Stock, the Depositary Shares or the Receipts which in its opinion may involve it in expense or liability unless indemnity reasonably satisfactory to it against all expense and liability be furnished as often as may be
        required.

       

      

      Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the Transfer Agent nor the Corporation, as the case may be, shall be liable for any action or any failure to act by it in reliance upon information from any Person
        presenting Series E Preferred Stock for deposit, any Holder of a Receipt or any other Person believed by it, in the absence of bad faith, to be competent to give such information. The Depositary, any Depositary’s Agent, any Registrar, any Transfer
        Agent and the Corporation, as the case may be, may each rely and shall each be protected in acting upon or omitting to act upon any written notice, request, direction or other document believed by it to be genuine and to have been signed or
        presented by the proper party or parties.

       

      

      
        13

        
          

      

      The Depositary, the Depositary’s Agent, any Registrar or Transfer Agent, as the case may be, shall not be responsible for any failure to carry out any instruction to vote any of the shares of the Series E Preferred Stock or for the manner or
        effect of any such vote made, as long as any such action or non-action is not taken with gross negligence, willful misconduct, fraud or bad faith (each as finally determined by a non-appealable judgment of a court of competent jurisdiction). The
        Depositary undertakes, and any Depositary’s Agent, Registrar and any Transfer Agent, as the case may be, shall be required to undertake, to perform such duties and only such duties as are specifically set forth in this Deposit Agreement, and no
        implied covenants or obligations shall be read into this Deposit Agreement against the Depositary or any Depositary’s Agent, Transfer Agent or Registrar.

       

      

      The Depositary, its parent, Affiliates, or subsidiaries, and Depositary’s Agents, and any Transfer Agent or Registrar, as the case may be, may own and deal in any class of securities of the Corporation and its Affiliates and in Receipts or
        Depositary Shares or become pecuniarily interested in any transaction in which the Corporation or its Affiliates may be interested or contract with or lend money to or otherwise act as fully or as freely as if it were not the Depositary, the
        parent, Affiliate or subsidiary of the Depositary or the Depositary’s Agent or Transfer Agent or Registrar hereunder. The Depositary may also act as transfer agent, trustee, or registrar of any of the securities of the Corporation and its
        Affiliates or act in any other capacity for the Corporation or its Affiliates.

        

      

      The Depositary shall not be under any liability for interest on any monies at any time received by it pursuant to any of the provisions of this Deposit Agreement or of the Receipts, the Depositary Shares or the Series E Preferred Stock nor shall
        it be obligated to segregate such monies from other monies held by it, except as required by law. The Depositary shall not be responsible for advancing funds on behalf of the Corporation and shall have no duty or obligation to make any payments if
        it has not timely received sufficient funds to make timely payments.

        

      

      In the event the Depositary, the Depositary’s Agents, any Transfer Agent or Registrar, as the case may be, reasonably believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other
        communication, paper or document received by the Depositary, the Depositary’s Agents, any Transfer Agent or Registrar hereunder, or in the administration of any of the provisions of this Deposit Agreement, the Depositary, the Depositary’s Agents,
        any Transfer Agent or Registrar shall deem it necessary or desirable that a matter be proved or established prior to taking, omitting or suffering to take any action hereunder, the Depositary, the Depositary’s Agents, any Transfer Agent or
        Registrar may, in its sole discretion upon providing written notice to the Corporation, refrain from taking any action and the Depositary, the Depositary’s Agents, any Transfer Agent or Registrar shall be fully protected and shall not be liable in
        any way to the Corporation, any Holders of Receipts or any other Person or entity for refraining from taking such action, unless the Depositary, the Depositary’s Agents, any Transfer Agent or Registrar receives written instructions or a certificate
        signed by a duly authorized officer of the Corporation which eliminates such ambiguity or uncertainty to the satisfaction of the Depositary or which proves or establishes the applicable matter to the satisfaction of the Depositary, the Depositary’s
        Agents, any Transfer Agent or Registrar. Such written instructions shall be full and complete authorization to the Depositary, the Depositary’s Agents, any Transfer Agent or Registrar, as the case may be, and the Depositary, the Depositary’s
        Agents, any Transfer Agent or Registrar shall incur no liability for or in respect of any action taken, suffered or omitted by it under the provisions of this Deposit Agreement in reliance upon such written instructions.

       

      

      In the event the Depositary, the Depositary’s Agent, the Registrar or the Transfer Agent, as the case may be, shall receive conflicting claims, requests or instructions from any Holders of Receipts, on the one hand, and the Corporation, on the
        other hand, the Depositary, the Depositary’s Agent, the Registrar or the Transfer Agent, as the case may be, shall be entitled to act on such claims, requests or instructions received from the Corporation, and shall incur no liability and shall be
        entitled to the full indemnification set forth in Section 5.7 hereof in connection with any action so taken.

       

      

      It is intended that the Depositary shall not be deemed to be an “issuer” of the securities under the federal securities laws or applicable state securities laws, it being expressly understood and agreed that the Depositary is acting only in a
        ministerial capacity as Depositary for the deposited Series E Preferred Stock. The Depositary will not be under any duty or responsibility to ensure compliance with any applicable federal or state securities laws in connection with the issuance,
        transfer or exchange of the Receipts, the shares of the Series E Preferred Stock or Depositary Shares; provided, however, that the Depositary agrees to comply with all information reporting and withholding requirements required to
        be complied by it under law or this Deposit Agreement as Depositary.

       

      

      
        14

        
          

      

      Neither the Depositary (or its officers, directors, employees or agents), any Depositary’s Agent nor any Registrar or any Transfer Agent makes any representation or has any responsibility as to the validity of any registration statement pursuant
        to which the Depositary Shares may be registered under the Securities Act, the deposited Series E Preferred Stock, the Depositary Shares, the Receipts (except its countersignature thereon) or any instruments referred to therein or herein, or as to
        the correctness of any statement made in any such registration statement or herein; provided, however, that the Depositary is responsible for its representations in this Deposit Agreement.

       

      

      The Depositary assumes no responsibility for the correctness of the description that appears in the Receipts. Notwithstanding any other provision herein or in the Receipts, the Depositary makes no warranties or representations as to the validity
        or genuineness of any shares of the Series E Preferred Stock at any time deposited with the Depositary hereunder or of the Depositary Shares, as to the validity or sufficiency of this Deposit Agreement, as to the value of the Depositary Shares or
        as to any right, title or interest of the record holders of Receipts in and to the Depositary Shares. The Depositary shall not be accountable for the use or application by the Corporation of the Depositary Shares or the Receipts or the proceeds
        thereof.

       

      

      The Depositary, Depositary’s Agent, any Registrar, and any Transfer Agent hereunder:

       

      

      (i) shall have no duties or obligations other than those specifically set forth herein (and no implied duties or obligations), or as may subsequently be agreed to in writing by the parties;

       

      

      (ii) shall have no obligation to make payment hereunder unless the Corporation shall have provided the necessary federal or other immediately available funds or securities or property, as the case may be, to pay in full amounts due and payable
        with respect thereto;

       

      

      (iii) shall not be obligated to take any legal or other action hereunder; if, however, the Depositary determines to take any legal or other action hereunder except as expressly set forth herein, and, where the taking of such action might in the
        Depositary’s judgment subject or expose it to any expense or liability, the Depositary shall not be required to act unless it shall have been furnished with an indemnity satisfactory to it;

       

      

      (iv) may rely on and shall be authorized and protected in acting or failing to act upon any certificate, instrument, opinion, notice, letter, telegram, telex, facsimile transmission or other document or security delivered to the Depositary and
        reasonably believed by the Depositary to be genuine and to have been signed by the proper party or parties, and shall have no responsibility for determining the accuracy thereof;

       

      

      (v)  may rely on and shall be authorized and protected in acting or failing to act upon the written, telephonic, electronic and oral instructions, with respect to any matter relating to the Depositary’s actions as Depositary covered by this
        Deposit Agreement (or supplementing or qualifying any such actions) of officers of the Corporation;

       

      

      (vi) shall not be called upon at any time to advise any Person with respect to the shares of the Series E Preferred Stock or Receipts;

       

      

      (vii) shall not be liable or responsible for any recital or statement contained in any documents relating hereto or the shares of the Series E Preferred Stock or Receipts; and

       

      

      (viii) shall not be liable in any respect on account of the identity, authority or rights of the parties (other than with respect to the Depositary) executing or delivering or purporting to execute or deliver this Deposit Agreement or any
        documents or papers deposited or called for under this Deposit Agreement.

       

      

      The obligations of the Corporation set forth in this Section 5.4 shall survive the replacement, removal or resignation of the Depositary, Registrar, Transfer Agent or Depositary’s Agent or termination of this Deposit Agreement.

       

      

      
        15

        
          

      

      Section 5.5       Resignation and Removal of the Depositary; Appointment of Successor Depositary.

       

      

      The Depositary may at any time resign as Depositary hereunder by delivering notice of its election to do so to the Corporation, such resignation to take effect upon the appointment of a successor Depositary and its acceptance of such appointment
        as hereinafter provided.

       

      

      The Depositary may at any time be removed by the Corporation by notice of such removal delivered to the Depositary, such removal to take effect upon the appointment of a successor Depositary hereunder and its acceptance of such appointment as
        hereinafter provided.

       

      

      In case at any time the Depositary acting hereunder shall resign or be removed, the Corporation shall, within 60 days after the delivery of the notice of resignation or removal, as the case may be, appoint a successor Depositary, which shall be
        a Person having its principal office in the United States of America and having a combined capital and surplus, along with its Affiliates, of at least $50,000,000. In the event of such removal or resignation, the Corporation will appoint a
        successor depositary and inform the Depositary of the name and address of any successor depositary so appointed, provided that no failure by the Corporation to appoint such a successor depositary shall affect the termination of this Deposit
        Agreement or the discharge of the Depositary as depositary hereunder. Upon payment of all outstanding fees and expenses hereunder, the Depositary shall promptly forward to the successor depositary or its designee any shares of stock held by it and
        any certificates, letters, notices and other document that the Depositary may receive after its appointment has so terminated.

       

      

      If no successor Depositary shall have been so appointed and have accepted appointment within 60 days after delivery of such notice, the resigning or removed Depositary may petition any court of competent jurisdiction for the appointment of a
        successor Depositary. Every successor Depositary shall execute and deliver to its predecessor and to the Corporation an instrument in writing accepting its appointment hereunder, and thereupon such successor Depositary, without any further act or
        deed, shall become fully vested with all the rights, powers, duties and obligations of its predecessor and for all purposes shall be the Depositary under this Deposit Agreement, and such predecessor, upon payment of all sums due it and on the
        written request of the Corporation, shall promptly execute and deliver an instrument transferring to such successor all rights and powers of such predecessor hereunder, shall duly assign, transfer and deliver all right, title and interest in the
        Series E Preferred Stock and any moneys or property held hereunder to such successor, and shall deliver to such successor a list of the Record Holders of all outstanding Receipts and such records, books and other information in its possession
        relating thereto.

       

      

      Any Person into or with which the Depositary may be merged, consolidated or converted, or any Person to which all or a substantial part of the assets of the Depositary may be transferred or which succeeds to the shareholder services business of
        the Depositary shall be the successor of the Depositary without the execution or filing of any document or any further act, and notice thereof shall not be required hereunder. Such successor Depositary may authenticate the Receipts in the name of
        the predecessor Depositary or its own name as successor Depositary.

       

      

      The removal or resignation of the Depositary shall automatically be deemed to be a removal of the Depositary as Registrar and Transfer Agent herein without any further act or deed.

       

      

      Section 5.6       Corporate Notices and Reports.

       

      

      The Corporation agrees that it will deliver to the Depositary, and the Depositary will, promptly after receipt of all necessary information and documents, transmit to the Record Holders of Receipts, in each case at the addresses recorded in the
        Depositary’s or Registrar’s books, copies of all notices and reports (including without limitation financial statements) required by law, by the rules of any national securities exchange upon which the Series E Preferred Stock, the Depositary
        Shares or the Receipts are listed or by the Corporation’s Certificate of Incorporation, as amended (including the Certificate of Designations), to be furnished to the Record Holders of Receipts. Such transmission will be at the Corporation’s
        expense and the Corporation will provide the Depositary with such number of copies of such documents as the Depositary may reasonably request. In addition, the Depositary will transmit to the Record Holders of Receipts at the Corporation’s expense
        such other documents as may be requested by the Corporation.

       

      

      
        16

        
          

      

      Section 5.7       Indemnification by the Corporation.

       

      

      The Corporation shall indemnify the Depositary, any Depositary’s Agent and any Registrar and any Transfer Agent (including each of their officers, directors, agents and employees) against, and hold each of them harmless from and against, any
        fee, loss, claim, damage, cost, penalty, fine, judgment, liability or expense (including the reasonable costs and expenses of its legal counsel) which may arise out of acts taken, suffered or omitted to be taken in connection with its acting as
        Depositary, Depositary’s Agent, Registrar or Transfer Agent, respectively, under this Deposit Agreement (including, without limitation, the enforcement of this Deposit Agreement) and the Receipts by the Depositary, any Registrar or any of their
        respective agents (including any Depositary’s Agent) and any transactions or documents contemplated hereby, except for any such fee, loss, claim, damage, cost, penalty, fine, judgment, liability or expense arising out of gross negligence, willful
        misconduct, fraud or bad faith (each as finally determined by a non-appealable judgment of a court of competent jurisdiction) on the respective parts of any such Person or Persons. The obligations of the Corporation and the rights of the Depositary
        set forth in this Section 5.7 shall survive any succession of any Depositary, Registrar, Transfer Agent or Depositary’s Agent or termination of this Deposit Agreement.

       

      

      Section 5.8       Fees, Charges and Expenses.

       

      

      The Corporation agrees promptly to pay the Depositary the compensation to be agreed upon with the Corporation for all services rendered by the Depositary, Depositary’s Agent, Registrar and Transfer Agent hereunder and to reimburse the Depositary
        for its reasonable out-of-pocket expenses (including reasonable counsel fees and expenses) incurred by the Depositary, Depositary’s Agent, Registrar and Transfer Agent without gross negligence, willful misconduct, fraud or bad faith on its part
        (each as finally determined by a non-appealable judgment of a court of competent jurisdiction) in connection with the services rendered by such Depositary, Depositary’s Agent, Registrar and Transfer Agent, as the case may be, hereunder. The
        Corporation shall pay all charges of the Depositary in connection with the initial deposit of the Series E Preferred Stock and the initial issuance of the Depositary Shares, all withdrawals of shares of Series E Preferred Stock by owners of
        Depositary Shares, and any redemption or exchange of the Series E Preferred Stock at the option of the Corporation. The Corporation shall pay all transfer and other taxes and charges arising solely from the existence of the depositary arrangements.
        All other transfer and other taxes and charges shall be at the expense of Holders of Depositary Shares evidenced by Receipts. If, at the request of a Holder of Receipts, the Depositary incurs charges or expenses for which the Corporation is not
        otherwise liable hereunder, such Holder will be liable for such charges and expenses; provided, however, that the Depositary may, at its sole option, require a Holder of a Receipt to prepay the Depositary any charge or expense the
        Depositary has been asked to incur at the request of such Holder of Receipts. The Depositary shall present its statement for charges and expenses to the Corporation at such intervals as the Corporation and the Depositary may agree.

       

      

      ARTICLE VI

        AMENDMENT AND TERMINATION

       

      

      Section 6.1       Amendment.

       

      

      The form of the Receipts and any provisions of this Deposit Agreement may at any time and from time to time be amended by agreement between the Corporation and the Depositary in any respect which they may deem necessary or desirable; provided,
        however, that no such amendment (other than any change in the fees of any Depositary, Depositary’s Agent, Transfer Agent, or Registrar, as the case may be) which shall materially and adversely alter the rights of the Holders of Receipts
        shall be effective against the Holders of Receipts unless such amendment shall have been approved by the Holders of Receipts representing in the aggregate at least 66 2/3% of the Depositary Shares then outstanding. Every Holder of an outstanding
        Receipt at the time any such amendment becomes effective shall be deemed, by continuing to hold such Receipt, to consent and agree to such amendment and to be bound by the Deposit Agreement as amended thereby. As a condition precedent to the
        Depositary’s execution of any amendment, the Corporation shall deliver to the Depositary a certificate from a duly authorized officer of the Corporation that states that the proposed amendment is in compliance with the terms of this Section 6.1.

       

      

      
        17

        
          

      

      Section 6.2       Termination.

       

      

      This Deposit Agreement may be terminated by the Corporation at any time upon not less than 60 days prior written notice to the Depositary, in which case, at least 30 days prior to the date fixed in such notice for such termination, the
        Depositary will mail notice of such termination to the record Holders of all Receipts then outstanding. If any Receipts shall remain outstanding after the date of termination of this Deposit Agreement, the Depositary thereafter shall discontinue
        the transfer of Receipts, shall suspend the distribution of dividends to the Holders of the Receipts thereof and shall not give any further notices (other than notice of such termination) or perform any further acts under this Deposit Agreement,
        except that the Depositary shall continue to collect dividends and other distributions pertaining to the Series E Preferred Stock, and shall continue to deliver the shares of Series E Preferred Stock and any money and other property, if any,
        represented by Receipts upon surrender thereof by the Holders of Receipts thereof. At any time after the expiration of two years from the date of termination, as may be instructed by the Corporation in writing, the Depositary shall (i) sell the
        shares of the Series E Preferred Stock then held hereunder at public or private sale, at such places and upon such terms as it deems proper and may thereafter hold the net proceeds of any such sale, together with any money and other property held
        by it hereunder, without liability for interest, for the benefit, pro rata in accordance with their holdings, of the Holders of Receipts that have not theretofore been surrendered, or (ii) return such shares of Series E Preferred Stock to the
        Corporation. After making such sale, the Depositary shall be discharged from all obligations under this Deposit Agreement except to account for such net proceeds and money and other property. The Depositary shall continue to receive its fees and
        expenses after termination of this Deposit Agreement so long as the Depositary continues to provide services in connection with this Deposit Agreement.

       

      

      Subject to the first paragraph of this Section 6.2, this Deposit Agreement may be terminated by the Corporation or the Depositary only if (i) all outstanding Depositary Shares issued hereunder have been redeemed pursuant to Section
          2.8, (ii) there shall have been made a final distribution in respect of the Series E Preferred Stock in connection with any liquidation, dissolution or winding up of the Corporation and such distribution shall have been distributed to the
        Holders of Receipts representing Depositary Shares pursuant to Section 4.1 or Section 4.2, as applicable, or (iii) upon the consent of Holders of Receipts representing in the aggregate not less than 66 2/3% of the Depositary Shares
        outstanding.

       

      

      Upon the termination of this Deposit Agreement, the Corporation shall be discharged from all obligations under this Deposit Agreement except for its obligations to the Depositary, any Depositary’s Agent and any Registrar under Section 5.7
        and Section 5.8; provided, however, that Section 5.3 and Section 5.7 shall survive the termination of this Deposit Agreement.

       

      

      ARTICLE VII

        MISCELLANEOUS

       

      

      Section 7.1       Counterparts.

       

      

      This Deposit Agreement may be executed in any number of counterparts, and by each of the parties hereto on separate counterparts, each of which counterparts, when so executed and delivered, shall be deemed an original, but all such counterparts
        taken together shall constitute one and the same instrument. A signature to this Deposit Agreement transmitted electronically shall have the same authority, effect, and enforceability as an original signature.

       

      

      Section 7.2       Exclusive Benefit of Parties.

       

      

      This Deposit Agreement is for the exclusive benefit of the parties hereto, and their respective successors hereunder, and shall not be deemed to give any legal or equitable right, remedy or claim to any other Person whatsoever.

       

      

      Section 7.3       Invalidity of Provisions.

       

      

      In case any one or more of the provisions contained in this Deposit Agreement or in the Receipts should be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions
        contained herein or therein shall in no way be affected, prejudiced or disturbed thereby.

       

      

      
        18

        
          

      

      Section 7.4       Notices.

       

      

      Any and all notices, requests, orders, approvals, instructions or directions to be given to the Corporation hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given if personally delivered or sent by mail
        or a nationally recognized overnight delivery service, or by facsimile transmission or electronic mail, confirmed either by (a) telephone with the recipient of such facsimile transmission or electronic mail or (b) letter, addressed to the
        Corporation at:

       

      

      Heartland Financial USA, Inc.

      1398 Central Avenue

      Dubuque, Iowa 52001

      Attention: General Counsel

      Email: jkim@htlf.com

      

      

      or at any other addresses of which the Corporation shall have notified the Depositary in writing.

       

      

      Any and all notices, requests, orders, approvals, instructions or directions to be given to the Depositary hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given if personally delivered or sent by mail or
        a nationally recognized overnight delivery service, or by facsimile transmission or electronic mail, confirmed either by (a) telephone with the recipient of such facsimile transmission or electronic mail or (b) letter, addressed to the Depositary
        at:

       

      

      Broadridge Corporate Issuer Solutions, Inc.

      51 Mercedes Way

      Edgewood, NY 11717

      Attention: General Counsel

      Email: legalnotices@broadridge.com

       

      

      With a copy to (which copy shall not constitute notice):

       

      

      Broadridge Financial Solutions, Inc.

      2 Gateway Center

      Newark, New Jersey 07102

      Attention: General Counsel

      Email: legalnotices@broadridge.com

       

      

      or at any other addresses of which the Depositary shall have notified the Corporation in writing.

       

      

      Any and all notices to be given to any Record Holder of a Receipt hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given if personally delivered, sent by a nationally recognized overnight delivery service
        or sent by mail or facsimile transmission, confirmed by letter, addressed to such Record Holder at the address of such Record Holder as it appears on the books of the Depositary, or if such Holder shall have timely filed with the Depositary a
        request that notices intended for such Holder be mailed to some other address, at the address designated in such request.

       

      

      Delivery of a notice sent by mail or by facsimile transmission shall be deemed to be effected at the time when a duly addressed letter containing the same (or a confirmation thereof in the case of a facsimile transmission) is deposited, postage
        prepaid, in a post office letter box. The Depositary or the Corporation may, however, act upon any facsimile transmission received by it from the other or from any Holder of a Receipt, notwithstanding that such facsimile transmission shall not
        subsequently be confirmed by letter or as aforesaid.

       

      

      Section 7.5       Depositary’s Agents.

       

      

      The Depositary may from time to time appoint Depositary’s Agents to act in any respect for the Depositary for the purposes of this Deposit Agreement and may at any time appoint additional Depositary’s Agents and vary or terminate the appointment
        of such Depositary’s Agents. The Depositary will promptly notify the Corporation of any such action.

       

      

      
        19

        
          

      

      Section 7.6       Appointment of Registrar, Dividend Disbursing Agent and Redemption Agent in Respect of the Series E Preferred Stock.

       

      

      The Corporation hereby appoints Broadridge as Registrar, Transfer Agent, dividend disbursing agent and redemption agent with respect to the shares of the Series E Preferred Stock deposited with the Depositary hereunder, and Broadridge hereby
        accept such respective appointments, subject to the express terms and conditions of this Deposit Agreement (and no implied terms or conditions) and, as such, will reflect changes in the number of shares of deposited Series E Preferred Stock held by
        it by notation, book-entry or other appropriate method. With respect to the appointment of Broadridge as Registrar, Transfer Agent, dividend disbursing agent and redemption agent in respect of the shares of the Series E Preferred Stock, Broadridge,
        in its respective capacities under such appointments, shall be entitled to the same rights, indemnities, immunities and benefits as the Depositary hereunder as if explicitly named in each such provision.

       

      

      Section 7.7       Holders of Receipts Are Parties.

       

      

      The Holders of Receipts from time to time shall be parties to this Deposit Agreement and shall be bound by all of the terms and conditions hereof and of the Receipts by acceptance of delivery thereof.

       

      

      Section 7.8       Governing Law.

       

      

      This Deposit Agreement and the Receipts and all rights hereunder and thereunder and provisions hereof and thereof shall be interpreted and construed in accordance with the laws of the State of New York. Any and all claims, controversies, and
        causes of action arising out of or relating to this Deposit Agreement and the Receipts, whether sounding in contract, tort, or statute, shall be governed by the laws of the State of New York, including its statutes of limitations, without giving
        effect to any conflict-of-laws rule that would result in the application of the laws of a different jurisdiction.

       

      

      Section 7.9       Inspection of Deposit Agreement.

       

      

      Copies of this Deposit Agreement shall be filed with the Depositary and the Depositary’s Agents and shall be made available for inspection during business hours upon reasonable notice to the Depositary by any Holder of a Receipt.

       

      

      Section 7.10     Headings.

       

      

      The headings of articles and sections in this Deposit Agreement and in the form of the Receipt set forth in Exhibit A hereto have been inserted for convenience only and are not to be regarded as a part of this Deposit Agreement or the
        Receipts or to have any bearing upon the meaning or interpretation of any provision contained herein or in the Receipts.

       

      

      Section 7.11     Force Majeure.

       

      

      Notwithstanding anything to the contrary contained herein, the Depositary will not be liable for any delays or failures in performance resulting from acts beyond its reasonable control including, without limitation, acts of God, terrorist acts,
        shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil
        unrest.

       

      

      Section 7.12     Further Assurances

       

      

      Each of the Corporation and the Depositary, respectively, agrees that it will perform, acknowledge, and deliver or cause to be performed, acknowledged or delivered, all such further and other acts, documents, instruments and assurances as the
        Depositary or the Corporation, respectively, may reasonably require in connection with the performance of this Deposit Agreement.

       

      

      
        20

        
          

      

      Section 7.13     Confidentiality.

       

      

      The Depositary and the Corporation agree that all books, records, information and data pertaining to the business of the other party, including inter alia, personal, non-public Holder information and the
        fees for services, which are exchanged or received pursuant to the negotiation or the carrying out of this Deposit Agreement, shall remain confidential, and shall not be voluntarily disclosed to any other Person, except as may be required by law or
        legal process. To avoid doubt, the parties hereto shall not be required to keep the terms of this Deposit Agreement confidential. To the extent Depositary processes personal information that would constitute EU Personal Data as defined under
        Regulation (EU) 2016/679 (General Data Protection Regulation), Depositary will comply with the provisions of the Broadridge GDPR Annex, found at https://www.broadridge.com/GDPR-Annex by using password ICS54903.

       

      

      [Remainder of page intentionally left blank; signature page follows.]

      
        21

        
          

        

      

      IN WITNESS WHEREOF, the Corporation and the Depositary have duly executed this Deposit Agreement as of the day and year first above set forth, and all Holders of Receipts shall become parties hereto by and upon acceptance by them of delivery of
        Receipts issued in accordance with the terms hereof.

       

      

      	 	
              HEARTLAND FINANCIAL USA, INC.

            
	 	 	 
	 	
              By

            	
              /s/ Bryan R. McKeag

            
	 	
              Name:

            	
              Bryan R. McKeag

            
	 	
              Title:

            	
              Chief Financial Officer

            
	 	

            	

            
	 	
              BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., as Depositary

            
	 	

            	

            
	 	
              By

            	
              /s/ Michael Golightly

            
	 	
              Name:

            	
              Michael Golightly

            
	 	
              Title:

            	
              Operations Supervisor

            
	 	 	 
	 	
              BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., as Transfer Agent and Registrar for the shares of the Corporation’s Series E Preferred Stock

            
	 	 	 
	 	
              By

            	
              /s/ Michael Golightly

            
	 	
              Name:

            	
              Michael Golightly

            
	 	
              Title:

            	
              Operations Supervisor

            

       

      

      
        
          [Signature Page to Deposit Agreement]

        

        
          

      

      
      EXHIBIT A

      

      

      
        [FORM OF FACE OF RECEIPT]

         

        

        [IF GLOBAL RECEIPT IS ISSUED: UNLESS THIS GLOBAL RECEIPT IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE DEPOSITARY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY RECEIPT ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED
          REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
          INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

         

        

        TRANSFERS OF THIS GLOBAL RECEIPT SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL RECEIPT
          SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN THE DEPOSIT AGREEMENT REFERRED TO BELOW.]

         

        

        DEPOSITARY SHARES,

        

        

        EACH REPRESENTING 1/400th OF ONE SHARE

        OF

        7.00% FIXED-RATE RESET NON-CUMULATIVE PERPETUAL PREFERRED STOCK, SERIES E

        OF

        HEARTLAND FINANCIAL USA, INC.

        

        

        SEE REVERSE FOR CERTAIN DEFINITIONS

        

        

        Dividend Payment Dates: When, as, and if declared by the board of directors or a duly authorized committee of the board of directors of Heartland Financial USA, Inc., a Delaware corporation (the “Corporation”), and to the extent the Corporation has the funds legally available, it will pay cash dividends on Series E Preferred Stock (as defined below) quarterly, in
          arrears, on January 15, April 15, July 15 and October 15 of each year, beginning on October 15, 2020.

         

        

        BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., as Depositary (the “Depositary”), hereby certifies that Cede & Co. is the registered owner
          of depositary shares (“Depositary Shares”), each Depositary Share representing 1/400th of
          one share of 7.00% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E, liquidation preference $10,000 per share, par value $1.00 per share (the “Series E Preferred
              Stock”), of the Corporation, on deposit with the Depositary, subject to the terms and entitled to the benefits of the Deposit Agreement, dated as of June 26, 2020 (the “Deposit

              Agreement”), among the Corporation, the Depositary and the Holders from time to time of the Receipts. By accepting this Depositary Receipt, the Holder hereof becomes a party to and agrees to be bound by all the terms and conditions
          of the Deposit Agreement. This Receipt shall not be valid or obligatory for any purpose or entitled to any benefits under the Deposit Agreement unless it shall have been executed by the Depositary by the manual or facsimile signature of a duly
          authorized officer and, if a Registrar for the Receipts (other than the Depositary) shall have been appointed, countersigned by such Registrar by the manual or facsimile signature of a duly authorized officer thereof.

         

        

        
          	
                  Dated:

                	 	
                  Dated:

                
	 	 	 	 	 
	
                  Broadridge Corporate Issuer Solutions, Inc., as

                  Depositary

                	 	
                  Broadridge Corporate Issuer Solutions, Inc.,

                  as Transfer Agent and Registrar

                
	 	 	 	 	

                
	
                  By:

                	

                	 	
                  By:

                	

                
	 	
                  Authorized Officer

                	 	 	
                  Authorized Officer

                

        

      

    

    

    

    
      A-1

      
        

    

    
      [FORM OF REVERSE OF RECEIPT]

       

      

      THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH REGISTERED HOLDER OF RECEIPTS WHO SO REQUESTS A COPY OF THE DEPOSIT AGREEMENT AND A COPY OF THE CERTIFICATE OF DESIGNATIONS OF 7.00% FIXED-RATE RESET NON-CUMULATIVE PERPETUAL PREFERRED STOCK,
        SERIES E, OF HEARTLAND FINANCIAL USA, INC. ANY SUCH REQUEST IS TO BE ADDRESSED TO THE DEPOSITARY NAMED ON THE FACE OF THIS RECEIPT.

       

      

      The Corporation will furnish without charge to each registered holder of receipts who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof of the
        Corporation, and the qualifications, limitations or restrictions of such preferences and/or rights. Such request may be made to the Corporation or to the Registrar.

       

      

      EXPLANATION OF ABBREVIATIONS

       

      

      The following abbreviations when used in the form of ownership on the face of this certificate shall be construed as though they were written out in full according to applicable laws or regulations. Abbreviations in addition to those appearing
        below may be used.

       

      

      
        	
                
                  Abbreviation

                

              	 	
                Abbreviation

              	 	
                Abbreviation

              	 	
                Equivalent Word

              
	
                JT TEN

              	 	
                As joint tenants, with right of survivorship and not as tenants in common

              	 	
                TEN BY ENT

              	 	
                As tenants by the entireties

              
	
                TEN IN COM

              	 	
                As tenants in common

              	 	
                UNIF GIFT MIN ACT

              	 	
                Uniform Gifts to Minors Act

              

      

    

    

  

  
    	
            
              Abbreviation

            

          	 	
            Equivalent Word

          	 	
            Abbreviation

          	 	
            Equivalent Word

          	 	
            Abbreviation

          	 	
            Equivalent Word

          
	
            ADM

          	 	
            Administrator(s),

              Administratrix

          	 	
            EX

          	 	
            Executor(s), Executrix

          	 	
            PL

          	 	
            Public Law

          
	
            AGMT

          	 	
            Agreement

          	 	
            FBO

          	 	
            For the benefit of

          	 	
            TR

          	 	
            (As) trustee(s), for, of

          
	
            ART

          	 	
            Article

          	 	
            FDN

          	 	
            Foundation

          	 	
            U

          	 	
            Under

          
	
            CH

          	 	
            Chapter

          	 	
            GDN

          	 	
            Guardian(s)

          	 	
            UA

          	 	
            Under Agreement

          
	
            CUST

          	 	
            Custodian for

          	 	
            GDNSHP

          	 	
            Guardianship

          	 	
            UW

          	 	
            Under will of, Of will of, Under last will & testament

          
	
            DEC

          	 	
            Declaration

          	 	
            MIN

          	 	
            Minor(s)

          	 	 	 	 
	
            EST

          	 	
            Estate, of Estate of

          	 	
            PAR

          	 	
            Paragraph

          	 	 	 	 

  

   

  

  
    A-2

    
      

  

  
    ASSIGNMENT

     

    

    For value received, _______________ hereby sell(s), assign(s) and transfer(s) unto

     

    

    INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE

     

    

    PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE

     

    

    Depositary Shares represented by the within Receipt, and do(es) hereby irrevocably constitute and appoint   Attorney to transfer the said Depositary Shares on the books of the within named Depositary with full power of substitution in the
      premises.

     

    

    	
            Dated:

          	  	

          	
            Signed:

          	  

    

    

    NOTICE: The signature to the assignment must correspond with the name as written upon the face of this Receipt in every particular, without alteration or enlargement or any change whatsoever.

     

    

    SIGNATURE GUARANTEED

     

    

    NOTICE: The signature(s) should be guaranteed by a participant in a Medallion Signature Guarantee Program at a guarantee level acceptable to the Corporation’s transfer agent. Guarantees by a notary public are not acceptable.

     

    

     

    

     A-3ex10-1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

Exhibit 10.1

 

 

 

 

 

LICENSE AND COLLABORATION AGREEMENT

 

 

 

BETWEEN

 

 

 

VISTAGEN THERAPEUTICS, INC.

 

 

AND

 

 EVERINSIGHT THERAPEUTICS INC.

 

 

 

-1-

 

 

 

LICENSE AND COLLABORATION AGREEMENT

 

This
LICENSE AND COLLABORATION AGREEMENT (this “Agreement”)
is made as of June 24, 2020 (“Effective Date”), by and
among VistaGen Therapeutics, Inc., a company organized under the
laws Nevada (“VistaGen”), and having an Affiliate of
the same name, and 
EverInsight Therapeutics Inc., a company
incorporated under the laws of the British Virgin Islands
(“EverInsight”) and having a registered address at
Vistra Corporate Services Centre, Wickhams Cay II, Road Town,
Tortola, VG1110, British Virgin Islands. VistaGen and EverInsight
are referred to individually as a “Party” and
collectively as the “Parties.”

 

 

RECITALS

 

WHEREAS,
VistaGen owns or controls certain intellectual property and
associated data and materials relating to a pharmaceutical compound
known as PH94B, which is an intranasal synthetic neuroactive
steroid product being developed for the treatment of social anxiety
disorder and other anxiety-related disorders;

 

WHEREAS,
VistaGen wishes to grant a license to EverInsight, and EverInsight
wishes to take a license, under such intellectual property and
associated items to develop, manufacture and commercialize PH94B in
certain territories in accordance with the terms and conditions set
forth below;

 

NOW,
THEREFORE, in consideration of the foregoing premises and the
mutual covenants herein contained, the receipt and sufficiency
which are hereby acknowledged, the Parties hereby agree as
follows.

 

ARTICLE 1 DEFINITIONS

 

Unless
the context otherwise requires, the terms in this Agreement with
initial letters capitalized, shall have the meanings set forth
below, or the meaning as designated in the indicated places
throughout this Agreement.

 

1.1            

“Active Pharmaceutical Ingredient”
or “API” means
any substance intended to be used in a pharmaceutical product that
when used becomes an active ingredient of that product intended to
exert a pharmacological, immunological or metabolic action with a
view to restoring, correcting or modifying physiological functions
in man or animal; but excluding formulation components such as
coatings, stabilizers, excipients or solvents, adjuvants or
controlled release technologies.

 

1.2            

“Affiliate” means, with respect to
a Party, any Person that, directly or indirectly through one or
more intermediaries, controls, is controlled by, or is under common
control with that Party, but for only so long as such control
exists. For the purpose of this definition, “control”
(including, with correlative meaning, the terms “controlled
by” and “under common control”) means (a) to
possess, directly or indirectly, the power to direct the management
or policies of an entity, whether through ownership of voting
securities, by contract relating to voting rights or

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-2-

 

 

corporate
governance, or otherwise; or (b) direct or indirect beneficial
ownership of more than fifty percent (50%), or such lesser
percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction, of the voting share
capital or other equity interest in such entity; provided however
that, notwithstanding the foregoing, EverInsight’s Affiliates
shall not include CBC Group or any of its portfolio
companies.

 

1.3            

“Applicable Laws” means the
applicable provisions of any and all national, supranational,
regional, federal, state and local laws, treaties, statutes, rules,
regulations, administrative codes, guidance, ordinances, judgments,
decrees, directives, injunctions, orders, permits (including MAAs)
of or from any court, arbitrator, Regulatory Authority or
Government Authority having jurisdiction over or related to the
subject item, including the FFDCA, DAL, and the Provisions for Drug
Registration of NMPA.

 

1.4            

“Auditor” has the meaning set forth
in Section 8.10 (Audit Dispute).

 

1.5            

“Business Day” means a day other
than a Saturday, Sunday or a bank or other public holiday in
Mainland China, Hong Kong or the State of California in the United
States.

 

1.6            

“Calendar Quarter” means each
respective period of three (3) consecutive months ending on 31
March, 30 June, 30 September, and 31 December, except that the
first Calendar Quarter of the Term shall commence on the Effective
Date and end on the day immediately prior to the first 1 January, 1
April, 1 July or 1 October to occur after the Effective Date, and
the last Calendar Quarter shall end on the last day of the
Term.

 

1.7            

“Calendar Year” means each
successive period of 12 calendar months commencing on 1 January and
ending on 31 December except that the first Calendar Year of the
Term shall commence on the Effective Date and end on 31 December of
the year in which the Effective Date occurs and the last Calendar
Year of the Term shall commence on 1 January of the year in which
the Term ends and end on the last day of the Term.

 

1.8            

“CFR” means the U.S. Code of
Federal Regulations.

 

1.9            

“Challenge” means to contest or
assist, directly or indirectly, in the contesting of the validity
or enforceability of any of the VistaGen Patents or EverInsight
Patents (as applicable), in whole or in part, in any court,
arbitration proceeding or other tribunal, including the United
States Patent and Trademark Office and the United States
International Trade Commission. For the avoidance of doubt, the
term “contest” includes: (a) filing an action under 28
U.S.C. §§ 2201-2202 seeking a declaration of invalidity
or unenforceability of any such Patents; (b) citation to the United
States Patent and Trademark Office pursuant to 35 U.S.C. § 301
of prior art patents or printed publications or statements of the
patent owner concerning the scope of any such Patents; (c) filing a
request under 35 U.S.C. § 302 for re-examination of any such
Patents; (d) filing, or joining in, a petition under 35 U.S.C.
§ 311 to institute inter parties review of any such Patents or
any portion thereof; (e) filing, or joining in, a petition under 35
U.S.C. § 321 to institute post-grant review of such Patents or
any portion thereof; (f) provoking or becoming a party to an
interference or a derivation proceeding with an application for any
such Patents pursuant to 35 U.S.C. § 135; (g) filing or
commencing any re-examination, opposition, cancellation, nullity
or

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-3-

 

 

similar
proceedings against any such Patents in any country; or (h) any
foreign equivalents of subsection (a) through (g) applicable in the
Territory; provided however, notwithstanding the foregoing,
“Challenge” shall not include (i) any action taken
by a Party in response to an action by the other Party to enforce
such Patents against such Party, or (ii) any argument made by
a Party in the course of patent prosecution that distinguish the
inventions claimed in such Party’s Patents from those
inventions claimed in the other Party’s Patent.

 

1.10            

“Claims” means all Third Party
demands, claims, actions, proceedings and liabilities (whether
criminal or civil, in contract, tort or otherwise) for losses,
damages, legal costs and other expenses of any nature.

 

1.11            

“CMC” means chemistry,
manufacturing, and controls.

 

1.12            

“Combination Product” means any
Licensed Product comprised of the following, either formulated
together (i.e., a fixed
dose combination), packaged together and sold for a single price,
or co-administered or jointly provided to patients, whether or not
packaged together: (a) the Compound, and (b) at least one other
API.

 

1.13            

“Commercialization” means the
conduct of all activities undertaken before and after Regulatory
Approval has been obtained relating to the promotion, marketing,
sale and distribution (including importing, exporting, transporting
for commercial sales, customs clearance, warehousing, invoicing,
handling and delivering the Licensed Product to customers) of the
Compound or the Licensed Product, including: (a) sales force
efforts, detailing, advertising, medical education, planning,
marketing, sales force training, and sales and distribution; and
(b) scientific and medical affairs. For clarity, Commercialization
does not include any Development activities, whether conducted
before or after Regulatory Approval. “Commercialize”
and “Commercializing” have correlative
meanings.

 

1.14            

“Commercialization Plan” has the
meaning set forth in Section 7.2 (Commercialization
Plan).

 

1.15            

“Commercially Reasonable Efforts”
means, with respect to each Party’s obligations under this
Agreement relating to the Development, Manufacturing, and
Commercialization activities with respect to the Compound or the
Licensed Product, the carrying out of such activities using efforts
and resources that are consistent with the exercise of customary
scientific and business practices as applied in the
biopharmaceutical industry for a company of a similar stage and
size as the entity and having similar resources, for development,
regulatory, manufacturing and commercialization activities
conducted with respect to products at a similar stage of
development or commercialization and having similar commercial
potential, taking into account relative safety and efficacy,
product profile, the regulatory environment, payers’ policies
and regulations, competitiveness of the marketplace and the market
potential of such products, the nature and extent of market
exclusivity, including patent coverage and regulatory data
protection, and price and reimbursement status. The Parties hereby
agree that the level of effort may be different for different
markets and may change over time, reflecting changes in the status
of the aforementioned attributes and potential of the Compound and
the Licensed Product. When used regarding obligations under this
Agreement other than the Development, Manufacturing,

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-4-

 

 

and
Commercialization activities with respect to the Compound or the
Licensed Product, the term “Commercially Reasonable
Efforts” shall mean the carrying out of such activities using
commercially reasonable efforts and financial, personnel and other
resources that are consistent with the exercise of customary
business practices as applied in the carrying out of such
activities generally by and on behalf of biopharmaceutical
companies of a similar stage and size and having similar
resources.

 

1.16            

“Compound” means PH94B, and all
salt, free acid/base, solvate, hydrate, prodrug, metabolite,
stereoisomer, and enantiomer thereof, and polymorphic forms
thereof.

 

1.17            

“Confidential Information” of a
Party means all Know-How, Inventions, unpublished patent
applications and other information and data of a financial,
commercial, business, operational or technical nature of such Party
that is disclosed or made available by or on behalf of such Party
or any of its Affiliates to the other Party or any of its
Affiliates, whether made available orally, in writing or in
electronic or other form. The terms of this Agreement are the
Confidential Information of both Parties.

 

1.18            

“Control” or “Controlled” means, with respect to
any Know-How, Patents, Regulatory Documentation or other
intellectual property rights, that a Party has the legal authority
or right (whether by ownership, license or otherwise, other than by
virtue of any license granted to such Party by the other Party
pursuant to this Agreement) to grant a license, sublicense, access
or other right (as applicable) under such Know-How, Patents,
Regulatory Documentation or other intellectual property rights to
the other Party on the terms and conditions set forth herein, in
each case without breaching the terms of any agreement with a Third
Party, infringing third party intellectual property, or
misappropriating third party trade secrets.

 

1.19            

“Controlling Party” has the meaning
set forth in Section 9.6 (Invalidity or Unenforceability Defenses
or Actions).

 

1.20            

“Corporate Names” has the meaning
set forth in Section 1.81 (Licensed Trademarks).

 

1.21            

“Cost of Goods” means, with respect
to any Compound or any Licensed Product, [*****].

 

1.22            

“CTA” means a Clinical Trial
Application that is required to initiate a clinical trial for
registering a drug product under the Drug Administration Law of the
People’s Republic of China and the Provisions for Drug
Registration of NMPA, and equivalents thereof under future Chinese
laws and regulations, and the laws and regulations of other
countries and jurisdictions in the Territory, in each as the same
may be amended from time to time.

 

1.23            

“DAL” means the Drug Administration
Law of the People’s Republic of China and the equivalent laws
of other countries and jurisdictions in the Territory, in each as
the same may be amended from time to time.

 

1.24            

“Develop” or “Development” means to develop
(including clinical, non-clinical and CMC development), analyze,
test and conduct preclinical, clinical and all other regulatory
trials for the Compound or Licensed Product, including all
post-approval clinical trials, as well as all

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-5-

 

 

related
regulatory activities and any and all activities pertaining to new
Indications, pharmacokinetic studies and all related activities
including work on new formulations, new methods of treatment and
CMC activities including new manufacturing methods.
“Developing” and “Development” have
correlative meanings.

 

1.25            

“Development Plan” has the meaning
set forth in Section 4.2 (Development Plan).

 

1.26            

“Disclosing Party” has the meaning
set forth in Section 10.1(a) (Duty of Confidence - subsection
(a)).

 

1.27            

“Dispute” has the meaning set forth
in Section 14.10(a) (Dispute Resolution - subsection
(a)).

 

1.28            

“Dollars” means U.S. dollars, and
“$” shall be interpreted accordingly.

 

1.29            

“EverInsight Development Data”
means any non-clinical or clinical data that are generated by
EverInsight through the Development, Manufacture and
Commercialization of the Compound and Licensed Product under this
Agreement, Controlled by EverInsight, and related to the Compound
or any Licensed Product or otherwise included in, or filed in
support of, the Regulatory Documentation filed by EverInsight, its
Affiliates or Sublicensees in the Territory.

 

1.30            

“EverInsight Know-How” means all
Know-How that is generated by EverInsight through the Development,
Manufacture and Commercialization of the Compound and Licensed
Product under this Agreement, Controlled by EverInsight as of the
Effective Date or during the Term, and necessary or reasonably
useful for the Development, Manufacture, Commercialization or other
Exploitation of any Compound or Licensed Product in the Licensed
Field, including EverInsight Sole Inventions, EverInsight’s
interest in any Joint Inventions, EverInsight Development Data and
EverInsight’s Regulatory Documentation.

 

1.31            

“EverInsight Indemnitees” has the
meaning set forth in Section 13.1 (Indemnification by
VistaGen).

 

1.32            

“EverInsight Patents” means
EverInsight Sole Invention Patents and EverInsight’s interest
in the Joint Patents, in each case necessary or reasonably useful
for the Development, Manufacture, Commercialization, or other
Exploitation of the Compound or any Licensed Product for use in the
Licensed Field.

 

1.33            

“EverInsight Sole Inventions” means
any Inventions that are conceived and reduced to practice solely by
employees of, or consultants or service providers to, EverInsight
and its Affiliates, at any time during the Term of this
Agreement.

 

1.34            

“EverInsight Sole Invention
Patents” means any Patents that contain one or more
claims that cover EverInsight Sole Inventions.

 

1.35            

“EverInsight Technology” means the
EverInsight Patents and the EverInsight Know-How.

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-6-

 

 

1.36            

“Excluded Claim” has the meaning
set forth in Section 14.10(g) (Dispute Resolution - subsection
(g)).

 

1.37            

“Executive Officers” has the
meaning set forth in Section 3.3(a) (JSC Decision Making -
subsection (a)).

 

1.38            

“Exploit” means to make, have made,
import, use, sell or offer for sale, including to research,
Develop, Commercialize, register, Manufacture, have Manufactured,
hold or keep (whether for disposal or otherwise), have used,
export, transport, distribute, promote, market or have sold or
otherwise dispose of.

 

1.39            

“Exploitation” means the act of
Exploiting the Compound, product or process.

 

1.40            

“FDA” means the United States Food
and Drug Administration or any successor entity
thereto.

 

1.41            

“FFDCA” means the United States
Federal Food, Drug, and Cosmetic Act, as amended from time to time,
together with any rules, regulations and requirements promulgated
thereunder (including all additions, supplements, extensions and
modifications thereto).

 

1.42            

“First Commercial Sale” means, with
respect to any Licensed Product in any jurisdiction in the
Territory, the first arm’s length sale of such Licensed
Product by EverInsight, its Affiliates or Sublicensees to a Third
Party for monetary value for use or consumption of such Licensed
Product by the end user in the general public after Regulatory
Approval for such Licensed Product in such jurisdiction has been
granted. Sales prior to receipt of Regulatory Approval for such
Licensed Product, such as so-called “treatment IND
sales,” “named patient sales,” and
“compassionate use sales,” shall not be construed as a
First Commercial Sale.

 

1.43            

“GAAP” means the then-current
Generally Accepted Accounting Principles or International Financial
Reporting Standards (IFRS), whichever is adopted as the standard
financial accounting guideline in the United States for public
companies, as consistently applied.

 

1.44            

“Generic Competition” means
[*****].

 

1.45            

“Generic Product” means, with
respect to a Licensed Product, any product that contains the same
Compound as such Licensed Product and that is sold under an
approved Marketing Authorization Application granted by a
Regulatory Authority to a Third Party that is not a Sublicensee of
EverInsight or its Affiliates and did not obtain such product in a
chain of distribution that includes any of EverInsight, its
Affiliates, or its Sublicensees.

 

1.46            

“Good Manufacturing Practices” or
“GMP” shall mean
all applicable Good Manufacturing Practices standards, including,
as applicable, those standards required by any Regulatory Authority
in the Territory.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-7-

 

 

1.47            

“Government Authority” means any
federal, state, national, state, provincial or local government, or
political subdivision thereof, or any multinational organization or
any authority, agency or commission entitled to exercise any
administrative, executive, judicial, legislative, police,
regulatory or taxing authority or power, any court or tribunal (or
any department, bureau or division thereof, or any governmental
arbitrator or arbitral body).

 

1.48            

“Hong Kong” means the Hong Kong
Special Administrative Region of the People’s Republic of
China.

 

1.49            

“IND” means a CTA or any other
investigational new drug application, clinical trial application,
clinical trial exemption or similar or equivalent application or
submission for approval to conduct human clinical investigation
filed with or submitted to the Regulatory Authority in the relevant
jurisdiction in conformance with the requirements of such
Regulatory Authority, including the FDA in the US and NMPA in
Mainland China.

 

1.50            

“Indemnification Claim Notice” has
the meaning set forth in Section 13.3(a) (Notice of
Claim).

 

1.51            

“Indemnified Party” has the meaning
set forth in Section 13.3(a) (Notice of Claim).

 

1.52            

“Indemnifying Party” has the
meaning set forth in Section 13.3(a) (Notice of
Claim).

 

1.53            

“Indication” means a separate and
distinct disease, disorder, illness or health condition for which a
separate MAA approval is required.

 

1.54            

“Indirect Costs” means, with
respect to a multi-regional clinical trial, all Third Party costs
and expenses incurred by VistaGen or EverInsight to conduct such
multi-regional clinical trial that are not directly allocable to a
Party’s territory (or to clinical sites within a
Party’s territory), including, without limitation, fees,
costs and expenses for data management, clinical evaluation
committees, data safety monitoring boards, physician consulting,
investigator meetings, travel, document translation and other
technology solutions and services that are not specific to a
territory or a clinical site within a territory.

 

1.55            

“Initiation” means, with respect to
a clinical trial, the first dosing (whether with investigational
drug, comparator drug or placebo) of the first subject in such
clinical trial.

 

1.56            

“Initial Supply Agreement” has the
meaning set forth in Section 6.3 (Supply Agreement).

 

1.57            

“In-License Agreement” has the
meaning set forth in Section 2.4(b) (In-License
Agreements).

 

1.58            

“Invention” means any technical,
scientific and other know-how and information, trade secrets,
knowledge, technology, means, methods, processes, practices,
formulae, instructions, skills, techniques, procedures,
experiences, ideas, technical assistance, designs, drawings,
assembly procedures, computer programs, apparatuses,
specifications, data, results and other

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-8-

 

 

material,
including: biological, chemical, pharmacological, toxicological,
pharmaceutical, physical and analytical, pre-clinical, clinical,
safety, manufacturing and quality control data and information,
including study designs and protocols, assays and biological
methodology process, composition of matter, article of manufacture,
discovery or finding, that is or may be patentable, that is made,
generated, conceived or otherwise invented as a result of a Party
exercising its rights or carrying out its obligations under this
Agreement, whether directly or via its Affiliates, agents or
independent contractors, including all rights, title and interest
in and to the intellectual property rights therein. For clarity,
“Invention” does not include VistaGen Development Data
or EverInsight Development Data.

 

1.59            

“Joint Steering Committee” or
“JSC” has the
meaning set forth in Section 3.1 (Joint Steering
Committee).

 

1.60            

“Joint Inventions” means any
Inventions that are conceived and reduced to practice by employees
of, or consultants or service providers to, VistaGen or its
Affiliates, on the one hand, jointly with employees of, or
consultants or service providers to, EverInsight or its Affiliates,
on the other hand, at any time during the Term of this Agreement
and that are made, generated, conceived or otherwise invented as a
result of VistaGen and EverInsight exercising their rights or
carrying out their obligations under this Agreement, whether
directly or via their Affiliates, agents or independent
contractors.

 

1.61            

“Joint Patents” means any Patents
that contain one or more claims that cover Joint
Inventions.

 

1.62            

“Know-How” means any information,
including discoveries, improvements, modifications, processes,
methods, techniques, protocols, formulas, data, inventions,
know-how, trade secrets and results, patentable or otherwise,
including physical, chemical, biological, toxicological,
pharmacological, safety, and preclinical and clinical data, dosage
regimens, control assays, and product specifications, but excluding
any Patents.

 

1.63            

“Licensed Field” means all uses in
humans.

 

1.64            

“Licensed Know-How” means all
Know-How that VistaGen (or its Affiliates) Controls as of the
Effective Date or during the Term that is necessary or reasonably
useful for the Development, Manufacture, Commercialization or other
Exploitation of the Compound or any Licensed Product for use in the
Licensed Field in the Territory, including all VistaGen Sole
Inventions, VistaGen’s interest in any VistaGen Joint
Inventions in the Territory, VistaGen Development Data and
VistaGen’s Regulatory Documentation (with respect to Compound
or a Licensed Product).

 

1.65            

“Licensed Manufacturing Know-How”
has the meaning set forth in Section 6.4 (Manufacturing Technology
Transfer).

 

1.66            

“Licensed Patents” means all
Patents Controlled by VistaGen or its Affiliates as of the
Effective Date or during the Term that are necessary or reasonably
useful for the Development, Manufacture, Commercialization, or
other Exploitation of the Compound or any Licensed

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-9-

 

 

Product
for use in the Licensed Field in the Territory, including any
VistaGen Sole Invention Patents and VistaGen’s interest in
the Joint Patents in the Territory. [*****].

 

1.67            

“Licensed Product” means any
pharmaceutical product that contains the Compound, alone or in
combination with one or more other molecules or agents in any
dosage form or formulation. For purposes of this Agreement, with
respect to a Licensed Product that has been approved for an initial
Indication, the approval of such License Product for one or more
additional Indications shall not constitute a new and separate
Licensed Product.

 

1.68            

“Licensed Technology” means the
Licensed Patents and the Licensed Know-How.

 

1.69            

“Licensed Trademarks” means any
corporate name or corporate logo (“Corporate Names”) of VistaGen or
its or Affiliates, and any Trademark that consists of or includes
any Corporate Name of VistaGen or its Affiliates, including the
Trademarks, names and logos identified on Exhibit B hereto and such
other Trademarks, names and logos as VistaGen may designate for
Licensed Product in a writing sent to EverInsight from time to time
during the Term.

 

1.70            

“MAA” or “Marketing Authorization
Application” means an application to the appropriate
Regulatory Authority for approval to market a Licensed Product (but
excluding Pricing Approval) in any particular jurisdiction, and all
amendments, renewals and supplements thereto, including, without
limitation, an NDA filed with the FDA in the U.S. and an NDA (or
any future equivalent thereto as defined in the DAL and the
Provisions for Drug Registration) filed with the NMPA in Mainland
China.

 

1.71            

“Mainland China” means the
People’s Republic of China, including Hainan Island, but
excluding Hong Kong, the Macau Special Administrative Region of the
People’s Republic of China and Taiwan.

 

1.72            

“Manufacture” and
“Manufacturing”
means all activities related to the production, manufacture,
processing, filling, finishing, packaging, labeling, in-process and
finished testing, shipping, storing, or release of a product or any
ingredient or intermediate thereof, including process development,
process qualification and validation, scale-up, pre-clinical,
clinical and commercial manufacture and analytic development,
product characterization, test method development and stability
testing, formulation, quality assurance and quality control of the
any compound, product or intermediate, and regulatory affairs with
respect to the foregoing.

 

1.73            

“Manufacturing Transfer Period” has
the meaning set forth in Section 6.2.

 

1.74            

“Milestone Event” has the meaning
set forth in Section 8.2(a) - (8.2 Development and Regulatory
Milestone Payments - clause (a)).

 

1.75            

“Milestone Payment” has the meaning
set forth in Section 8.2(a) - (8.2 Development and Regulatory
Milestone Payments - clause (a)).

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-10-

 

 

1.76            

“NDA” means a New Drug Application
(as more fully defined in 21 C.F.R. §314.5 et seq. or successor regulation) and
all amendments and supplements thereto filed with the FDA and any
other equivalent filing(s) in the Territory.

 

1.77            

“Net Sales” means, [*****].

 

1.78            

“NMPA” means the National Medical
Products Administration of the People’s Republic of China,
formerly known as the China Food and Drug Administration, or its
successor.

 

1.79            

“Patent” means all patents and
patent applications, including all provisionals, divisionals,
reissues, reexaminations, renewals, continuations,
continuations-in-part, substitute applications, priority
applications and inventors’ certificates, extensions and
supplemental certificates and any and all foreign equivalents of
the foregoing.

 

1.80            

“Payment” has the meaning set forth
in Section 8.8(b).

 

1.81            

“Person” means any individual,
partnership, limited liability company, firm, corporation,
association, trust, unincorporated organization or other
entity.

 

1.82            

“PH94B” means the compound known as
PH94B and having the chemical structure shown in Exhibit
C.

 

1.83            

“Phase 1 Clinical Trial” means a
human clinical trial that would satisfy the requirements for a
Phase 1 study as defined in 21 CFR § 312.21(a) (or any amended
or successor regulations) or any equivalent regulations in
jurisdictions in the Territory, regardless of where such clinical
trial is conducted.

 

1.84            

“Phase 3 Clinical Trial” means a
human clinical trial that would satisfy the requirements for a
Phase 3 study as defined in 21 CFR § 312.21(c) (or any amended
or successor regulations) or any equivalent regulations in
jurisdictions in the Territory, regardless of where such clinical
trial is conducted.

 

1.85            

“Pricing Approval” means such
governmental approval, agreement, determination or decision
establishing prices for a Licensed Product that can be charged
and/or reimbursed in a regulatory jurisdiction where the applicable
Government Authority approves or determines the price and/or
reimbursement of pharmaceutical products and where such approval or
determination is necessary for the commercial sale of such Licensed
Product in such jurisdiction.

 

1.86            

“Product Infringement” has the
meaning set forth in Section 9.4(a) (Notice).

 

1.87            

“Product Trademarks” means the
Trademark(s) used or to be used by EverInsight or its Affiliates or
its or their Sublicensees for the Commercialization of Licensed
Product in the Licensed Field in the Territory and any
registrations thereof or any pending applications relating thereto
in the Territory (excluding, in any event, any Corporate Names of
EverInsight, its Affiliates or its or their Sublicensees and any
Licensed Trademarks that consist of or include any Corporate Name
of VistaGen or its Affiliates or (sub)licensees).

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-11-

 

 

1.88            

“Receiving Party” has the meaning
set forth in Section 10.1(a) (Duty of Confidence - subsection
(a)).

 

1.89            

“Regulatory Approval” means, with
respect to a jurisdiction in the Territory, any and all approvals
(including approvals of Marketing Authorization Applications),
licenses, registrations or authorizations of any Regulatory
Authority necessary to commercially distribute, sell or market a
Licensed Product in such jurisdiction, including, where applicable:
(a) pricing or reimbursement approval in such jurisdiction; (b)
pre- and post-approval marketing authorizations (including any
prerequisite Manufacturing approval or authorization related
thereto); and (c) labelling approval.

 

1.90            

“Regulatory Authority” means any
applicable Government Authority responsible for granting Regulatory
Approvals for any Licensed Product, including the FDA, the NMPA,
and any corresponding national or regional regulatory
authorities.

 

1.91            

“Regulatory Documentation” means:
all (a) applications (including all Regulatory Filings, INDs, CTAs
and Marketing Authorization Applications), registrations, licenses,
authorizations and approvals (including Regulatory Approvals); (b)
correspondence and reports submitted to or received from Regulatory
Authorities (including minutes and official contact reports
relating to any communications with any Regulatory Authority) and
all supporting documents with respect thereto, including all
adverse event files and complaint files; and (c) clinical and other
data contained or relied upon in any of the foregoing; in each case
(a), (b) and (c)) relating to the Compound or a Licensed
Product.

 

1.92            

“Regulatory Exclusivity” means any
exclusive marketing rights or data exclusivity rights conferred by
any Regulatory Authority with respect to a pharmaceutical product
other than Patents, and including, without limitation, orphan drug
exclusivity, new chemical entity exclusivity, data exclusivity or
pediatric exclusivity.

 

1.93            

“Regulatory Filings” means, with
respect to the Compound or Licensed Product, any submission to a
Regulatory Authority of any appropriate regulatory application
specific to the Compound or Licensed Product, and shall include,
without limitation, any submission to a regulatory advisory board
and any supplement or amendment thereto. For the avoidance of
doubt, Regulatory Filings shall include any IND, CTA, NDA, MAA,
Regulatory Approval or the corresponding application in any other
country or jurisdiction.

 

1.94            

“Representative” has the meaning
set forth in Section 10.1(c) (Duty of Confidence - Subsection
(c)).

 

1.95            

“Respective Territory” means, in
the case of EverInsight, the Territory, and in the case of
VistaGen, all countries of the world outside the
Territory.

 

1.96                       

“Retained Rights” means, with
respect to the Compound and Licensed Product, the rights of
VistaGen, its Affiliates and its and their licensors,
(sub)licensees and contractors to:

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-12-

 

 

(a)           perform
VistaGen’s obligations under this Agreement;

 

(b)           Manufacture
and have Manufactured (including CMC and manufacturing process
development work) the Compound or Licensed Product within the
Territory solely for Exploitation outside the
Territory;

 

(c)           Develop
and have Developed the Compound and Licensed Product in the
Territory but only as part of a global Phase 3 Clinical Trial that
EverInsight elects to participate in pursuant to Section 4.4(b);
and

 

(d)           Develop,
Manufacture, Commercialize and otherwise Exploit the Compound and
Licensed Product for any and all purposes outside the
Territory.

 

1.97            

“Royalty Term” has the meaning set
forth in Section 8.4(b) (Royalty Term).

 

1.98            

“SEC” has the meaning set forth in
Section 10.5 (Publicity/Use of Names - subsection
(a)).

 

1.99            

“Sublicense” means a license or
sublicense granted by EverInsight (or a Sublicensee) to Develop,
make, use, import, promote, offer for sale or sell the Compound or
any Licensed Product, including any license given to any of the
rights granted to EverInsight under Section 2.1(Licenses to
EverInsight).

 

1.100                       

“Subcontractor” has the meaning set
forth in Section 2.8 (Subcontracting).

 

1.101                       

“Sublicensee” means a Third Party
to whom EverInsight or its Affiliate has granted a Sublicense in
accordance with the terms of this Agreement.

 

1.102                       

“Tax” or “Taxes” means any (a) all federal,
provincial, territorial, state, municipal, local, foreign or other
taxes, imposts, rates, levies, assessments and other charges in the
nature of a tax (and all interest and penalties thereon and
additions thereto imposed by any Government Authority), including
without limitation all income, excise, franchise, gains, capital,
real property, goods and services, transfer, value added, gross
receipts, windfall profits, severance, ad valorem, personal
property, production, sales, use, license, stamp, documentary
stamp, mortgage recording, employment, payroll, social security,
unemployment, disability, escheat, estimated or withholding taxes,
and all customs and import duties, together with all interest,
penalties and additions thereto imposed with respect to such
amounts, in each case whether disputed or not; (b) any liability
for the payment of any amounts of the type described in subsection
(a) as a result of being or having been a member of an affiliated,
consolidated, combined or unitary group; and (c) any liability for
the payment of any amounts as a result of being party to any tax
sharing agreement or arrangement or as a result of any express or
implied obligation to indemnify any other person with respect to
the payment of any amounts of the type described in subsection (a)
or (b).

 

1.103                       

“Term” has the meaning set forth in
Section 11.1 (Term).

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-13-

 

 

1.104                       

“Territory” means Greater China
(Mainland China, Taiwan, Hong Kong and Macau), South Korea,
Southeast Asia (Singapore, Malaysia, Thailand, Indonesia,
Philippines, and Vietnam).

 

1.105                       

“Third Party” means any Person
other than a Party or an Affiliate of a Party.

 

1.106                       

“Third Party Infringement Claim”
has the meaning set forth in Section 9.5 (Infringement claims by
Third Parties).

 

1.107                       

“Trademark” means any word, name,
symbol, color, shape, designation or any combination thereof,
including any trademark, service mark, trade name, brand name,
sub-brand name, trade dress, product configuration rights, program
name, delivery form name, certification mark, collective mark,
logo, tagline, slogan, design or business symbol, that functions as
an identifier of source, origin or quality, whether or not
registered, and all statutory and common law rights therein and all
registrations and applications therefor, together with all goodwill
associated with, or symbolized by, any of the
foregoing.

 

1.108                       

“Transfer Tax” has the meaning set
forth in Section 8.8(c) (Transfer Tax).

 

1.109                       

“United States” or
“U.S.” means the
United States of America including its territories and
possessions.

 

1.110                       

“Valid Claim” means, with respect
to any jurisdiction in the Territory, a claim of an issued and
unexpired Licensed Patent (as may be extended through supplementary
protection certificate or patent term extension or the like) that
has not been cancelled, revoked, held invalid or unenforceable by a
decision of a patent office or other Government Authority of
competent jurisdiction from which no appeal can be taken (or from
which no appeal was taken within the allowable time period) and
which claim has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue, re-examination or
disclaimer or otherwise; provided that in any jurisdiction in the
Territory, a Valid Claim shall cease to be a Valid Claim in such
jurisdiction if its scope is such that it does not reasonably block
or prevent the entry, or Commercialization, of Generic
Products.

 

1.111                       

“VistaGen CMO” has the meaning set
forth in Section 6.2 (Manufacturing Technology
Transfer)

 

1.112                       

“VistaGen Development Data” means
any nonclinical or clinical data that are Controlled by VistaGen
and related to the Compound or any Licensed Product or otherwise
included in, or filed in support of, the Regulatory Documentation
filed by VistaGen, its Affiliates, licensees or sublicensees
outside of the Territory.

 

1.113                       

“VistaGen Indemnitees” has the
meaning set forth in Section 13.2 (Indemnification by
EverInsight).

 

1.114                       

“VistaGen Sole Inventions” means
any Inventions that are conceived and reduced to practice solely by
employees of, or consultants or service providers to, VistaGen, at
any time

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-14-

 

 

during
the Term of this Agreement and that are made, generated, conceived
or otherwise invented as a result of a Party exercising its rights
or carrying out its obligations under this Agreement, whether
directly or via its Affiliates, agents or independent
contractors.

 

1.115                       

“VistaGen Sole Invention Patents”
means any Patents that contain one or more claims that cover
VistaGen Sole Inventions.

 

1.116                       

Interpretation. In
this Agreement, unless otherwise specified:

 

(a)            

“includes”
and “including” shall mean, respectively, includes
without limitation and including without limitation;

 

(b)            

words denoting the
singular shall include the plural and vice versa and words denoting
any gender shall include all genders;

 

(c)            

words such as
“herein”, “hereof”, and
“hereunder” refer to this Agreement as a whole and not
merely to the particular provision in which such words appear;
and

 

(d)            

the Exhibits and
other attachments form part of the operative provision of this
Agreement and references to this Agreement shall include references
to the Exhibits and attachments.

 

ARTICLE 2 LICENSES

 

2.1            

License to EverInsight.

 

(a)            

Subject to the
terms and conditions of this Agreement, VistaGen hereby grants to
EverInsight an exclusive (even as to VistaGen), royalty-bearing
license and sublicense, as the case may be, under the Licensed
Technology solely to Exploit Licensed Product in the Licensed Field
in the Territory, with the right to grant sublicenses in accordance
with Section 2.3 (Sublicense Rights).

 

(b)            

In addition,
VistaGen hereby grants to EverInsight a non-exclusive license and
sublicense, as the case may be, under the Licensed Technology to
Manufacture and have Manufactured the Compound and Licensed Product
outside the Territory solely for Exploitation in the Territory,
with the right to grant sublicenses in accordance with Section 2.3
(Sublicense Rights).

 

2.2            

License to VistaGen. Subject to the
terms and conditions of this Agreement, EverInsight hereby grants
to VistaGen an exclusive (even as to EverInsight), royalty-free
license under the EverInsight Technology solely to Exploit Licensed
Product in the Licensed Field outside the Territory, with the right
to grant sublicenses in accordance with Section 2.3 (Sublicense
Rights).

 

2.3            

Sublicense Rights.

 

(a)            

Affiliates. Subject to the terms of this
Section 2.3 (Sublicense Rights), EverInsight may grant a sublicense
of the license granted in Section 2.1 (License to

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-15-

 

 

EverInsight)
through multiple tiers to Affiliates of EverInsight without prior
notice to or the prior consent of VistaGen; provided that (i)
Licensed Know-How may only be sublicensed along with the Licensed
Patents; (ii) EverInsight shall cause each Affiliate to comply with
the applicable terms and conditions of this Agreement, as if such
Affiliate were a Party to this Agreement; and (iii) EverInsight
shall be responsible for all actions, activities and obligations to
VistaGen of such Affiliate. Subject to the terms of this Section
2.3 (Sublicense Rights), VistaGen may grant a sublicense of the
license granted in Section 2.2 (License to VistaGen) through
multiple tiers to Affiliates of VistaGen without prior notice to or
the prior consent of EverInsight; provided that (i) EverInsight
Know-How may only be sublicensed along with the EverInsight
Patents; (ii) VistaGen shall cause each Affiliate to comply with
the applicable terms and conditions of this Agreement, as if such
Affiliate were a Party to this Agreement; and (iii) VistaGen shall
be responsible for all actions, activities and obligations to
EverInsight of such Affiliate.

 

(b)            

Third Parties. Upon the prior written
consent of VistaGen, such consent not to be unreasonably withheld,
conditioned, or delayed, EverInsight may grant a sublicense of the
rights granted under the license in Section 2.1 (License to
EverInsight) through multiple tiers to any Third Party; provided
that (i) Licensed Know-How may only be sublicensed along with the
Licensed Patents (other than in the case of a sublicense to a
fee-for-service Subcontractor in the context of subcontracting
pursuant to Section 2.8 (Subcontracting)); (ii) each sublicense
granted to a Third Party shall be in writing, and shall incorporate
terms and conditions that are consistent with, and expressly made
subject to, the terms and conditions of this Agreement; (iii)
VistaGen shall be provided by EverInsight with a copy of such
sublicense agreement within thirty (30) days of execution, which
copy may redact any financial or other proprietary terms; and (iv)
EverInsight shall be responsible to VistaGen for a breach of this
Agreement due to the breach by such Third Party of such sublicense
agreement. EverInsight hereby waives any requirement that VistaGen
exhaust any right, power or remedy, or proceed against any such
sublicensee for any obligation or performance under this Agreement
prior to proceeding directly against EverInsight. Upon the prior
written consent of EverInsight, such consent not to be unreasonably
withheld, conditioned, or delayed, VistaGen may grant a sublicense
of the rights granted under the license in Section 2.2 (License to
VistaGen) through multiple tiers to any Third Party; provided that
(i) EverInsight Know-How may only be sublicensed along with the
EverInsight Patents (other than in the case of a sublicense to a
fee-for-service Subcontractor pursuant to Section 2.8
(Subcontracting)); (ii) each sublicense granted to a Third Party
shall be in writing, and shall incorporate terms and conditions
that are consistent with, and expressly made subject to, the terms
and conditions of this Agreement; (iii) EverInsight shall be
provided by VistaGen with a copy of such sublicense agreement
within thirty (30) days of execution, which copy may redact any
financial or other priority terms; and (iv) VistaGen shall be
responsible to EverInsight for a breach of this Agreement due to
the breach by such Third Party of such sublicense agreement.
VistaGen hereby waives any requirement that EverInsight exhaust any
right, power or remedy, or proceed against any sublicensee for any
obligation or performance under this Agreement prior to proceeding
directly against VistaGen.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-16-

 

 

2.4            

VistaGen’s Retained Rights; Limitations
of License Grants.

 

(a)            

Retained Rights.

 

(i)            

Notwithstanding
anything to the contrary in this Agreement and without limitation
of any rights granted by or reserved to VistaGen pursuant to any
other term or condition of this Agreement, VistaGen hereby
expressly retains, on behalf of itself and its Affiliates (and on
behalf of its and their direct and indirect Third Party licensors
under any In-License Agreement, (sub)licensees and contractors) all
right, title and interest in and to the Licensed Patents, the
Licensed Know-How, VistaGen Development Data, VistaGen’s
interests in and to Joint Patents and Joint Know-How, Regulatory
Documentation of VistaGen and the Corporate Names of VistaGen and
their Affiliates, in each case, for purposes of performing or
exercising the Retained Rights.

 

(ii)            

Notwithstanding
anything to the contrary in this Agreement and without limitation
of any rights granted by or reserved to EverInsight pursuant to any
other term or condition of this Agreement, EverInsight hereby
expressly retains, on behalf of itself and its Affiliates (and on
behalf of its and their direct and indirect Third Party licensors
under any In-License Agreement, (sub)licensees and contractors) all
right, title and interest in and to the EverInsight Patents, the
EverInsight Know-How, EverInsight Development Data,
EverInsight’s interests in and to Joint Patents and Joint
Know-How, Regulatory Documentation of EverInsight and the Corporate
Names of EverInsight and their Affiliates, in each case, for
purposes of performing its obligations or exercising its rights
under this Agreement, and also for purposes of Manufacturing or
having Manufactured the Compound and Licensed Product outside the
Territory solely for Exploitation in the Territory.

 

(b)            

In-License Agreements.

 

(1)            

If VistaGen or any
of its Affiliates negotiates with a Third Party at arms’
length to obtain a license to any Know-How or Patent that are
necessary or reasonably useful for the Development, Manufacture,
Commercialization or other Exploitation of the Compound or any
Licensed Product (such Know-How or Patent, “VistaGen Third Party IP”, such
license, an “In-License
Agreement”), then VistaGen shall promptly notify
EverInsight and identify the relevant VistaGen Third Party IP, with
a copy to the JSC. The applicable VistaGen Third Party IP shall be
included in the license granted to EverInsight under Section 2.1
(License to EverInsight) and considered VistaGen Patents and
VistaGen Know-How, respectively, only if VistaGen discloses the
substantive terms of the In-License Agreement to EverInsight, which
VistaGen hereby agrees to do, and EverInsight agrees in writing to
(A) comply with all the relevant obligations of such In-License
Agreement, and (B) pay [*****]
of the portion of all upfront, milestone, royalty and other
payments under the In-License Agreement that are allocable to the
Development, Manufacture or Commercialization of the Compound or
any Licensed Product in the Licensed Field in the Territory;
provided, however, that, such upfront, milestone, royalty and other
payments

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-17-

 

 

should
be (x) at fair market value for such a license in the Territory;
and (y) directly attributable to the Development, Manufacture or
Commercialization of the Compound or any Licensed Product in the
Licensed Field in the Territory by EverInsight or any of its
Affiliates or any Sublicensees; and (z) for any such payment that
is applicable to the Respective Territories of both Parties (such
as upfront payment), such payment shall be allocated between the
Parties’ Respective Territories based on the relative value
of the market for the Licensed Product in each Party’s
Respective Territory, and EverInsight shall pay [*****]
of the portion allocable to the Territory (for clarity, VistaGen
shall be solely responsible for, and EverInsight shall have no
obligation to pay any portion of, all such payment that is not
allocable to the Territory, such as royalty payment for the sale of
Licensed Product outside the Territory). For the avoidance of
doubt, if EverInsight reasonably determines that such VistaGen
Third Party IP under the In-License Agreement is not necessary for
the Development, Manufacture or Commercialization of the Compound
or any Licensed Product in the Licensed Field in the Territory,
EverInsight has the right not to pay any costs associated with such
In-License Agreement, in which case such VistaGen Third Party IP
shall not be included in the license granted to EverInsight under
Section 2.1 (License to EverInsight) and shall not be considered to
be VistaGen Patents and VistaGen Know-How.

 

(2)            

If EverInsight or
any of its Affiliates or Sublicensees negotiates with a Third Party
at arms’ length to obtain a license to any Know-How or Patent
that are necessary or reasonably useful for the Development,
Manufacture, Commercialization or other Exploitation of the
Compound or any Licensed Product and actually applies such Know-How
or Patent in the Development, Manufacture, Commercialization or
other Exploitation of the Compound or any Licensed Product (such
Know-How or Patent, “EverInsight Third Party IP”, such license, an
“EverInsight
In-License
Agreement”), then EverInsight shall promptly notify
VistaGen and identify the relevant EverInsight Third Party IP, with
a copy to the JSC. The applicable EverInsight Third Party IP shall
be included in the license granted by EverInsight to VistaGen under
Section 2.2 (License to VistaGen) and considered EverInsight
Patents and EverInsight Know-How, respectively, only if EverInsight
discloses the substantive terms of such EverInsight In-License
Agreement to VistaGen, which EverInsight hereby agrees to do, and
VistaGen agrees in writing to (A) comply with all the relevant
obligations of such EverInsight In-License Agreement; (B) pay
[*****]
of the portion of all upfront, milestone, royalty and other
payments under the EverInsight In-License Agreement that are
allocable to the Development, Manufacture or Commercialization of
the Compound or any Licensed Product in the Licensed Field in the
Territory, which VistaGen hereby agrees to do; and (C) pay
[*****]
of the portion of all upfront, milestone, royalty and other
payments applicable to the Development, Manufacture or
Commercialization of the Compound or any Licensed Product in the
Licensed Field outside the Territory; provided, however, that, such
upfront, milestone, royalty and other payments under clause (B)
above should be (x) at fair market value for such a license in
the

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-18-

 

 

Territory; and (y)
directly attributable to the Development, Manufacture or
Commercialization of the Compound or any Licensed Product in the
Licensed Field in the Territory by EverInsight or any of its
Affiliates or any Sublicensees; and (z) for any such payment that
is applicable to the Respective Territories of both Parties (such
as upfront payment), such payment shall be allocated between the
Parties’ Respective Territories based on the relative value
of the market for the Licensed Product in each Party’s
Respective Territory, and VistaGen shall pay [*****]
of the portion allocable to the Territory (for clarity, pursuant to
clause (C) above, VistaGen shall be solely responsible for, and
shall reimburse EverInsight for, all such payment that is not
allocable to the Territory, such as royalty payment for the sale of
Licensed Product outside the Territory). For the avoidance of
doubt, if VistaGen reasonably determines that such EverInsight
Third Party IP is not necessary for the Development, Manufacture or
Commercialization of the Compound or any Licensed Product in the
Licensed Field outside the Territory, VistaGen has the right not to
pay the costs associated with such EverInsight In-License Agreement
outside the Territory under clause (C) above (for further clarity,
VistaGen shall remain obligated to pay its share of the costs
associated with such EverInsight In-License Agreement in the
Territory under clause (B) above), in which case such EverInsight
Third-Party IP shall not be included in the license granted to
VistaGen under Section 2.2 (License to VistaGen) and shall not be
considered to be EverInsight Patents and EverInsight Know-How. In
the event that VistaGen does agree to accept such Third-Party
license outside of the Territory, the provisions of clauses (3),
(4) and (5) of this Section 2.4(b) (In-License Agreements) shall
apply, mutatis mutandis, to any such Third Party
license.

 

(3)            

Subject to this
Section 2.4(b) (In-License Agreements), the licenses granted by
VistaGen in Section 2.1 (License to EverInsight) include
sublicenses solely under the applicable license rights granted to
VistaGen or its Affiliates by Third Parties under the In-License
Agreements. Any Sublicense with respect to Know-How or Patents of a
Third Party hereunder and any right of EverInsight (if any) to
grant a further sublicense thereunder, shall be subject and
subordinate to the terms and conditions of the In-License Agreement
under which such sublicense is granted and shall be effective
solely to the extent permitted under the terms of such agreement.
Without limitation of the foregoing, in the event and to the extent
that any In-License Agreement requires that particular terms or
conditions of such In-License Agreement be contained or
incorporated in any agreement granting a sublicense thereunder,
such terms and conditions are hereby deemed to be incorporated
herein by reference and made applicable to the sublicense granted
herein under such In-License Agreement.

 

(4)            

The Parties shall
cooperate with each other in good faith to support each other in
negotiating rights under EverInsight Third Party IP in order for
VistaGen to obtain such rights outside of the Territory and in
complying with VistaGen’s and its Affiliates’
obligations under each In-License Agreement. Without limitation to
the foregoing, (A) the Parties shall, from time to time, upon
the

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-19-

 

 

reasonable request
of either Party, discuss the terms of an In-License Agreement and
agree upon, to the extent reasonably possible, a consistent
interpretation of the terms of such In-License Agreement in order
to, as fully as possible, allow VistaGen and its Affiliates to
comply with the terms of such In-License Agreement; (B) to the
extent there is a conflict between any terms of this Agreement and
any terms of any In-License Agreement (including with respect to
sublicensing rights, diligence obligations, prosecution,
maintenance, enforcement, defense, any obligations for a
counterparty to such In-License Agreement to maintain a
Party’s information as confidential and any obligations for a
Party to maintain as confidential the information of a counterparty
to such In-License Agreement), the terms of such In-License
Agreement shall control with respect to the relevant Know-How,
Patents or other rights granted to EverInsight hereunder; and (C)
EverInsight and its Affiliates and Sublicensees shall comply with
any applicable reporting and other requirements under the
In-License Agreements, and the provisions regarding currency
conversion, international payments and late payments, and any other
relevant definitions and provisions, of the relevant In-License
Agreements shall apply to the calculation of the payments due under
the relevant In-License Agreements.

 

(5)            

On an In-License
Agreement-by-In-License Agreement basis, from and after the date on
which EverInsight agrees in writing pursuant to Section 2.4(b)(1)
to accept the Patents and Know-How covered by such In-License
Agreement as Licensed Technology under this Agreement, VistaGen
shall maintain such In-License Agreement in full force and effect,
shall not enter into any subsequent agreement with any other party
to such In-License Agreement that modifies or amends such
In-License Agreement in any way that would materially adversely
affect EverInsight’s rights or interest under this Agreement
without EverInsight’s prior written consent, which shall not
be unreasonably withheld, conditioned or delayed, and shall provide
EverInsight with a copy of all modifications to or amendments of
such In-License Agreement, regardless of whether
EverInsight’s consent was required with respect
thereto.

 

2.5            

Transfer of Know-How. Within
[*****]
days following the Effective Date, VistaGen shall commence
disclosing and making available to EverInsight the Licensed
Know-How (including the VistaGen Development Data therein)
necessary or reasonably required for EverInsight to file a CTA
covering a Licensed Product and to Develop the Compound and
Licensed Product in the Licensed Field in the Territory. In
addition, throughout the Term of this Agreement, VistaGen shall
promptly disclose and make available to EverInsight any Licensed
Know-How (including the VistaGen Development Data therein) that has
not previously been provided to EverInsight, or is developed or
generated or otherwise comes into VistaGen’s Control after
the Effective Date. Such disclosure and transfer shall be made at
no additional cost to EverInsight and according to a timeline
mutually agreed by EverInsight and VistaGen, each of which shall
cooperate with each other in good faith to enable a smooth transfer
of the Licensed Know-How from VistaGen to EverInsight. Upon
EverInsight’s reasonable request during such transfer,
VistaGen shall provide reasonable technical assistance, at no
additional cost to EverInsight, including making appropriate
employees available to EverInsight at reasonable

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-20-

 

 

times,
places and frequency, and upon reasonable prior notice, for the
purpose of assisting EverInsight to understand and use the Licensed
Know-How in connection with EverInsight’s filing of such CTA
covering such Licensed Product and the Development of the Compound
and Licensed Product in the Licensed Field in the
Territory.

 

2.6            

No Implied Licenses; Negative Covenant.
Except as set forth herein, no Party shall acquire any license or
other intellectual property interest, by implication or otherwise,
under any Know-How, Patents, trademarks or other intellectual
property rights owned or Controlled by any other Party. EverInsight
hereby covenants not to practice, and not to permit or cause any of
its Affiliates or any Third Party to practice, any Licensed
Technology for any purpose other than as expressly authorized in
this Agreement.

 

2.7            

Non-Diversion.

(a)            

EverInsight hereby
covenants and agrees that it will not, and will ensure that its
Affiliates will not, and will ensure its Sublicensees and
subcontractors are bound by contractual obligations not to, either
directly or indirectly, promote, market, solicit, distribute,
import, sell or have sold Licensed Product outside the Territory.
In furtherance of the foregoing, EverInsight shall not and will
ensure that its Affiliates do not, and shall use Commercially
Reasonable Efforts to ensure that its or their Sublicensees or
distributors do not knowingly distribute, market, promote, offer
for sale or sell the Compound or any Licensed Product directly or
indirectly to any Person outside the Territory or to any Person
inside the Territory that EverInsight or any of its Affiliates or
any of its or their Sublicensees or distributors knows has directly
or indirectly distributed, marketed, promoted, offered for sale or
sold, or has reasonable grounds to believe intends to directly or
indirectly distribute, market, promote, offer for sale or sell, the
Compound or any Licensed Product for use outside the Territory. If
EverInsight or any of its Affiliates receives or becomes aware of
the receipt by it or any Sublicensee or distributor of any orders
for the Compound or any Licensed Product for use outside the
Territory, such Person shall refer such orders to
VistaGen.

 

(b)            

VistaGen hereby
covenants and agrees that it will not, and shall ensure that its
Affiliates will not, and will ensure its licensees and sublicensees
(other than EverInsight, its Affiliates and Sublicensees) and
subcontractors are bound by contractual obligations not to, either
directly or indirectly, promote, market, solicit, distribute,
import, sell or have sold Licensed Product in the Territory. In
furtherance of the foregoing, VistaGen shall not and will ensure
that its Affiliates do not, and shall use Commercially Reasonable
Efforts to ensure that its or their licensees and sublicensees
(other than EverInsight, its Affiliates and Sublicensees) or
distributors do not knowingly distribute, market, promote, offer
for sale or sell the Compound or any Licensed Product directly or
indirectly to any Person in the Territory or to any Person outside
the Territory that VistaGen or any of its Affiliates or any of its
or their licensees or sublicensees (other than EverInsight, its
Affiliates and Sublicensees) or distributors knows has directly or
indirectly distributed, marketed, promoted, offered for sale or
sold, or has reasonable grounds to believe intends to directly or
indirectly distribute, market, promote, offer for sale or sell, the
Compound or any Licensed Product for use in the Territory. If
VistaGen or any of its Affiliates receives or becomes aware of the
receipt by it or any licensees, sublicensee (other than
EverInsight, its Affiliates and Sublicensees) or distributor of any
orders for the Compound or any Licensed Product for use in the
Territory, such Person shall refer such orders to
EverInsight.

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-21-

 

 

2.8            

Non-Compete. During the Term of this
Agreement, neither Party shall, and each Party shall cause its
Affiliates and their respective Sublicensees not to, directly or
indirectly, enable or assist any Person that is not a Party to this
Agreement to, Develop, Manufacture or Commercialize any intra-nasal
formulation of Androstadienol in the Territory for the treatment of
social anxiety disorder, other than the Compound and the Licensed
Product in accordance with this Agreement (the “Competing Product”). If
EverInsight requests a waiver of this Section with regard to a
particular product and/or a particular transaction, VistaGen will
in good faith give due consideration to such request.
Notwithstanding the foregoing, if EverInsight is acquired by or
merges or consolidates with a Third Party that, at the time of such
acquisition, is actively Developing, Manufacturing and/or
Commercializing a Competing Product in the Territory, then the
activities of EverInsight, its Affiliates and their respective
Sublicensees under and in accordance with the terms of such license
agreement and the activities of such Third Party acquirer for the
continued development, manufacturing and/or commercialization of
the Competing Product, respectively, shall not be deemed to breach
this Section 2.8.

 

2.9            

Subcontracting. Notwithstanding Section
2.3 (Sublicense Rights), each Party may, without the other
Party’s consent, subcontract on a fee-for-service basis with
a Third Party to perform any or all of its obligations hereunder (a
“Subcontractor”), including by
appointing one or more distributors, and grant a sublicense to the
Subcontractor solely to the extent necessary to perform such
subcontracted obligations; provided that (a) no such permitted
subcontracting shall relieve the subcontracting Party of any
obligation hereunder (except to the extent satisfactorily performed
by such Subcontractor) or any liability and the subcontracting
Party shall be and remain fully responsible and liable therefor;
(b) the agreement pursuant to which the subcontracting Party
engages any Subcontractor must be consistent in all material
respects with this Agreement, including terms consistent with the
confidentiality, restrictions on use and intellectual property
provisions of this Agreement, and (c) the subcontracting Party
shall be responsible to the other Party for the breach of this
Agreement due to breach of any subcontracting agreement by its
Subcontractors. The subcontracting Party hereby waives any
requirement that the other Party exhaust any right, power or
remedy, or proceed against any Subcontractor for any obligation or
performance under this Agreement prior to proceeding directly
against the subcontracting Party.

 

2.10            

Statements and Compliance with Applicable
Laws. Each Party shall and shall cause its Affiliates and
its and their respective licensees and Sublicensees to comply with
all Applicable Laws with respect to the Exploitation of Licensed
Product, including the extranational application of U.S. laws and
regulations as related, for example, to regulatory matters, export
controls and transfer of technology to certain countries and to
foreign corrupt practices. Each Party shall, and shall cause its
Affiliates to, and shall use Commercially Reasonable Efforts to
cause its and their licensees, Sublicensees, employees,
representatives, agents, and distributors to avoid taking, or
failing to take, any actions that such Party knows or reasonably
should know would jeopardize the goodwill or reputation of the
other Party or its Affiliates or the Licensed Product or any
Trademark associated therewith. Without limitation to the
foregoing, each Party shall in all material respects conform its
practices and procedures relating to the Commercialization of the
Licensed Product and educating the medical community in its
Respective Territory with respect to the Licensed Product to any
applicable industry association

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-22-

 

 

regulations,
policies and guidelines, as the same may be amended from time to
time, and Applicable Laws. Each Party agrees that in performing its
obligations under this Agreement, it will not employ or engage any
Person who has been debarred or disqualified by any Regulatory
Authority, or, to its knowledge, is the subject of debarment or
disqualification proceedings by a Regulatory
Authority.

 

2.11            

Section 365(n). All rights and licenses
granted under or pursuant to this Agreement by VistaGen or
EverInsight are, and will otherwise be deemed to be, for the
purposes of Section 365(n) of the U.S. Bankruptcy Code, and any
similar law in the Territory, licenses of rights to
“intellectual property” as defined under Section 101 of
the U.S. Bankruptcy Code or any similar law in the Territory. The
Parties agree that each Party, as licensees of such rights under
this Agreement, will retain and may fully exercise all of its
rights and elections under the U.S. Bankruptcy Code or any similar
law in the Territory. The Parties further agree that, in the event
of the commencement of a bankruptcy proceeding by or against either
Party under the U.S. Bankruptcy Code or any similar law in the
Territory, the Party that is not a party to such proceeding will be
entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of
such intellectual property, and same, if not already in their
possession, will be promptly delivered to them (a) upon any such
commencement of a bankruptcy proceeding upon their written request
therefor, unless the Party subject to such proceeding elects to
continue to perform all of its obligations under this Agreement, or
(b) if not delivered under (a) above, following the rejection of
this Agreement by or on behalf of the Party subject to such
proceeding upon written request therefor by the non-subject
party.

 

2.12            

Technology Escrow. Promptly after the
Effective Date, VistaGen shall deposit all existing Licensed
Know-How (for clarity, including all Licensed Manufacturing
Know-How) with an escrow agent selected by EverInsight and
reasonably acceptable to VistaGen and pursuant to an escrow
agreement that requires the escrow agent to release the Licensed
Know-How to EverInsight upon the commencement of a bankruptcy
proceeding by or against VistaGen under the U.S. Bankruptcy Code or
any similar law in the Territory. Throughout the term of this
Agreement, VistaGen shall periodically (no less than annually)
update such technology escrow to include any new Licensed Know-How
that is developed or generated or otherwise comes into
VistaGen’s Control after the Effective Date. The Parties
shall share equally the cost of establishing and maintaining such
technology escrow.

 

 

ARTICLE 3 GOVERNANCE

 

3.1            

Joint Steering Committee. As soon as
practicable after the Effective Date, the Parties shall establish a
joint steering committee (the “Joint Steering Committee” or the
“JSC”), composed
of equal number of representatives of VistaGen and representatives
of EverInsight, to coordinate the Development and Commercialization
of the Compound and Licensed Product in the Licensed Field in the
Territory. Each JSC representative shall have appropriate knowledge
and expertise and sufficient seniority within the applicable Party
to make decisions arising within the scope of the JSC’s
responsibilities. The JSC shall:

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-23-

 

 

 

(a)            

serve as a forum
for discussing Development of the Compound and Licensed Product in
the Licensed Field in the Territory, including by reviewing the
Development Plan and coordinating the conduct of the Development
activities;

 

(b)            

serve as a forum
for discussing the Manufacture and supply of Compound and Licensed
Product in the Licensed Field in the Territory, including by
reviewing the Development strategy and Commercialization strategy
for the Territory and coordinating the conduct of the Manufacturing
and supply activities;

 

(c)            

serve as a forum
for discussing Development of the Compound and Licensed Product in
the Licensed Field in the Territory, including by (i) providing
EverInsight with a forum at each meeting to disclose
EverInsight’s, or its Affiliates’ or
Sublicensees’ activities with respect to achieving Regulatory
Approvals of Licensed Product in the Territory; material clinical
study results; and the Marketing Authorization Applications that
EverInsight or any of its Affiliates reasonably expect to make,
seek or attempt to obtain in the Territory; (ii) reviewing the
current Development Plan and, with the JSC’s approval, making
any amendments or updates to the Development Plan; and (iii)
coordinating the conduct of the Development
activities;

 

(d)            

serve as a forum to
keep EverInsight updated on the Development of the Compound and
Licensed Product in the Licensed Field outside the Territory,
including material clinical study results and any Marketing
Authorization Application for the Licensed Product filed outside
the Territory;

 

(e)            

coordinate the
activities of VistaGen and EverInsight under this
Agreement;

 

(f)            

establish a Joint
Manufacturing Committee to enable regular information exchange on
CMC issues, discuss possible costs reductions and review potential
CMOs and prepare joint manufacturing plans, transfers and
selections of joint manufacturing partners, and a Joint
Commercialization Committee for discussing and coordinating the
launch activities for the Licensed Product (for clarity, neither
such subcommittee nor the JSC shall have any decision making
authority over commercialization of the Licensed Product anywhere
in the Territory); and

 

(h)            

perform such other
functions as are set forth herein or as the Parties may mutually
agree in writing, except where in conflict with any provision of
this Agreement.

 

The JSC
shall have only such powers as are expressly assigned to it in this
Agreement, and such powers shall be subject to the terms and
conditions of this Agreement. For clarity, the JSC shall not have
any right, power or authority: (i) to determine any issue in a
manner that would conflict with the express terms and conditions of
this Agreement; or (ii) to modify or amend the terms and conditions
of this Agreement.

 

3.2            

JSC Membership and
Meetings.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-24-

 

 

(a)            

JSC Members. Each Party will designate
equal number (at least two) of representatives to the JSC within
thirty (30) days after the Effective Date. Each Party may replace
its JSC representatives on written notice to the other Party, but
each Party shall strive to maintain continuity. The Alliance
Managers shall jointly prepare and circulate the meeting agenda at
least five (5) Business Days in advance of each meeting, and shall
also promptly, but in no event later than thirty (30) days after
such meeting, prepare and circulate for review and approval of the
Parties the minutes of such meeting.

 

(b)            

JSC Meetings. The JSC will hold its
first meeting within thirty (30) days of establishment of the JSC
pursuant to Section 3.1 (Joint Steering Committee). At this first
meeting, the JSC will address the initial transfer of Licensed
Know-How provided for in Section 2.5 (Transfer of Know-How) and any
other topics the Parties deem appropriate. Thereafter, the JSC
shall hold meetings at such times as it elects to do so, but in no
event shall such meetings be held less frequently than once per
Calendar Quarter. Meetings may be held in person, or by audio or
video teleconference; provided, that unless otherwise agreed by
VistaGen and EverInsight, at least one (1) meeting per year shall
be held in person, and all in-person JSC meetings shall be held at
locations mutually agreed upon by VistaGen and EverInsight. Each
Party shall be responsible for all of its own expenses of
participating in JSC meetings.

 

(c)            

Non-Member Attendance. Each of VistaGen
and EverInsight may from time to time invite a reasonable number of
participants, in addition to its representatives, to attend JSC
meetings in a non‐voting capacity; provided, that if either
VistaGen or EverInsight intends to have any Third Party (including
any consultant) attend such a meeting, such Party shall provide at
least five (5) Business Days’ prior written notice to the
other Party and obtain the other Party’s approval for such
Third Party to attend such meeting, which approval shall not be
unreasonably withheld or delayed. Such Party shall ensure that such
Third Party is bound by confidentiality and non-use obligations
consistent with the terms of this Agreement. The Party inviting any
such Third Party shall be responsible for all of such Third
Party’s costs and expenses of participating in JSC meetings,
unless such invitation is mutually made by VistaGen and
EverInsight, in which case they shall equally share such costs and
expenses.

 

3.3            

JSC Decision-Making. All decisions of
the JSC shall be made by unanimous vote, with VistaGen’s
representatives and EverInsight’s representatives each
collectively having one (1) vote. If after reasonable discussion
and good faith consideration of each of their views on a particular
matter before the JSC, the representatives of VistaGen and
EverInsight cannot reach an agreement as to such matter within
thirty (30) calendar days after such matter was brought to the JSC
for resolution, such disagreement shall:

 

(a)            

be referred to the
Chief Executive Officer of VistaGen (or his or her designee) and
the Chief Executive Officer of EverInsight (or his or her designee)
(collectively, the “Executive
Officers”) for resolution, who shall use good faith
efforts to resolve such matter within forty-five (45) calendar days
after it is referred to them and, if such matter is resolved by the
Executive Officers, such resolution shall be implemented by and
binding on the Parties.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-25-

 

 

(b)            

If the Executive
Officers are unable to reach consensus on any such matter during
such forty-five (45) calendar day period, then

 

(i) the
Chief Executive Officer of EverInsight shall have the right to make
the final decision if such matter (A) involves the Development of,
Regulatory Approval for, Commercialization or other Exploitation of
the Compound or a Licensed Product in the Territory and (B) is not
reasonably expected to have a material adverse effect on the
Development of, Regulatory Approval for, Commercialization or
Exploitation of the Compound or a Licensed Product outside the
Territory;

 

(ii)
the Chief Executive Officer of VistaGen shall have the right to
make the final decision if such matter (A) involves the Development
of, Regulatory Approval for, Commercialization or other
Exploitation of the Compound or a Licensed Product outside the
Territory, and (B) is not reasonably expected to have a material
adverse effect on the Development of, Regulatory Approval for, or
Commercialization or Exploitation of the Compound or a Licensed
Product in the Territory; or

 

(iii)
in all other cases, such matter will be resolved in accordance with
Section 14.10 (Dispute Resolution).

 

(c)            

If the Parties
dispute whether a matter subject to the decision making mechanism
set forth above is reasonably expected to have a material adverse
effect on the Development of, Regulatory Approval for, or
Commercialization or Exploitation of the Compound or a Licensed
Product in a Party’s Respective Territory, such dispute shall
be resolved by an independent, impartial and conflicts-free Third
Party expert, who shall be experienced in the global aspects of the
development, manufacture and commercialization of pharmaceutical
products similar to the Licensed Product (the “Expert”). For clarity, such
dispute shall not be subject to the dispute resolution mechanism
set forth in Section 14.10. Within fifteen (15) days after a Party
alleges material adverse impact in its Respective Territory as set
forth above and the other Party disagrees with such allegation, the
Parties shall mutually agree upon the Expert and, as promptly as
possible thereafter, the Parties shall jointly retain the Expert.
If the Parties are unable to agree on a mutually acceptable Expert
within such fifteen (15) day period, each Party will select one (1)
Expert and those two (2) Party selected Experts will select a third
Expert within ten (10) days thereafter, and such third Expert shall
be the sole Expert to resolve such dispute in accordance with this
Section 3.3(c). Each Party shall bear its own costs associated such
Expert decision and share the costs of the Expert equally. The
determination of the Expert shall be binding on the Parties and the
Parties shall act in accordance with the Expert’s
decision.

 

3.4            

Alliance Manager. Each Party will assign
an Alliance Manager, who will be a non-voting member of the JSC and
the primary contact for all non-technical matters of governance,
who will organize JSC meetings as reasonably necessary and lead the
drafting of minutes. Either Alliance Manager may also call for
ad-hoc meetings if one of the Parties deems that
necessary.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-26-

 

 

ARTICLE 4 DEVELOPMENT

 

4.1            

General. Subject to the terms and
conditions of this Agreement (including without limitation the
Retained Rights), EverInsight shall be solely responsible for the
Development of the Compound and Licensed Product in the Licensed
Field in the Territory, including the performance of preclinical
and clinical studies of any Compound or any Licensed Product in the
Licensed Field in the Territory. Notwithstanding the foregoing,
VistaGen shall be solely responsible for conducting a six (6) month
rat toxicology study in China, which study will be conducted by
[*****]
at VistaGen’s own cost and expense.

 

4.2            

Development Plan. EverInsight’s
initial plan for the Development of the Compound and Licensed
Product (the “Development
Plan”) is attached hereto as Exhibit D. The
Development Plan will include, among other things, critical
activities to be undertaken, certain timelines, go/no go decision
points and relevant decision criteria and certain allocations of
responsibilities between the Parties to facilitate the
registration, launch, and Commercialization of the Compound and
Licensed Product in the Territory. The Development Plan will be
focused on efficiently obtaining Regulatory Approval for a Licensed
Product in the Licensed Field in the Territory, with an emphasis on
Mainland China and South Korea. EverInsight shall conduct all
Development of the Compound and Licensed Product in the Licensed
Field in the Territory in accordance with the Development Plan. The
Development Plan also shall take into consideration Development,
Regulatory Approval, or commercial impacts on the Licensed Product
outside the Licensed Field and Territory. From time to time, but at
least once per Calendar Year, EverInsight will, with the assistance
of the JSC, update the Development Plan and submit such updated
plan to the JSC for review, discussion, and approval. Any
disagreement or dispute in the JSC regarding the Development Plan
shall be resolved in the manner set forth in Section 3.3 (JSC
Decision-Making). If any updated or new terms of the Development
Plan contradict, or create inconsistencies or ambiguities with, the
terms of this Agreement, then the terms of this Agreement shall
govern.

 

4.3            

Diligence.

 

(a)            

Commercially Reasonable Efforts by
EverInsight. EverInsight, directly and/or with or through
its Affiliates or Sublicensees, shall use Commercially Reasonable
Efforts to Develop and obtain Regulatory Approval for the Compound
and the Licensed Product in the Licensed Field in Mainland China
and South Korea in accordance with the Development
Plan.

 

(b)            

Commercially Reasonable Efforts by
VistaGen. VistaGen, directly and/or with or through its
Affiliates or Sublicensees, shall use Commercially Reasonable
Efforts to Develop and obtain Regulatory Approval for the Compound
and the Licensed Product in the Licensed Field in the
U.S.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-27-

 

 

4.4            

Development Costs.

 

(a)            

As between the
Parties, EverInsight shall be solely responsible for the cost for
the Development of the Compound and the Licensed Product in the
Licensed Field in the Territory and VistaGen shall be solely
responsible for the cost for the Development of the Compound and
the Licensed Product in the Licensed Field outside the Territory,
except as otherwise provided in Section 4.1 and 4.4(b). For
clarity, VistaGen shall be responsible for the cost of the
toxicology study to be conducted in China as described in Section
4.1.

(b)            

EverInsight shall
have the option, but not the obligation, to participate in global
Phase 3 Clinical Trial and long-term safety study in social anxiety
disorder conducted by VistaGen (or its Affiliates or
(sub)licensees) to support Regulatory Approval in the Territory.
VistaGen shall keep EverInsight informed on its global development
plan for the Compound and Licensed Product. Before initiating any
global Phase 3 Clinical Trial and long-term safety study for the
Licensed Product, VistaGen shall notify EverInsight and provide
EverInsight with relevant study plan and protocol for review and
consideration. If EverInsight elects to participate in such global
Phase 3 Clinical Trial or long-term safety study, then the Parties
shall ensure that sufficient number of subjects in the Territory
are enrolled in such clinical trial in order to support Regulatory
Approval in the Territory, and EverInsight shall (i) be responsible
for the conduct of, and all direct costs and expenses of
conducting, such clinical trial in the Territory (provided however
that if VistaGen requests in writing that EverInsight enrolls in
the Territory more subjects than the minimum number required for
Regulatory Approval in the Territory, then the Parties shall
discuss such request in good faith, and if EverInsight agrees to
enroll such excess subjects, VistaGen shall reimburse EverInsight
for the clinical trial cost for such excess subjects); and (ii) pay
or reimburse VistaGen for a pro
rata portion (based on the number of subject enrolled in the
Territory vs worldwide in such clinical trial) of all of the
Indirect Costs of such global clinical trial outside of the
Territory, not to exceed [*****]
of the total Indirect Costs of such global clinical trial. VistaGen
shall provide EverInsight with reasonable supporting documents
(including Third Party invoices) for the Indirect Costs of such
global clinical trial. For clarity and notwithstanding the
foregoing, the cost sharing in this subsection (b) shall not apply
to the first U.S. Phase 3 Clinical Trial, the cost of which shall
be solely born by VistaGen.

 

4.5            

Development Records and
Reports.

 

(a)            

EverInsight shall,
and shall cause its Affiliates and its and their Sublicensees to,
maintain, in good scientific manner, complete and accurate records
and reports pertaining to Development of Licensed Product
hereunder, in sufficient detail for VistaGen to verify
EverInsight’s compliance with its obligations under this
Agreement. Such records and reports shall (i) be summarized in
English in sufficient detail for VistaGen to verify
EverInsight’s compliance with its obligations under this
Agreement and for VistaGen to properly use such records and reports
for patent and regulatory purposes, (ii) be appropriate for patent
and regulatory purposes; (iii) be in compliance with Applicable
Laws; (iv) properly reflect all work done and results achieved in
the performance of its

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-28-

 

 

Development
activities hereunder; (v) record only such activities and not
include or be commingled with records of activities outside the
scope of this Agreement; and (vi) be retained by EverInsight for at
least five (5) years after the expiration or termination of this
Agreement in its entirety or for such longer period as may be
required by Applicable Laws.

 

(b)            

Starting on
[*****],
EverInsight shall provide VistaGen with an annual written report
summarizing in sufficient detail for VistaGen to verify
EverInsight’s compliance with its obligations under this
Agreement (i) the Development activities conducted in the preceding
Calendar Year by it and its Affiliates and Sublicensees, and (ii)
the Development activities planned to be conducted in such Calendar
Year by it and its Affiliates and Sublicensees. If at any time
VistaGen’s representatives on the JSC are not fully able to
perform their rights and duties on the JSC in the absence of a
review of any of such books and records, EverInsight shall, upon
reasonable written request from such JSC representative, provide a
copy of such records to the JSC.

 

 

ARTICLE 5 REGULATORY

 

5.1            

Regulatory Responsibilities. EverInsight
shall be responsible, at its cost and subject to the Retained
Rights and except as set forth in this ARTICLE 5, for all
regulatory activities necessary to prepare, obtain and maintain
Marketing Authorization Applications, Regulatory Filings and other
Regulatory Approvals for the Compound and Licensed Product in the
Licensed Field in the Territory. EverInsight shall keep VistaGen
informed of regulatory developments related to the Compound or
Licensed Product in the Licensed Field in the Territory via the
JSC.

 

5.2            

Regulatory Reports. Starting on
[*****],
EverInsight shall provide VistaGen with an annual written report
summarizing the clinical data and safety results generated from the
regulatory activities performed in the preceding Calendar Year by
it and its Affiliates and Sublicensees, in sufficient detail for
VistaGen to verify EverInsight’s compliance with its
obligations under this Agreement and for VistaGen to properly use
data and results for patent and regulatory purposes.

 

5.3            

Regulatory Cooperation.

 

(a)            

EverInsight. EverInsight shall notify
VistaGen of all material Regulatory Documentation submitted or
received by EverInsight or its Affiliates or Sublicensees that are
related to any Licensed Product in the Territory reasonably prior
to such submission or reasonably after receipt. Moreover, with
respect to Regulatory Filings in the Territory, EverInsight will
provide VistaGen with the draft of such Regulatory Filings and an
English summary thereof reasonably prior to submission so that
VistaGen may have reasonable opportunity to review and comment on
them. EverInsight shall consider all comments of VistaGen in good
faith, taking into account the best interests of the Development,
Regulatory Approval and/or Commercialization of the Licensed
Product, but has no obligation to accept any comments of VistaGen,
except to the extent that ignoring such comment could reasonably be
expected to have a material adverse effect on

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-29-

 

 

the
Development of, Regulatory Approval for, or Commercialization or
Exploitation of the Compound or a Licensed Product outside the
Territory. Material submissions made by EverInsight to, or
correspondence with, Regulatory Authorities will be provided to
VistaGen reasonably in advance to enable translation by VistaGen,
if any such submissions or correspondence are not available in
English. VistaGen shall not provide any Regulatory Documentation of
EverInsight, its Affiliates, or Sublicensees to any of
VistaGen’s sublicensees who does not agree pursuant to
Section 5.3(b) (VistaGen) to permit its Regulatory Documentation to
be shared with EverInsight, its Affiliates, and its
Sublicensees.

 

(b)            

VistaGen. VistaGen shall provide or make
available to EverInsight copies of all material Regulatory
Documentation submitted or received by VistaGen or its Affiliates
that are related to any Licensed Product outside the Territory
reasonably after such submission or receipt. VistaGen shall use
Commercially Reasonable Efforts to negotiate an agreement with each
sublicensee to make available to EverInsight copies of all material
Regulatory Documentation that are related to any Licensed Product
outside the Territory that are Controlled by its such sublicensee.
Upon reasonable request, VistaGen will support EverInsight’s
regulatory filing efforts, as necessary, and in alignment with
VistaGen’s formal role as the global study sponsor. This may
include participation in certain meetings with regulatory
authorities, if requested by EverInsight, and signing or co-signing
the clinical study site contracts, if global sponsor’s
signature is required by the study site in the Territory. Due to
requirement by many leading clinical trial hospitals in China that
the global sponsor listed on the protocol is a party to the site
contracts, VistaGen agrees to accept this responsibility.
EverInsight shall indemnify VistaGen for such contractual
liabilities in the Territory.

 

(c)            

Confidentiality. Any information of a
Party to which the other Party obtains access pursuant to this
Section 5.3 (Regulatory Cooperation) shall, subject to ARTICLE 10
(Confidentiality; Publication), be deemed the Confidential
Information of such first Party.

 

5.4            

Rights of Reference.

 

(a)            

Without any
additional consideration to VistaGen, VistaGen hereby grants to
EverInsight and its Affiliates and Sublicensees a Right of
Reference and Use, as that term is defined in 21 C.F.R. §
314.3(b) and any foreign counterpart to such regulation, to all
VistaGen Regulatory Documentation and the VistaGen Development Data
to the extent necessary or reasonably useful for EverInsight to
Exploit the Compound or Licensed Product in the Licensed Field in
the Territory.

 

(b)            

Without any
additional consideration to EverInsight, EverInsight hereby grants
to VistaGen and its Affiliates, and any current or future direct or
indirect (sub)licensee of VistaGen with respect to the Compound or
a Licensed Product, a Right of Reference and Use, as that term is
defined in 21 C.F.R. § 314.3(b) and any foreign counterpart to
such regulation, to the EverInsight Development Data to the extent
necessary or reasonably

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-30-

 

 

useful
for VistaGen to Exploit the Compound, Licensed Product(s) in the
Licensed Field outside of the Territory.

 

(c)            

Promptly after a
Party, its Affiliate or its or their licensees or Sublicensees
generate(s) any VistaGen Development Data or EverInsight
Development Data (as applicable), such Party shall provide the
other Party with copies of such data, and the other Party may use
such data pursuant to the license granted to it under Section 2.1
or 2.2 (as applicable).

 

(d)            

Each Party will
provide a signed statement to this effect, if requested by the
other Party, that is consistent with the requirements of 21 C.F.R.
§ 314.50(g)(3) or any foreign counterpart to such regulation,
in the case of a request by either Party, for the limited purpose
described in this Section 5.4 (Rights of Reference).

 

(e)            

Other than as
expressly set forth in this Section 5.4 (Rights of Reference),
nothing in this Section 5.4 shall require either Party to take, or
forbear to take, any action.

 

(f)            

Any information of
a Party to which the other Party obtains access pursuant to this
Section 5.4 (Rights of Reference) shall, subject to Sections 10.1
(Duty of Confidence) and 10.2 (Exceptions), be deemed the
Confidential Information of such first Party. For avoidance of
doubt, a Party’s submission of information of the other Party
to which such Party obtains access pursuant to this Section 5.4
(Rights of Reference) to a Regulatory Authority shall be governed
by and subject to the terms of ARTICLE 10 (Confidentiality;
Publication).

 

5.5            

Recalls, Suspensions or Withdrawals.
Each Party shall notify the other Party promptly following its
determination that any event, incident or circumstance has occurred
that would reasonably be expected to result in the need for a
recall, market suspension or market withdrawal of a Licensed
Product in the Licensed Field and shall include in such notice the
reasoning behind such determination and any supporting facts. As
between the Parties, EverInsight shall have the right to make the
final determination whether to voluntarily implement any such
recall, market suspension or market withdrawal in the Licensed
Field in the Territory; provided that prior to any implementation
of such a recall, market suspension or market withdrawal,
EverInsight shall consult with VistaGen and shall consider
VistaGen’s comments in good faith. If a recall, market
suspension or market withdrawal is mandated by a Regulatory
Authority in the Territory, as between the Parties, EverInsight
shall initiate such a recall, market suspension or market
withdrawal in compliance with Applicable Laws. For all recalls,
market suspensions or market withdrawals undertaken pursuant to
this Section 5.5 (Recalls, Suspensions or Withdrawals), as between
the Parties, EverInsight shall be solely responsible for the
execution thereof. Subject to ARTICLE 13 (Indemnification;
Liability), EverInsight shall be responsible for all costs and
expenses of any such recall, market suspension or market
withdrawal. Notwithstanding the foregoing, any recall, market
suspension or market withdrawal that relates to the Manufacture and
supply of a Compound or Licensed Product by VistaGen to EverInsight
shall be governed by the terms and conditions of the Initial Supply
Agreement.

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-31-

 

 

 

5.6            

Pharmacovigilance Agreement; Global Safety
Database. The Parties shall enter into a pharmacovigilance
agreement at least [*****]
days prior to the Initiation of any Clinical Trial of Licensed
Product(s) by EverInsight in the Territory providing for the terms
pursuant to which (i) VistaGen shall establish, hold and maintain
(at VistaGen’s sole cost and expense) the global safety
database for Licensed Product and (ii) the Parties will establish a
mutually agreed procedure for safety data sharing, adverse event
reporting and prescription events monitoring related to the
Licensed Product(s), which procedure shall be in accordance with,
and enable the Parties to fulfill, their respective regulatory
reporting obligations under, all applicable laws. Each Party shall
be responsible for reporting safety data, adverse events, quality
complaints related to the Products to the global safety database
and to the applicable Regulatory Authorities in its Respective
Territory, as well as responding to safety issues and to all
requests of Regulatory Authorities related to the Licensed Product
in its Respective Territory, in each case at its own cost. VistaGen
shall provide EverInsight with access to the global safety database
to allow EverInsight to comply with its regulatory reporting
obligations under applicable laws in the Territory.

 

5.7            

Regulatory Inspections. If any
Regulatory Authority (i) contacts a Party, its Affiliates or their
respective licensees or Sublicensees with respect to the alleged
improper Development, Manufacture or Commercialization of any
Licensed Product; (ii) conducts, or gives notice of its intent to
conduct, an inspection at such Party’s, its Affiliate’s
or licensee’s or Sublicensee’s facilities used in the
Development or Manufacturing of Licensed Product or (iii) takes, or
gives notice of its intent to take, any other regulatory action
with respect to any activity of such Party, its Affiliates or
licensees or Sublicensees that could reasonably be expected to
materially adversely affect any Development, Manufacture or
Commercialization activities with respect to the Licensed Product,
whether in or outside the Territory, then such will promptly notify
the other Party of such contact, inspection or notice and shall
provide the other Party with copies of all materials,
correspondence, statements, forms and records filed with or
received from the Regulatory Authority in connection
therewith.

 

 

ARTICLE 6 SUPPLY

 

6.1            

Supply. Subject to the first sentence of
Section 6.2(a), before the completion of the manufacturing
technology transfer under Section 6.2(b), EverInsight shall
exclusively obtain its supply of Licensed Product from VistaGen,
and VistaGen shall supply to EverInsight all the Licensed Product
requested by EverInsight for Development in the Territory
[*****].
Nothing will prevent VistaGen from manufacturing or having
manufactured all or any portion of the Licensed Product in the
Territory.

 

6.2            

Potential Alternative
Suppliers.

 

(a)            

The Parties will
collaborate and jointly explore opportunities for identification
and qualification of alternative suppliers of the Licensed Product
with the mutual intent of reducing substantially the Cost of Goods
for the supply of the Licensed Product, for EverInsight, its
Affiliates, licensees and sublicensees after Regulatory Approval in
the Territory and for VistaGen and its Affiliates, licensees and
sublicensees outside the Territory after Regulatory

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-32-

 

 

Approval.
Upon mutual identification and qualification of such alternative
supplier(s) capable of reducing substantially the Cost of Goods for
the supply of the Licensed Product, VistaGen shall, pursuant to
Section 6.4, conduct a technology transfer of all relevant
manufacturing process it possesses to such alternative supplier(s)
to allow the Parties to obtain supply of Licensed Product from such
alternative supplier(s) at reduced Cost of Goods.

 

(b)            

If the Parties are
unable to agree on the alternative supplier(s) under Section 6.2(a)
before the [*****],
then, at EverInsight’s option and at no additional cost,
VistaGen will, pursuant to Section 6.4, conduct a technology
transfer of all relevant manufacturing processes it possesses to
EverInsight or a Third Party manufacturer(s) that has been chosen
by EverInsight for commercial supply in the Territory. VistaGen
shall make a good faith effort to complete such technology transfer
within [*****]
days of EverInsight’s selection of the manufacturer(s)
(“Manufacturing Transfer
Period”). The Parties agree on a timely and proactive
sharing of manufacturing data to facilitate such manufacture
technology transfer. This data sharing might be done through the
JSC or through a Joint Manufacturing Committee that may be
established by the Parties.

 

6.3            

Supply Agreement.

 

(a)            

Initial Supply Agreement. VistaGen and
EverInsight agree to negotiate in good faith within [*****]
days after the Effective Date a separate agreement concerning the
short-term supply of the Compound and Licensed Product for
EverInsight’s Development use (including preclinical and/or
clinical use) (the “Initial
Supply Agreement”), [*****].
Under this Initial Supply Agreement, EverInsight shall provide
written notice to VistaGen with rolling forecasts (at least
quarterly) promptly following its decision on initiating
preclinical experiments or clinical trials. Notwithstanding the
foregoing, nothing in this Agreement nor the Initial Supply
Agreement shall restrict, impair or otherwise limit
VistaGen’s ability to manufacture the Compound or Licensed
Product in the Territory for use outside the Territory. The Initial
Supply Agreement shall include language on VistaGen’s
Commercially Reasonable Efforts to reduce the manufacturing costs
and an audit right for EverInsight to review such manufacturing
costs

 

(b)            

Commercial Supply Agreement. Upon
EverInsight’s request, VistaGen shall introduce EverInsight
to VistaGen’s contract manufacturer(s) and reasonably
cooperate with EverInsight in its negotiation of a commercial
supply agreement for the Licensed Product directly with such
contract manufacturer(s).

 

(c)            

Quality Agreement. In connection with
negotiation of the Initial Supply Agreement, VistaGen and
EverInsight agree to negotiate in good faith a separate agreement
concerning the quality of the Compound and Licensed Product
supplied by VistaGen to EverInsight (the “Quality
Agreement”). The Quality Agreement might either be an
attachment of the Initial Supply Agreement or a
stand-alone-agreement. Such Quality Agreement will include language
about the acceptance criteria and ways to handle failures of the
quality criteria among other terms.

 

6.4            

Manufacturing Technology Transfer. In
order to enable the Parties to have Manufactured the Compound and
Licensed Product by the mutually-designated
Third-Party

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-33-

 

 

manufacturer(s)
consistent with the terms of Section 6.2(a) (Potential Alternative
Suppliers), or if such mutually agreed Third-Party manufacturer
cannot be found by the [*****],
to enable EverInsight to Manufacture or have Manufactured the
Compound and Licensed Product for the Territory pursuant to Section
6.2(b), VistaGen shall (a) perform or facilitate technology
transfer to such mutually-designated Third Party manufacturer,
EverInsight or the Third Party manufacturer selected by EverInsight
(the “Designated
Manufacturer(s)”) as is necessary or reasonably useful
in the Manufacture of the Compound and Licensed Product and as of
such date are being used by VistaGen or VistaGen CMO (as defined
below) to Manufacture the Compound and Licensed Product (the
“Licensed Manufacturing
Know-How”) solely for the Designated Manufacturer(s)
to Manufacture the Compound and Licensed Products in accordance
with the terms and conditions of this Agreement; (b) identify in
writing all Subcontractors who Manufacture Compounds or Licensed
Product for VistaGen (each, an “VistaGen CMO”); and (c) provide
technical assistance (both on site and otherwise) in the transfer
and demonstration of the Licensed Manufacturing Know-How that is
necessary to Manufacture the Compound and Licensed Product. To the
extent that any Licensed Manufacturing Know-How is in the Control
of VistaGen but is in the possession of a VistaGen CMO (and is not
in VistaGen’s possession), then during the Manufacturing
Transfer Period, VistaGen will use Commercially Reasonable Efforts
to facilitate the transfer of such Licensed Manufacturing Know-How
from such VistaGen CMO to the Designated Manufacturer(s), and/or
cause such VistaGen CMO to make such Licensed Manufacturing
Know-How available to the Designated Manufacturer(s). VistaGen
shall be solely responsible for the cost and expense of such
technology transfer and no payment shall be due from EverInsight to
VistaGen or any Third Party (including VistaGen CMO) for such
technology transfer.

 

 

ARTICLE 7 COMMERCIALIZATION

 

7.1            

General. Subject to the terms and
conditions of this Agreement and the Commercialization Plan,
EverInsight shall be responsible for all aspects of the
Commercialization of the Licensed Product in the Licensed Field in
the Territory, including: (a) developing and executing a commercial
launch and pre-launch plan, (b) negotiating with applicable
Government Authorities regarding the price and reimbursement status
of the Licensed Product and obtaining and maintaining Pricing
Approvals; (c) marketing, medical affairs, and promotion; (d)
booking sales and distribution and performance of related services;
(e) subject to the provisions of Section 5.5 (Recalls, Suspensions
or Withdrawals) handling all aspects of order processing, invoicing
and collection, inventory and receivables; (f) providing customer
support, including handling medical queries, and performing other
related functions; and (g) conforming its practices and procedures
to Applicable Laws relating to the marketing, detailing and
promotion of Licensed Product in the Licensed Field in the
Territory. As between the Parties, EverInsight shall be solely
responsible for the costs and expenses of Commercialization of the
Licensed Product in the Licensed Field in the
Territory.

 

7.2            

Commercialization Plan. EverInsight
shall conduct all Commercialization of Compound and Licensed
Product in the Licensed Field in the Territory in accordance with a
commercialization plan (as amended from time to time in accordance
with this Agreement, the “Commercialization Plan”), the
initial version of which EverInsight will prepare and provide
to

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-34-

 

 

the JSC
no later than [*****]
prior to the anticipated First Commercial Sale of Licensed Product
in the Licensed Field in the Territory and which initial
Commercialization Plan shall be subject to the review (but not
approval) of the Parties through the JSC. From time to time, but at
least once every Calendar Year, EverInsight will update the
Commercialization Plan and submit such updated plan to the JSC for
review and discussion. If any updated Commercialization Plan omits
details that a VistaGen representative reasonably believes is
necessary for (i) the proper functioning of the JSC or (ii) to
verify EverInsight’s compliance with its obligations under
this Agreement, then EverInsight shall take into reasonable
consideration such comments and, if necessary, further update such
Commercialize Plan. If the terms of the Commercialization Plan
contradict, or create inconsistencies or ambiguities with, the
terms of this Agreement, then the terms of this Agreement shall
govern.

 

7.3            

Commercial Diligence. Upon Regulatory
Approval of a Licensed Product in mainland China or South Korea,
EverInsight, directly and/or with or through Affiliates or
Sublicensees, shall use Commercially Reasonable Efforts to
Commercialize such Licensed Product in the Licensed Field in such
jurisdiction.

 

 

ARTICLE 8 FINANCIAL PROVISIONS

 

8.1            

Upfront Payment.

 

(a)            

As partial
consideration of the rights granted by VistaGen to EverInsight
hereunder, within thirty (30) Business Days after the Effective
Date, EverInsight shall pay to VistaGen a one-time, non-refundable
and non-creditable upfront payment of five million Dollars
($5,000,000).

 

8.2            

Regulatory Milestone
Payments.

 

(a)            

As additional
consideration of the rights granted by VistaGen to EverInsight
hereunder, within [*****]
calendar days after the first achievement of the regulatory
milestone events below (“Regulatory Milestone Events”) by or on behalf
of EverInsight or any of its Affiliates or Sublicensees,
EverInsight or its Affiliate or Sublicensee shall notify VistaGen
of the achievement of such Regulatory Milestone Event. The
Regulatory Milestone Event triggers the corresponding milestone
payment due to VistaGen (“Milestone Payment”) and VistaGen
shall invoice EverInsight for the applicable non-refundable,
non-creditable Milestone Payment corresponding to the Regulatory
Milestone Event as shown below, and EverInsight shall remit payment
within [*****]
Business Days of the receipt of such invoice, as described in
Section 8.6 (Currency; Exchange Rate; Payments). For clarity, each
Regulatory Milestone Payment set forth above shall be due and
payable only once upon the first achievement of the corresponding
Regulatory Milestone Event, regardless of how many times such
Regulatory Milestone Event is achieved in the
Territory.

 

●

Regulatory
Milestone Event for Licensed Product Regulatory Milestone Payment
(in U.S. Dollars):

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-35-

 

 

 

(1)
[*****].

 

(2)
[*****].

 

8.3            

Commercial Milestones.

 

(a)            

Within [*****]
calendar days after the end of the first Calendar Year in which
aggregate annual Net Sales for that Calendar Year for the Licensed
Product in the Territory reach any threshold indicated in the
Commercial Milestone Events listed below, EverInsight shall notify
VistaGen of the achievement of such Commercial Milestone Event and
VistaGen shall invoice EverInsight for the corresponding
non-refundable, non-creditable Milestone Payment set forth below
and EverInsight shall remit payment to VistaGen within [*****]
Business Days after the receipt of the invoice, as described in
Section 8.6 (Currency; Exchange Rate; Payments).

 

Annual
Net Sales Milestones for Licensed Product Milestone Payments (in
Dollars) (each a “Commercial
Milestone Event”):

 

(1).
[*****]

 

(2).
[*****]

 

(3).
[*****]

 

(4).
[*****]

 

(5).
[*****]

 

(b)            

For the purposes of
determining whether a Net Sales Milestone Event has been achieved,
Net Sales of Licensed Product(s) in the Territory shall be
aggregated. For clarity, the annual Net Sales Milestone Payments
set forth in this Section 8.3 (Commercial Milestones) shall be
payable only once, upon the first achievement of the applicable
Commercial Milestone Event, regardless of how many times such
Commercial Milestone Event is achieved.

 

(c)            

If a Commercial
Milestone Event in Section 8.3 (Commercial Milestones) is achieved
and payment with respect to any previous Commercial Milestone Event
in Section 8.3 has not been made, then such previous Commercial
Milestone Event shall be deemed achieved and EverInsight shall
notify VistaGen within fifteen (15) calendar days of such
achievement. VistaGen shall then invoice EverInsight for such
unpaid previous Commercial Milestone Event(s) and EverInsight shall
pay VistaGen such unpaid previous milestone payment(s) within
thirty (30) Business Days of receipt of such invoice.

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-36-

 

 

(d)            

In the event that,
VistaGen believes any Commercial Milestone Event under Section
8.3(a) has occurred but EverInsight has not given VistaGen the
notice of the achievement of such Commercial Milestone Event, it
shall so notify EverInsight in writing and shall provide to
EverInsight data, documentation or other information that supports
its belief. Any dispute under this Section 8.3(d) (Commercial
Milestones - subsection (d)) that relates to whether or not a
Commercial Milestone Event has occurred shall be referred to the
JSC to be resolved in accordance with ARTICLE 3 (Governance) and
shall be subject to resolution in accordance with Section 14.10
(Dispute Resolution). The Milestone Payments made for each
Commercial Milestone Event shall be non-creditable and
non-refundable.

 

8.4            

Royalty Payments.

 

(a)            

Royalty Rate. Subject to the terms and
conditions of this Agreement (including Section 8.5), in partial
consideration of the rights granted by VistaGen to EverInsight
hereunder, EverInsight shall pay to VistaGen non-refundable,
non-creditable royalties based on the aggregate Net Sales of all
Licensed Product sold by EverInsight, its Affiliates and/or its or
their respective Sublicensees in the Territory during a Calendar
Year at the rates set forth in the table below. The obligation to
pay royalties will be imposed only once with respect to the same
unit of a Licensed Product.

 

Calendar Year Net
Sales (in Dollars) for all Licensed Product in the Territory
Royalty Rates as a Percentage (%) of Net Sales

 

(1).
[*****]

 

(2).
[*****]

 

(b)            

Royalty Term. Royalties under this
Section 8.4 (Royalty Payments) shall be payable on a
jurisdiction-by-jurisdiction and Licensed Product-by-Licensed
Product basis from the First Commercial Sale of a Licensed Product
in a jurisdiction until the latest to occur of: (i) expiration of
the last‐to‐expire Valid Claim that effectively
provides market exclusivity of such Licensed Product in such
jurisdiction in the Territory; (ii) expiration of Regulatory
Exclusivity for such Licensed Product in such Jurisdiction in the
Territory; and (iii) ten (10) years after the First Commercial Sale
of the Licensed Product in such jurisdiction in the Territory (the
“Royalty Term”
for the Licensed Product in the relevant jurisdiction). After
expiration of the Royalty Term for a particular Licensed Product in
a particular jurisdiction, the license granted by VistaGen to
EverInsight hereunder shall continue and shall become fully
paid-up, royalty free, perpetual and irrevocable with respect to
such Licensed Product in such jurisdiction.

 

(c)            

Royalty Reports and Payment. Within
ninety (90) calendar days after each Calendar Quarter of each
Calendar Year, commencing with the Calendar Quarter during which
the First Commercial Sale of any Licensed Product is made anywhere
in the Territory, EverInsight shall provide VistaGen with a report
that contains the following information for the applicable Calendar
Quarter, on a jurisdiction-by-jurisdiction basis:

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-37-

 

 

(A) Net
Sales in the Territory; (B) a calculation of the royalty payment
due on Net Sales in the Territory; and (C) the exchange rates used.
After the receipt of such royalty report, VistaGen shall invoice
EverInsight for the royalty payment set forth in such royalty
report. Within thirty (30) Business Days after the receipt of the
invoice, EverInsight will pay VistaGen all royalties owed with
respect to Net Sales for such Calendar Quarter. If, during the
following Calendar Quarter, EverInsight discovers that it reported
an incorrect amount of Net Sales in the Territory and/or the
amounts payment due on such Net Sales in the immediately preceding
Calendar Quarter, then EverInsight may, subject to review by
VistaGen, adjust and reconcile any such calculation of Net Sales
and/or any such underpayment or overpayment of royalty payments
due, and shall timely report the same within thirty (30) calendar
days after such following Calendar Quarter.

 

8.5            

Royalty Adjustments. Except as otherwise
set forth in this Agreement, royalties due hereunder are subject to
adjustment as set forth below (such adjustments to be prorated for
the Calendar Quarter in which the adjustment becomes
applicable):

 

(a)            

Royalty Adjustment for Patent
Expiration. In the event that in any jurisdiction in the
Territory in any Calendar Quarter during the Royalty Term for a
Licensed Product, there is no Valid Claim that provides effective
market exclusivity for such Licensed Product (or the Compound
contained in such Licensed Product) in such jurisdiction in such
Calendar Quarter, then the royalty rate set forth in Section 8.4(a)
(Royalty Rate) with respect to such Licensed Product in such
jurisdiction in such Calendar Quarter shall be reduced by
[*****];

 

(b)            

Royalty Adjustment for Generic
Competition. In the event that in any jurisdiction in the
Territory in any Calendar Quarter during the Royalty Term for a
Licensed Product, there is Generic Competition for such Licensed
Product in such jurisdiction in such Calendar Quarter, then the
royalty rate set forth in Section 8.4(a) (Royalty Rate) with
respect to such Licensed Product in such jurisdiction in such
Calendar Quarter shall be reduced by [*****]
(provided however that the royalty reduction under Section 8.5(a)
shall not apply to such Licensed Product in such jurisdiction in
such Calendar Quarter if the royalty reduction under Section 8.5(b)
applies).

 

8.6            

Currency; Exchange Rate; Payments. All
payments required to be made by EverInsight under this Agreement
shall be made in Dollars. All payments payable to, or invoiced from
or on behalf of, VistaGen shall be paid bank wire transfer in
immediately available funds to one or more bank accounts of
VistaGen as designated in written notice from VistaGen. If any
currency conversion shall be required in connection with any
payment hereunder, such conversion shall be made by using the
exchange rates at the closing on the last Business Day of the
Calendar Quarter to which such payment relates as reported in The
Wall Street Journal on the following day.

 

8.7            

Late Payments. Any payments or portions
thereof due hereunder that are not paid on the date such payments
are due under this Agreement shall bear interest at an annual rate
equal to two (2) percentage points above the prime rate as
published by The Wall Street Journal or any

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-38-

 

 

 

successor
thereto on the first day of each Calendar Quarter in which such
payments are overdue calculated on the number of days such payment
is delinquent.

 

8.8            

Taxes.

 

(a)            

Taxes on Income. Notwithstanding
anything else set forth in this Section 8.8 (Taxes), each Party
shall solely bear and pay all Taxes imposed on such Party’s
net income or gain (however denominated) arising directly or
indirectly from the activities of the Parties under this
Agreement.

 

(b)            

Tax Payments. The upfront payment,
milestone payments, royalties, and any other payment payable by
EverInsight to VistaGen pursuant to this Agreement (each, a
“Payment”) shall
be paid free and clear of any and all Taxes (which, for clarity,
shall be the responsibility of EverInsight), except for any Taxes
required by Applicable Laws to be withheld or deducted. The Parties
agree to cooperate with one another and use reasonable efforts to
avoid or reduce Tax withholding or similar obligations in respect
of the payments made under this Agreement. To the extent
EverInsight is required to deduct and withhold Taxes on any payment
to VistaGen, EverInsight shall deduct those Taxes from the
remittable payment, pay the Taxes to the proper tax authority in a
timely manner, and promptly send proof of payment to VistaGen.
VistaGen shall provide EverInsight any tax forms that may be
reasonably necessary in order for EverInsight to not withhold tax
or to withhold tax at a reduced rate under an applicable bilateral
income tax treaty. VistaGen shall use reasonable efforts to provide
any such tax forms to EverInsight in advance of the due
date.

 

8.9            

Financial Records and Audit. EverInsight
shall (and shall ensure that its Affiliates and Sublicensees will)
maintain complete and accurate books and records pertaining to the
Commercialization of Licensed Product hereunder, including books
and records of invoiced sales and Net Sales of Licensed Product, in
sufficient detail to calculate and verify all amounts payable
hereunder and in sufficient detail to permit VistaGen to confirm
the accuracy of any royalty payments, other amounts paid or payable
under this Agreement and to verify the achievement of Milestone
Events under this Agreement. EverInsight shall and shall cause its
Affiliates and its and their Sublicensees to, retain such books and
records until the later of (a) three (3) years after the end of the
period to which such books and records pertain; (b) the expiration
of the applicable tax statute of limitations (or any extensions
thereof); and (c) for such period as may be required by Applicable
Laws. Upon at least thirty (30) Business Days’ prior notice,
such records shall be open for examination, during regular business
hours, for a period of three (3) Calendar Years from the end of the
Calendar Year to which such records pertain, and not more often
than once each Calendar Year, by an independent and internationally
recognized certified public accountant selected by VistaGen and
reasonably acceptable to EverInsight, for the sole purpose of
verifying for VistaGen the accuracy of the financial reports
furnished by EverInsight under this Agreement or of any payments
made, or required to be made, by EverInsight to VistaGen pursuant
to this Agreement. The independent public accountant shall disclose
to VistaGen only (x) the accuracy of Net Sales reported and the
basis for royalty, Milestone Payments and any other payments made
to VistaGen under this Agreement and (y) the difference, if any, by
which such reported and paid amounts vary from amounts determined
as a result of the audit and the

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-39-

 

 

details
concerning such difference. Except as required by Applicable Laws,
no other information shall be provided to VistaGen. No record may
be audited more than once. VistaGen shall bear the full cost of
such audit unless such audit reveals an underpayment by EverInsight
of more than one hundred thousand Dollars ($100,000) or five
percent (5%) of the amount actually due (whichever is greater) for
any Calendar Year being audited, in which case EverInsight shall
reimburse VistaGen for the reasonable costs and expenses for such
audit. Unless disputed pursuant to Section 8.10 (Audit Dispute),
EverInsight shall pay to VistaGen any underpayment discovered by
such audit within thirty (30) days after the accountant’s
report, plus interest (as set forth in Section 8.7 (Late Payments))
from the original due date. If the audit reveals an overpayment by
EverInsight, then EverInsight may take a credit for such
overpayment against any future payments due to VistaGen and, if
there will be no future payment due, VistaGen shall promptly refund
such overpayment to EverInsight.

 

8.10            

Audit Dispute. If EverInsight disputes
the results of any audit conducted pursuant to Section 8.9
(Financial Records and Audit), the Parties shall work in good faith
to resolve the disagreement. If the Parties are unable to reach a
mutually acceptable resolution of any such dispute within thirty
(30) days, the dispute shall be submitted for resolution to a
certified public accounting firm jointly selected by each
Party’s certified public accountants or to such other Person
as the Parties shall mutually agree (the “Auditor”). The decision of the
Auditor shall be final and the costs of such procedure shall be
borne between the Parties in such manner as the Auditor shall
determine. If the Auditor determines that there has been an
underpayment by EverInsight, EverInsight shall pay to VistaGen the
underpayment within thirty (30) days after the Auditor’s
decision, plus interest (as set forth in Section 8.7 (Late
Payments)) from the original due date. If the Auditor determines
that there has been an overpayment by EverInsight, then EverInsight
may take a credit for such overpayment against any future payments
due to VistaGen and, if there will be no future payment due,
VistaGen shall promptly refund such overpayment to
EverInsight.

 

 

ARTICLE 9 INTELLECTUAL PROPERTY RIGHTS

 

9.1            

Ownership
of Intellectual Property

 

(a)            

Ownership of Technology. As between the
Parties:

 

(1)            

VistaGen shall
solely own on a worldwide basis all right, title and interest in
and to any and all VistaGen Sole Inventions, whether or not
patented or patentable, and any and all VistaGen Sole Invention
Patents; and

 

(2)            

EverInsight shall
solely own on a worldwide basis all right, title and interest in
and to any and all EverInsight Sole Inventions, whether or not
patented or patentable, and any and all EverInsight Sole Invention
Patents.

 

For
clarity, each Party shall own on a worldwide basis and retain all
right, title and interest in and to any and all Know-How,
Inventions, Patents and other intellectual property rights that are
owned or otherwise Controlled (other than pursuant to the
license

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-40-

 

 

grants
set forth in Section 2.1 (Licenses to EverInsight) and 2.2 (License
to VistaGen)) by such Party or its Affiliates or its or their
(sub)licensees (or Sublicensees) (as applicable) outside of this
Agreement.

 

(b)            

Ownership of Joint Patents and Joint
Inventions. As between the Parties:

 

(1)            

Each of VistaGen
and EverInsight shall own an equal, undivided interest in any and
all Joint Inventions and Joint Invention Patents; and

 

(2)            

Each of VistaGen
and EverInsight shall promptly disclose to the other in writing,
and shall cause its Affiliates and its and their respective
Sublicensees to so disclose, the development, making, conception or
reduction to practice of any Joint Inventions. Subject to the
licenses granted under Section 2.1 (License to EverInsight) and
Section 2.2 (License to VistaGen), each of VistaGen and EverInsight
shall have the right to Exploit the Joint Inventions and Joint
Invention Patents without the duty of accounting or seeking consent
from the other Party.

 

(c)            

United States Law. The determination of
whether Inventions, Know-How and other intellectual property rights
are conceived, discovered, developed or otherwise made by a Party
for the purpose of allocating proprietary rights (including Patent,
copyright or other intellectual property rights) therein, shall,
for purposes of this Agreement, be made in accordance with
Applicable Laws in the United States as such law exists as of the
Effective Date irrespective of where or when such conception,
discovery, development or making occurs; provided that if the
application of such United States Applicable Laws prevents or
materially impairs the proper prosecution or maintenance of Patent
Rights in any jurisdiction in the Territory, then the Parties shall
mutually agree to the application of an appropriate Applicable Laws
in order to best advance and maintain the prosecution and
maintenance of such Patents in such jurisdiction in the Territory.
Each of VistaGen and EverInsight shall, and does hereby, assign,
and shall cause its Affiliates and its and their (sub)licensees and
Sublicensees to so assign, to the other Party, without additional
compensation, such right, title and interest in and to any
Inventions, Know-How, Patents and other intellectual property
rights with respect thereto, as is necessary to fully effect, as
applicable, the sole or joint ownership as provided for in Section
9.1(a) (Ownership of Technology) or 9.1(b) (Ownership of Joint
Patents and Joint Inventions); subject to the license granted under
this Agreement.

 

(d)            

Assignment Obligation. Each Party shall
cause all Persons who perform Development activities, Manufacturing
activities or regulatory activities for such Party under this
Agreement or who conceive, discover, develop or otherwise make any
Inventions, Know-How or other intellectual property rights by or on
behalf of either Party or its Affiliates or its or their
(sub)licensees (or Sublicensees) under or in connection with this
Agreement to be under an obligation to assign to such Party their
rights in any Inventions, Know-How, Patents and other intellectual
property to the extent related to the Compound or Licensed Product,
except where Applicable Laws requires otherwise and except in the
case of governmental, not-for-profit and public institutions that
have standard policies against such an assignment and except in the
case of generally

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-41-

 

 

applicable (i.e.,
applicable generally to products other than the Licensed Product)
Inventions, Know-How, Patents and other intellectual property (in
each case, a suitable license or right to obtain such a license,
shall be obtained).

 

(e)            

Ownership of Product Trademarks. Subject
to Section 11.3 (Effect of Termination), as between the Parties,
(i) EverInsight shall own all right, title and interest in and to
the Product Trademarks in the Territory, (ii) EverInsight shall
have the right to market the Licensed Product in the Licensed Field
in the Territory under the Product Trademarks and all goodwill
associated therewith will inure to the benefit of EverInsight and
(iii) VistaGen may not use the Product Trademarks without obtaining
a proper trademark license from EverInsight (except to the extent
necessary to perform its obligations under this
Agreement).

 

(f)            

Ownership of Corporate Names. As between
the Parties, each Party shall retain all right, title and interest
in and to its Corporate Names.

 

(g)            

Ownership of Development Data. Subject
to ARTICLE 2 (Licenses) and Section 11.3 (Effect of Termination),
EverInsight shall own EverInsight Development Data and VistaGen
shall own VistaGen Development Data.

 

9.2            

Patent Prosecution and
Maintenance.

 

(a)            

VistaGen shall have
the first right, but not the obligation, to control the
preparation, filing, prosecution (including any interferences,
reissue proceedings and reexaminations) and maintenance of all
Licensed Patents and Joint Patents, both in and outside the
Territory, by counsel of its own choice, except that such counsel
in the Territory shall be reasonably acceptable to EverInsight
(such acceptance not to be unreasonably withheld, delayed or
conditioned). VistaGen shall consult with EverInsight and keep
EverInsight informed of the status of such Patents in the Territory
and also in the US and EU, and shall promptly provide EverInsight
with all material correspondence received from any patent authority
in the Territory and also in the US and EU in connection therewith.
In addition, VistaGen shall promptly provide EverInsight with
drafts of all proposed material filings and correspondence to any
patent authority in the Territory and also in the US and EU with
respect to such Patents for EverInsight’s review and comment
at least thirty (30) days prior to the submission of such proposed
filings and correspondence. VistaGen shall confer with EverInsight
and consider in good faith EverInsight’s comments prior to
submitting such filings and correspondence, provided that
EverInsight provides such comments within fifteen (15) days (or a
shorter period reasonably designated by VistaGen if fifteen (15)
days is not practicable given the filing deadline) of receiving the
draft filings and correspondence from VistaGen. VistaGen shall also
keep EverInsight informed as to the payment schedule for patent
maintenance fee for the Licensed Patents and Joint Patents.
VistaGen shall be responsible for the costs and expenses incurred
by VistaGen for the preparation, filing, prosecution and
maintenance of the Licensed Patents and Joint Patents both in and
outside the Territory. For the avoidance of doubt, VistaGen shall
be responsible for all costs incurred prior to the Effective Date
with respect to the prosecution and maintenance of any
Licensed

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-42-

 

 

Patents. If
EverInsight reasonably determines that a Licensed Patent added
after the Effective Date (other than Patent Rights added by an
In-License Agreement that EverInsight has accepted pursuant to
Section 2.4(b)(1) (In-License Agreements)) or Joint Patent that
EverInsight subsequently determines is of low value to EverInsight,
then EverInsight has the right upon at least sixty (60) days’
prior written notice to remove such Licensed Patent or Joint Patent
from the Licensed Technology hereunder, in which case, following
delivery of such notice to VistaGen, (1) the license of Licensed
Technology to EverInsight under Section 2.1 (License to
EverInsight) as to such Licensed Patent or Joint Patent shall be
terminated; (2) the claims of such Licensed Patent or Joint Patent,
as the case may be, shall be excluded from Valid Claim; and (3) if
requested by VistaGen, EverInsight shall assign, and shall cause
its Affiliates and its and their (sub)licensees and Sublicensees to
so assign, to VistaGen, without additional compensation,
EverInsight’s right, title and interest in and to the
relevant Joint Patent (provided that EverInsight shall retain a
non-exclusive, fully paid, royalty free, sublicenseable (through
multiple tiers), perpetual and irrevocable license and right under
the Joint Patent assigned to VistaGen).

 

(b)            

In the event that
VistaGen desires to abandon or cease prosecution or maintenance of
any Licensed Patent in the Territory (or any jurisdiction therein)
or any Joint Patent anywhere in the world, VistaGen shall provide
reasonable prior written notice to EverInsight of such intention to
abandon (which notice shall, to the extent possible, be given no
later than thirty (30) days prior to the next deadline for any
action that must be taken with respect to any such Patent in the
relevant patent office). In such case, upon EverInsight’s
written election provided no later than twenty (20) days after such
notice from VistaGen, EverInsight shall have the right to assume
prosecution and maintenance of such Licensed Patent or Joint Patent
at EverInsight’s sole cost and expense. If EverInsight does
not provide such election within twenty (20) days after such notice
from VistaGen, VistaGen may, in its sole discretion, abandon or
cease prosecution and maintenance of such Patent in the Territory
(or the relevant jurisdiction).

 

(c)            

EverInsight shall
have the sole right, but not the obligation, to control the
preparation, filing, prosecution (including any interferences,
reissue proceedings and reexaminations) and maintenance of all
EverInsight Patents throughout the world, at EverInsight’s
own cost and expense.

 

9.3            

Cooperation of the Parties. Each Party
agrees to cooperate fully in the preparation, filing, prosecution
and maintenance of Patents under Section 9.2 (Patent Prosecution
and Maintenance), at its own cost. Such cooperation includes: (a)
executing all papers and instruments, or requiring its employees or
contractors, to execute such papers and instruments, so as enable
the applicable Party to apply for and to prosecute patent
applications in any country as permitted by Section 9.2 (Patent
Prosecution and Maintenance); and (b) promptly informing the other
Party of any matters coming to such Party’s attention that
may affect the preparation, filing, prosecution or maintenance of
any such patent applications.

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-43-

 

 

 

9.4            

Infringement by Third
Parties.

 

(a)            

Notice. In the event that either
VistaGen or EverInsight becomes aware of any infringement or
threatened infringement by a Third Party of any Licensed Patent or
Joint Patent in and/or outside the Territory, which infringing
activity involves the using, making, importing, offering for sale
and/or selling of a Licensed Product or any product that falls
within the scope of the Licensed Patents (regardless of whether or
not EverInsight and/or VistaGen is currently Developing using,
making, importing, offering for sale, selling, and/or otherwise
Commercializing the same Licensed Product), or the submission to a
Party or a Regulatory Authority in and/or outside the Territory of
an application for a product referencing a Licensed Product, or any
declaratory judgment or equivalent action challenging any Licensed
Patent or Joint Patent in and/or inside the Territory in connection
with any such infringement (each, a “Product Infringement”), it will
promptly notify the other Party in writing to that effect. Any such
notice shall include evidence to support an allegation of
infringement or threatened infringement, or declaratory judgment or
equivalent action, by such Third Party.

 

(b)            

Enforcement of Licensed Patents and Joint
Patents. To the extent permitted by the Pherin License,
EverInsight shall have the first right, as between VistaGen and
EverInsight, but not the obligation, to bring an appropriate suit
or take other action against any Person or entity engaged in, or to
defend against, such Product Infringement in the Territory of any
Licensed Patent or Joint Patent, at its own expense and by counsel
of its own choice. VistaGen shall have the right, at its own
expense, to be represented in any such action in the Territory by
counsel of its own choice, and EverInsight and its counsel will
reasonably cooperate with VistaGen and its counsel in strategizing,
preparing and prosecuting any such action or proceeding. If
EverInsight fails to bring an action or proceeding in the Territory
with respect to such Product Infringement of any Licensed Patent or
Joint Patent within (A) ninety (90) days following the notice of
alleged infringement or declaratory judgment or (B) sixty (60) days
before the time limit, if any, set forth in the Applicable Laws for
the filing of such actions, whichever comes first, VistaGen shall
have the right, but not the obligation, to bring and control any
such action in the Territory at its own expense and by counsel of
its own choice, and EverInsight shall have the right, at its own
expense, to be represented in any such action by counsel of its own
choice. Except as otherwise agreed by the Parties as part of a
cost-sharing arrangement, any recovery or damages realized as a
result of such action or proceeding with respect to Product
Infringement of any Licensed Patent or Joint Patent, or settlement
of the same, shall be used (A) first, to reimburse the
Parties’ documented out-of-pocket legal expenses relating to
the action or proceeding; and (B) any remainder after such
reimbursement is made shall be retained by the enforcing Party,
provided, that if EverInsight is the enforcing Party, then to the
extent that any award or settlement (whether by judgment or
otherwise) with respect to any Licensed Patent or Joint Patent is
attributable to loss of sales or profits with respect to a Licensed
Product in the Licensed Field in the Territory, such amounts
(except punitive damages) that may be recovered or realized by
EverInsight after reimbursement of enforcement cost shall be
considered Net Sales and subject to the royalty obligations under
Section 8.4 (Royalty Payments) and the commercial Milestone Payment
obligations under Section 8.3 (Commercial Milestones)

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-44-

 

 

(provided that such
amount shall be evenly spread (on Calendar Quarterly basis) over
the time period during which the lost sales or profits occurred for
the purpose of determine aggregate annual Net Sales, royalty tiers
and achievement of commercial milestones). Notwithstanding anything
to the contrary in this Article 9, in the event that patent
enforcement or patent defense litigation regarding the Licensed
Patents occurs in multiple countries, within or outside the
Territory, then VistaGen shall have the first right but not the
obligation to bring an appropriate suit or take other appropriate
action.

 

(c)            

Cooperation. In the event a Party brings
an action in accordance with this Section 9.4 (Infringement by
Third Parties), the other Party shall cooperate fully at its own
expense, including, if required to bring such action, and providing
access to relevant documents and other evidence including, without
limitation, making its employees available at reasonable business
hours to the Party’s counsel for all pre-trial and trial
proceedings, as well as the furnishing of a power of attorney or
being named as a party to such action as may reasonably be
necessary.

 

(d)            

Other Infringement. VistaGen shall have
the sole right, but not the obligation, to bring and control, at
its own cost and expense, any legal action in connection with any
Product Infringement of any Licensed Patent or Joint Patent outside
the Territory and any legal action in connection with any
infringement of any Licensed Patent that is not a Product
Infringement; provided, however, that such legal action is not
combined with a legal action involving a Product Infringement. The
Parties shall jointly control any legal action in connection with
any infringement of any Joint Patent anywhere in the world that is
not a Product Infringement and is not combined with a Product
Infringement legal action. Any recovery or damages realized as a
result of such action or proceeding with respect to Product
Infringement of any Licensed Patent or Joint Patent shall be used
(A) first, but only if a Joint Patent was the subject of such legal
action, to reimburse the Parties’ documented out-of-pocket
legal expenses relating to such action or proceeding; and (B) any
remainder after such reimbursement, if applicable, shall be
retained by the Party initiating such action or proceeding (or, in
the case of Joint Patent, shared by the Parties
equally).

 

(e)            

Effect of Pherin License. The Parties
acknowledge that provisions of the Pherin License may affect the
standing and ability of a Party to bring and control infringement
litigation, notwithstanding the contemplated allocation of
litigation-related enforcement rights as between the Parties in
this Agreement.

 

9.5            

Infringement Claims by Third Parties. If
the Exploitation of a Licensed Product in the Licensed Field in the
Territory pursuant to this Agreement results in, or is reasonably
expected to result in, any claim, suit or proceeding by a Third
Party against EverInsight or any of its Affiliates or Sublicensees
alleging infringement by EverInsight or any of its Affiliates or
its or their Sublicensees, distributors or customers (a
“Third Party Infringement
Claim”), including any defense or counterclaim in
connection with a Product Infringement action initiated pursuant to
Section 9.4(b) (Enforcement of Licensed Patents and Joint Patents),
the Party first becoming aware of such alleged infringement shall
promptly notify the other Party thereof in writing. As between the
Parties, subject to ARTICLE 13 (Indemnification; Liability): (a)
VistaGen shall be

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-45-

 

 

responsible
for defending any such claim, suit or proceeding at its sole cost
and expense, using counsel of VistaGen’s choice; (b)
EverInsight may participate in any such claim, suit or proceeding
with counsel of its choice at its sole cost and expense; provided
that VistaGen shall retain the right to control such claim, suit or
proceeding; (c)EverInsight shall, and shall cause its Affiliates
to, assist and co-operate with VistaGen, as VistaGen may reasonably
request from time to time, in connection with its activities set
forth in this Section 9.5 (Infringement Claims by Third Parties),
including where necessary, furnishing a power of attorney solely
for such purpose or joining in, or being named as a necessary party
to, such action, providing access to relevant documents and other
evidence and making its employees available at reasonable business
hours; provided that VistaGen shall reimburse EverInsight for its
reasonable and verifiable out-of-pocket costs and expenses incurred
in connection therewith; (d) VistaGen shall keep EverInsight
reasonably informed of all material developments in connection with
any such claim, suit or proceeding; (e) VistaGen agrees to provide
EverInsight with copies of all material pleadings filed in such
action and to allow EverInsight reasonable opportunity to
participate in the defense of the Claims; and (f) any damages, or
awards, including royalties, incurred or awarded in connection with
any Third Party Infringement Claim defended under this Section 9.5
(Infringement Claims by Third Parties) shall be borne by VistaGen,
and VistaGen shall indemnify and hold EverInsight Indemnitee
harmless from such Third Party Infringement Claim pursuant Section
13.1(d).

 

9.6            

Invalidity or Unenforceability Defenses or
Actions. Each Party shall promptly notify the other Party in
writing of any alleged or threatened assertion of invalidity or
unenforceability of any of the Licensed Patents, Joint Patents or
EverInsight Patents worldwide, by a Third Party and of which such
Party becomes aware. As between the Parties: (a) VistaGen and
EverInsight shall coordinate with each other to defend and control
the defense of the validity and enforceability of any Joint Patents
in the Territory and share the cost and expense thereof; (b)
VistaGen shall have the first right, but not the obligation, to
defend and control the defense of the validity and enforceability
of any Licensed Patents, at its sole cost and expense, using
counsel of VistaGen’s choice; (c) EverInsight shall have the
first right, but not the obligation, to defend and control the
defense of the validity and enforceability of any EverInsight
Patents, at its sole cost and expense, using counsel of
EverInsight’s choice; provided however that, notwithstanding
the foregoing, Section 9.4 shall control with respect to any such
claim that is a Product Infringement or is a counter claim in an
enforcement action against a Project Infringement. For purposes of
this Section 9.6 (Invalidity or Unenforceability Defenses or
Actions), the Party defending and controlling the defense of the
validity and enforceability pursuant to the foregoing sentence with
respect to a Patent shall be the “Controlling Party”.
With respect to any such claim, suit or proceeding in the Territory
under this Section 9.6 (Invalidity or Unenforceability Defenses or
Actions), the non-Controlling Party may participate in such claim,
suit or proceeding with counsel of its choice at its sole cost and
expense; provided that the Controlling Party shall retain control
of the defense in such claim, suit or proceeding. If the
Controlling Party elects not to defend the applicable Patents in a
suit, then the Controlling Party shall notify the non-Controlling
Party of such election at least sixty (60) days before the time
limit, if any, set forth in Applicable Laws for defending such
actions, with the proviso that if the Controlling Party is
VistaGen, then, to the extent permitted under the Pherin License,
EverInsight shall have the right, but not the obligation, for any
such Invalidity or Unenforceability Defenses or Actions, to assume
control of the defense of any such claim, suit or proceeding at its
sole cost and expense. The non-

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-46-

 

 

Controlling
Party in such an action shall, and shall cause its Affiliates to,
assist and co-operate with the Controlling Party, as such
Controlling Party may reasonably request from time to time. in
connection with its activities set forth in this Section 9.6
(Invalidity or Unenforceability Defenses or Actions), including
where necessary, furnishing a power of attorney solely for such
purpose or joining in, or being named as a necessary party to, such
action, providing access to relevant documents and other evidence
and making its employees available at reasonable business hours;
provided that the Controlling Party shall reimburse the
non-Controlling Party for its reasonable and verifiable
out-of-pocket costs and expenses incurred in connection therewith.
In connection with any activities with respect to a defense, claim
or counterclaim relating to the Licensed Patents, EverInsight
Patents or Joint Patents licensed under Section 2.1 (License to
EverInsight) or Section 2.2 (License to VistaGen), the Controlling
Party shall (i) consult with the non-Controlling Party as to the
strategy for such activities, (ii) consider in good faith any
comments from the non-Controlling Party and (iii) keep the
non-Controlling Party reasonably informed of any material steps
taken and provide copies of all material documents filed, in
connection with such defense, claim or counterclaim.

 

9.7            

Consent for Settlement. Neither Party
shall unilaterally enter into any settlement or compromise of any
action or proceeding under this ARTICLE 9 (Intellectual Property
Rights) that would in any manner alter, diminish, or be in
derogation of the other Party’s rights under this Agreement
or otherwise without the prior written consent of such other Party,
which shall not be unreasonably withheld, conditioned or
delayed.

 

9.8            

Common Ownership under Joint Research
Agreement. Notwithstanding anything to the contrary in this
ARTICLE 9, no Party shall have the right to make an election under
35 U.S.C. 102(c) when exercising its rights under this ARTICLE 9
without the prior written consent of the other Party. With respect
to any such permitted election, the Parties shall co-ordinate their
activities with respect to any submissions, filings or other
activities in support thereof. The Parties acknowledge and agree
that this Agreement is a “joint research agreement” as
defined in 35 U.S.C. 100(h).

 

9.9            

Patent Extensions. VistaGen and
EverInsight shall jointly, following consultation with each other,
have decision making authority regarding, and they shall cooperate
with each other, in obtaining, patent term restoration,
supplemental protection certificates or their equivalents, and
patent term extensions with respect to the Licensed Patents, Joint
Patents, and EverInsight Patents in the Territory where applicable.
If mutually agreed, EverInsight shall file for such extensions at
the Parties’ shared cost and expense. If the Parties cannot
agree, the matter will be referred to the JSC for decision pursuant
to Section 3.3 (JSC Decision Making).

 

9.10            

Trademarks. VistaGen and EverInsight
shall provide to the other Party prompt written notice of any
actual or threatened infringement of the Product Trademarks or
Licensed Trademarks in the Territory and of any actual or
threatened Claim that the use of the Product Trademarks or Licensed
Trademarks in the Territory violates the rights of any Third Party,
in each case, of which such Party becomes aware. EverInsight shall
have the right to select and register, and shall own and be
responsible for, at its expense, all Product Trademarks, trade
names, branding or logos related to the Compound or Licensed
Product in the Licensed Field in the Territory. EverInsight shall
have the sole right to take such action as EverInsight
deems

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-47-

 

 

necessary
against a Third Party based on any alleged, threatened or actual
infringement, dilution, misappropriation or other violation of or
unfair trade practices or any other like offense relating to, the
Product Trademarks by a Third Party in the Territory at its sole
cost and expense and using counsel of its own choice and
EverInsight shall retain any damages or other amounts collected in
connection therewith.

 

9.11            

Licensed Trademarks. If EverInsight is lawfully
required by any Regulatory Authority or otherwise desires to use
any of the Licensed Trademarks or any other Trademark used by
VistaGen (either in connection with or in lieu of Product
Trademarks selected by EverInsight) to market, promote, distribute
and/or sell any Licensed Product in the Licensed Field outside the
Territory for the purpose of Commercialization of the relevant
Licensed Product in a jurisdiction in the Territory, EverInsight
shall promptly notify VistaGen, and VistaGen shall immediately
grant EverInsight an exclusive, fully-paid, royalty-free and
sublicensable license to use such Licensed Trademark or such other
Trademark solely in connection with the Commercialization of the
relevant Licensed Product in the Licensed Field in such
jurisdiction in the Territory; provided that any such license shall
automatically terminate upon the expiration or termination of this
Agreement with respect to such Licensed Product in such
jurisdiction.

 

 

ARTICLE 10 CONFIDENTIALITY; PUBLICATION

 

10.1            

Duty of Confidence. Subject to the other
provisions of this ARTICLE 10 (Confidentiality;
Publication):

 

(a)            

all Confidential
Information disclosed by a Party (the “Disclosing Party”) or its
Affiliates under this Agreement will be maintained in confidence
and otherwise safeguarded by the recipient Party (the
“Receiving
Party”) and its Affiliates using at least the same
standard of care as the Receiving Party uses to protect its own
proprietary or Confidential Information (but in no event less than
reasonable care);

 

(b)            

the Receiving
Party, its Affiliates and Representatives may only use any such
Confidential Information for the purposes of performing its
obligations or exercising its rights under this Agreement;
and

 

(c)            

the Receiving Party
may disclose Confidential Information of the Disclosing Party only
to: (i) the Receiving Party’s Affiliates; and (ii) employees,
directors, agents, contractors, Subcontractors, consultants and
advisers of the Receiving Party and its Affiliates and, in the case
of EverInsight as the Receiving Party, its Sublicensees, in each
case to the extent reasonably necessary for the purposes of, and
for those matters undertaken pursuant to, this Agreement
(collectively, the “Representatives”); provided, that
such Representatives are bound to maintain the confidentiality, and
not to make any unauthorized use, of the Confidential Information
in a manner consistent with this ARTICLE 10 (Confidentiality;
Publication).

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-48-

 

 

10.2            

Exceptions. The foregoing obligations as
to particular Confidential Information of a Disclosing Party shall
not apply to the extent that the Receiving Party can demonstrate by
competent evidence that such Confidential Information:

 

(a)            

is known by the
Receiving Party at the time of its receipt, and not through a prior
disclosure by the Disclosing Party, as demonstrated by
documentation or other competent proof of the Receiving Party, but
excluding Joint Inventions or the terms of this
Agreement;

 

(b)            

is in the public
domain by use and/or publication before its receipt from the
Disclosing Party, or thereafter enters the public domain through no
fault of, or breach of this Agreement by, the Receiving
Party;

 

(c)            

is subsequently
disclosed to the Receiving Party on a non-confidential basis by a
Third Party who, to the Receiving Party’s knowledge after
reasonable inquiry, may lawfully do so and is not under an
obligation of confidentiality to the Disclosing Party;
or

 

(d)            

is developed by the
Receiving Party independently and without use of or reference to
any Confidential Information disclosed to, or materials provided
to, it by or on behalf of the Disclosing Party, as shown by
contemporaneous written documents of the Receiving
Party.

 

10.3            

Authorized Disclosures. Notwithstanding
the obligations set forth in Section 10.1 (Duty of Confidence), the
Receiving Party may disclose Confidential Information of the
Disclosing Party and the terms of this Agreement to the extent such
disclosure is reasonably necessary for such Disclosing Party to
perform its obligations or exercise its rights under this
Agreement, in the following instances:

 

(a)            

filing or
prosecuting of Patents as permitted by this Agreement;

 

(b)            

enforcing the
Receiving Party’s rights under this Agreement or performing
the Receiving Party’s obligations under this
Agreement;

 

(c)            

in Regulatory
Filings for Licensed Product that such Party has the right to file
under this Agreement;

 

(d)            

prosecuting or
defending litigation as permitted by this Agreement;

 

(e)            

to the Receiving
Party’s Representatives and actual or potential Sublicensees
(in the case of EverInsight), in each case, who have a need to know
such Confidential Information in order for the Receiving Party to
exercise its rights or fulfill its obligations under this
Agreement; provided, in each case, that any such Person agrees to
be bound by terms of confidentiality and non-use (or, in the case
of the Receiving Party’s attorneys and independent
accountants, such Person is obligated by applicable professional or
ethical obligations) at least as restrictive as those set forth in
this ARTICLE 10 (Confidentiality; Publication);

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-49-

 

 

(f)            

to actual or
potential investors, investment bankers, lenders, other financing
sources or acquirers (and attorneys and independent accountants
thereof) in connection with potential investment, acquisition,
collaboration, merger, public offering, due diligence or similar
investigations by such Third Parties or in confidential financing
documents; provided, in each case, that any such Third Party agrees
to be bound by terms of confidentiality and non-use (or, in the
case of the Receiving Party’s attorneys and independent
accountants, such Third Party is obligated by applicable
professional or ethical obligations) that are no less stringent
than those contained in this Agreement (except to the extent that a
shorter confidentiality period is customary in the industry);
and

 

(g)            

such disclosure is
required by court order, judicial or administrative process or
Applicable Laws; provided that in such event the Receiving Party
shall promptly inform the Disclosing Party of such required
disclosure and provide the Disclosing Party an opportunity to
challenge or limit the disclosure obligations. Confidential
Information that is disclosed as required by court order, judicial
or administrative process or Applicable Laws shall remain otherwise
subject to the confidentiality and non-use provisions of this
ARTICLE 10 (Confidentiality; Publication), and the Receiving Party
shall take all steps reasonably necessary, including seeking of
confidential treatment or a protective order, to ensure the
continued confidential treatment of such Confidential
Information.

 

10.4            

Publication. Prior to publishing or
presenting the results of any studies carried out under this
Agreement or otherwise related to the Compound or Licensed Product,
the publishing or presenting Party shall submit the draft of the
publication or presentation to the other Party no later than
forty-five (45) calendar days prior to the planned submission for
publication or presentation for the other Party’s review and
comment. The publishing or presenting Party shall: (a) consider in
good faith any comments thereto provided by the other Party within
such review period; and (b) remove any Confidential Information of
the other Party if requested by the other Party. The other Party
shall be deemed to have consented to such publication or
presentation if it has not sent any response to the publishing or
presenting Party’s request within thirty (30) calendar days
of receipt of the draft publication or presentation from the
publishing or presenting Party. The other Party may reasonably
request a reasonable delay in publication or presentation in order
to protect patentable information. If the other Party reasonably
requests a delay, then the publishing or presenting Party shall,
and shall ensure that its Affiliate(s) or the Sublicensee(s) shall,
delay submission or presentation for a period of sixty (60)
calendar days (or such shorter period as may be mutually agreed by
the Parties) to enable the other Party to file patent applications
protecting the other Party’s rights in such
information.

 

10.5            

Publicity/Use of Names. The Parties
intend to agree upon the content of one (1) or more press releases,
the release of which the Parties shall coordinate in order to
accomplish such release promptly upon execution of this Agreement.
Other than as set forth in the prior sentence, no other disclosure
of the existence, or the terms, of this Agreement may be made by
either Party or its Affiliates, and neither Party shall use the
name, trademark, trade name or logo of the other Party, its
Affiliates or their respective employee(s) in any publicity,
promotion, news release or disclosure relating to this Agreement or
its subject matter, without the prior express written

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-50-

 

 

 

permission
of the other Party, except as may be required by Applicable Laws.
Notwithstanding the above, each Party and its Affiliates may
disclose on its website, in news releases, its promotional
materials and other disclosures relating to this Agreement that the
other Party is a development and commercialization partner of such
Party for the Licensed Product in the Territory and may use the
other Party’s name and logo in conjunction with such
disclosure. Notwithstanding the foregoing:

 

(a)            

A Party may
disclose this Agreement and its terms, and material developments or
material information generated under this Agreement, in news
releases and securities filings with the U.S. Securities and
Exchange Commission (“SEC”) (or equivalent foreign
agency) to the extent required by Applicable Laws after complying
with the procedure set forth in this Section 10.5 (Publicity/Use of
Names). In such event, the Party seeking to make such disclosure
will prepare a draft of such disclosure together with, if
applicable, a confidential treatment request to request
confidential treatment for this Agreement and proposed redacted
version of this Agreement, and the other Party agrees to promptly
(and in any event, no less than three (3) Business Days after
receipt of such request for disclosure required for 8-K and no less
than five (5) Business Days for other disclosure, including, if
applicable, proposed redactions) give its input in a reasonable
manner in order to allow the Party seeking disclosure to file its
request within the time lines prescribed by applicable SEC
regulations. The Party seeking such disclosure shall exercise
Commercially Reasonable Efforts to obtain confidential treatment of
this Agreement from the SEC as represented by the redacted version
reviewed and agreed upon in good faith by the other
Party.

 

(b)            

Further, each Party
acknowledges that the other Party may be legally required, or may
be required by the listing rules of any exchange on which the other
Party’s or its Affiliate’s securities are traded or
advised by its counsel, to make public disclosures (including in
filings with the SEC or other agency) of certain material
developments or material information generated under this Agreement
and agrees that each Party may make such disclosures as required by
law, listing rules or advice; provided that the Party seeking such
disclosure shall provide the other Party with a copy of the
proposed text of such disclosure sufficiently in advance of the
scheduled release to afford such other Party a reasonable
opportunity to review and comment thereon.

 

(c)            

If either Party
desires to issue a press release or make a public announcement
concerning the material terms of this Agreement or the Development,
Commercialization or Exploitation of the Compound or the Licensed
Product under this Agreement, such as the achievement of Regulatory
Approvals of the Licensed Product or data from a clinical trial,
such Party shall provide the other Party with the proposed text of
such announcement for prior review and, except to the extent such
press release or public announcement is permitted by subsection (a)
or (b) above, approval by such other Party.

 

(d)            

The Parties agree
that after a public disclosure has been made or a press release or
other public announcement has been issued in compliance with
subsection (a), (b) or (c) hereof, each Party may make subsequent
public disclosures or issue press releases or

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-51-

 

 

other
public announcements disclosing the same content without having to
obtain the other Party’s prior consent and
approval.

 

10.6            

Reporting of Financial Information. From
and after the Effective Date, to the extent required by the SEC (or
equivalent foreign agency) in connection with EverInsight or an
Affiliate of EverInsight registering securities in a public
offering, VistaGen shall (a) cooperate with EverInsight or its
Affiliates and their respective accountants and auditors by
providing copies of books, and records related to the Licensed
Product as EverInsight may reasonably request in connection with
the preparation by EverInsight or its Affiliates of historical and
pro forma financial statements related to the Licensed Product as
may be required to be included in any filing made by EverInsight or
any of its Affiliates under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, and the
regulations promulgated thereunder, including Regulation S-X (or
equivalent foreign laws and regulations) and (b) without limiting
the foregoing, shall provide EverInsight with such information as
is required for EverInsight or its Affiliates to prepare audited
“carve out” financial statements related to the
Licensed Product, for the three (3) Calendar Years prior to the
Effective Date (or such shorter period as agreed to by EverInsight)
and information requested by EverInsight and reasonably necessary
to prepare any applicable pro forma financial information required
to be filed by EverInsight with the SEC (or equivalent foreign
agency). EverInsight may also derive such “carve out”
financial statements from VistaGen’s historical financial
statements and accurately present in all material respects the
financial position of the Licensed Product in the Licensed Field in
the Territory as of the dates thereof. EverInsight shall (i) submit
to VistaGen any proposed filing containing or incorporating by
reference any financial statements provided to EverInsight under
this Section 10.6 (Reporting of Financial Information) as far in
advance as reasonably practicable (and in no event, unless
inconsistent with Applicable Laws, less than fifteen (15) days
prior to the anticipated date of filing) so as to provide VistaGen
a reasonable opportunity to comment thereon and (ii) in good faith
consider incorporating such comments. All information of VistaGen
obtained by or on behalf of EverInsight under this Section 10.6
(Reporting of Financial Information) shall be deemed Confidential
Information of VistaGen.

 

10.7            

Privileged Communications. In
furtherance of this Agreement, it is expected that the Parties may,
from time to time, disclose to one another privileged
communications with counsel, including opinions, memoranda, letters
and other written, electronic and verbal communications. Such
disclosures are made with the understanding that they shall remain
confidential in accordance with this ARTICLE 10 (Confidentiality;
Publication), that they will not be deemed to waive any applicable
attorney-client or attorney work product or other privilege and
that they are made in connection with the shared community of legal
interests existing between VistaGen and EverInsight, including the
community of legal interests in avoiding infringement of any valid,
enforceable patents of Third Parties and maintaining the validity
of the Licensed Patents, EverInsight Patents and Joint Patents. In
the event of any litigation (or potential litigation) with a Third
Party related to this Agreement or the subject matter hereof, the
Parties shall, upon either Party’s request, enter into a
reasonable and customary joint defense or common interest
agreement. In any event, each Party shall consult in a timely
manner with the other Party before engaging in any conduct (e.g.,
producing Information or documents) in connection with litigation
or other proceedings that could conceivably implicate privileges
maintained by the other Party. Notwithstanding anything contained
in this Section 10.7 (Privileged Communications),
nothing

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-52-

 

 

in this
Agreement shall prejudice a Party’s ability to take discovery
of the other Party in disputes between them relating to the
Agreement and no information otherwise admissible or discoverable
by a Party shall become inadmissible or immune from discovery
solely by this Section 10.7 (Privileged
Communications).

 

 

ARTICLE 11 TERM AND TERMINATION

 

11.1            

Term. Unless earlier terminated as
permitted by this Agreement, the term of this Agreement will
commence upon the Effective Date and continue in full force and
effect, on a jurisdiction-by-jurisdiction and Licensed
Product-by-Licensed Product basis, until expiration of the Royalty
Term for such Licensed Product in such jurisdiction the Territory
(the “Term”).
Following the expiration (but not the earlier termination) of the
Royalty Term for a Licensed Product in a jurisdiction in the
Territory, the grants in Section 2.1 (Licenses to EverInsight)
shall continue and become exclusive, fully-paid, royalty-free, and
irrevocable for such Licensed Product (existing at the time of such
expiration) in such jurisdiction. For clarity, (a) upon the
expiration (but not the earlier termination) of the Term, the
grants in Section 2.1 (Licenses to EverInsight) shall become
exclusive, fully-paid, royalty-free, and irrevocable in their
entirety solely as to the Licensed Product in the Territory at the
time of such expiration and (b) upon the expiration (but not the
earlier termination) of the Term, the grant in Section 2.2 (License
to VistaGen) shall become an exclusive, perpetual, fully- paid,
royalty-free and irrevocable license under the EverInsight
Technology to Exploit the Licensed Product (existing at the time of
such expiration) in the Licensed Field outside the Territory, in
each case with the right to grant sublicenses.

 

11.2            

Termination.

 

(a)            

Automatic Termination for Nonpayment of Upfront
Payment. If EverInsight fails to pay VistaGen the upfront
payment set forth in Section 8.1 (Upfront Payment) within thirty
(30) Business Days after the Effective Date; then, in any such
case, this Agreement will automatically and immediately
terminate.

 

(b)            

Termination by EverInsight for Convenience. At any
time, EverInsight may terminate this Agreement (either in its
entirety or on a Licensed Product-by-Licensed Product and
jurisdiction-by-jurisdiction basis), at its sole discretion and for
any reason or no reason, by providing written notice of termination
to VistaGen, which notice includes an effective date of termination
at least [*****]
after the date of the notice.

 

(c)            

Termination for Cause. If either
VistaGen or EverInsight believes that the other Party is in
material breach of its obligations hereunder, then the
non-breaching Party may deliver notice of such breach to the other
Party. The allegedly breaching Party shall have (i) [*****]
Business
Days in the case of a payment breach and or (ii) [*****]
Business Days in the case of a non-payment breach, to cure such
breach from the receipt of the notice. If the allegedly breaching
Party fails to cure that breach within the applicable period set
forth above, or has not undertaken reasonable steps to cure the
breach if a complete cure is not reasonably to be expected within
such period, then the

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-53-

 

 

Party
originally delivering the notice of breach may terminate this
Agreement on written notice of termination. Any right to terminate
this Agreement under this Section 11.2(c) (Termination for Cause)
shall be stayed and the applicable cure period tolled in the event
that, during such cure period, the Party alleged to have been in
material breach shall have initiated dispute resolution in
accordance with Section 14.10 (Dispute Resolution) with respect to
the alleged breach, which stay and tolling shall continue until
such dispute has been resolved in accordance with Section 14.10
(Dispute Resolution). If a Party is determined to be in material
breach of this Agreement, the other Party may terminate this
Agreement if the breaching Party fails to cure the breach within
thirty (30) Business Days after the conclusion of the dispute
resolution procedure (and such termination shall then be effective
upon written notification from the notifying Party to the breaching
Party).

 

(d)            

Termination for Patent Challenge.
VistaGen may terminate this Agreement immediately upon prior
written notice to EverInsight if EverInsight or its Affiliates or
its or their Sublicensees, individually or in association with any
other person or entity, directly or indirectly, commences or
participates in a Challenge to the validity or enforceability of
any Licensed Patents, unless EverInsight, such Affiliate or
Sublicensee dismisses or withdraws such Challenge within
[*****]
days, or in the case of a Challenge by a Sublicensee, EverInsight
terminates the sublicense agreement with such Sublicensee within
[*****]
days. EverInsight may terminate the license granted by EverInsight
to VistaGen this Agreement (but retain the license granted by
VistaGen to EverInsight hereunder) immediately upon prior written
notice to VistaGen if VistaGen or its Affiliates or its or their
Sublicensees, individually or in association with any other person
or entity, directly or indirectly, commences or participates in a
Challenge to the validity or enforceability of any EverInsight
Patents, unless VistaGen, such Affiliate or Sublicensee dismisses
or withdraws such Challenge within [*****]
days, or in the case of a Challenge by a Sublicensee, VistaGen
terminates the sublicense agreement with such Sublicensee within
[*****]
days.

 

(e)            

Termination for Bankruptcy. This
Agreement may be terminated at any time during the Term by either
Party upon the other Party’s filing or institution of
bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the
assets for the benefit of creditors by the other Party; provided
that in the case of any involuntary bankruptcy proceeding such
right to terminate shall only become effective if the Party
consents to the involuntary bankruptcy or such proceeding is not
dismissed within [*****]
days after the filing thereof.

 

11.3            

Effect of Termination. Upon termination
of this Agreement by either Party, the following consequences shall
apply and shall be effective as of the effective date of such
termination (if this Agreement is terminated on a Licensed
Product-by-Licensed Product and jurisdiction-by-jurisdiction basis,
then this Section 11.3 shall only apply to the terminated Licensed
Product in the terminated jurisdiction):

 

(a)            

EverInsight’s
license under Section 2.1 (License to EverInsight) shall terminate
and all milestone and any other payments accruing prior to the
effective date of termination will be paid by EverInsight on or
before the termination date and all reports

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-54-

 

 

and
accountings that are due prior to the effective date of termination
shall be submitted by EverInsight on or before the termination
date.

 

(b)            

If this Agreement
is terminated in its entirety by VistaGen pursuant to Section
11.2(c) (Termination for Cause), 11.2(d) (Termination for Patent
Challenge), or 11.2(e) (Termination for Bankruptcy), or if this
Agreement is terminated by EverInsight in its entirety pursuant to
Section 11.2(b) (Termination by EverInsight for Convenience), then
EverInsight hereby grants to VistaGen, effective only upon such
termination, an exclusive (even as to EverInsight), royalty-free,
fully-paid, perpetual and irrevocable license, with the right to
grant sublicenses through multiple tiers, under the EverInsight
Technology, EverInsight Development Data and EverInsight Regulatory
Documentation, to Develop, make, have made, use, import, offer for
sale, sell and otherwise Commercialize or Exploit the Compound and
any product containing the Compound anywhere in the world in all
fields of use. During a reasonable period of time (but no more than
six (6) months) after termination, EverInsight shall reasonably
cooperate with VistaGen to facility the transfer of the Development
and regulatory activities for the Compound and Licensed Product to
VistaGen.

 

(c)            

If this Agreement
is terminated by EverInsight pursuant to Section 11.2(c)
(Termination for Cause), or 11.2(e) (Termination for Bankruptcy),
then VistaGen may request, within [*****]
days of such termination, that EverInsight enter into good faith
negotiations for no more than [*****]
days concerning the terms of an agreement with EverInsight granting
to VistaGen an exclusive (even as to EverInsight) license under the
EverInsight Technology, EverInsight Development Data and
EverInsight Regulatory Documentation. If no agreement is reached,
then the license to VistaGen under Section 2.2 (License to
VistaGen) shall terminate.

 

(d)            

If this Agreement
is terminated in its entirety, VistaGen shall be solely responsible
for all future worldwide Development, Manufacture and
Commercialization of the Compound and Licensed Product in the
Licensed Field, at its sole cost and expense.

 

(e)            

If this Agreement
is terminated in its entirety, each Party shall return to the other
Party or destroy, at the other Party’s election, all
Confidential Information of the other Party, including all copies
thereof and all materials, substances and compositions delivered or
provided by or on behalf of the other Party; except that (i) each
Party may retain one copy of the other Party’s Confidential
Information for legal archival purpose, and neither Party shall be
required to delete or destroy any electronic back-up tapes or other
electronic back-up files that have been created solely by automatic
or routine archiving and back-up procedures; and (ii) if the
Parties reach agreement with respect to a license grant by
EverInsight to VistaGen under clause (c) or VistaGen has license
rights under clause (b), then VistaGen shall not be required to
return or destroy EverInsight’s Confidential Information to
the extent VistaGen has the right to use such Confidential
Information solely as necessary to practice such
license.

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-55-

 

 

(f)            

If VistaGen
automatically has license rights under clause 11.3(b) or the
Parties reach agreement with respect to a license grant by
EverInsight to VistaGen under clause 11.3(c) then:

 

(i)            

EverInsight shall
deliver to VistaGen all Regulatory Filings and Regulatory Approvals
for the Compound and any Licensed Product, all EverInsight
Development Data and all EverInsight Know-How.

 

(ii)            

EverInsight shall
(1) disclose to VistaGen all EverInsight Know-How, EverInsight
Development Data and all Joint Inventions to the extent not already
known to VistaGen, which may be necessary or reasonably useful for
VistaGen to continue to Develop, Manufacture and Commercialize the
Compound and Licensed Product in the Licensed Field; and (2), at
VistaGen’s request, provide reasonable technical assistance
and transfer all EverInsight Know-How, EverInsight Development Data
and Joint Inventions necessary to Manufacture the Compound or
Licensed Product to VistaGen or its designee; provided that
VistaGen shall reimburse EverInsight for the reasonable cost and
expense of such technical assistance.

 

(iii)            

EverInsight shall,
at VistaGen’s request and election, introduce VistaGen to
EverInsight’s Third Party providers of clinical research,
manufacturing and/or distribution services and assign any contracts
with such entities to VistaGen to the extent such contracts (or
portions thereof, such as a work order under a master services
agreement) relate solely to the Licensed Product and are assignable
to VistaGen.

 

(iv)            

EverInsight shall
transfer to VistaGen all units of the Compound and the Licensed
Product in its possession, provided that VistaGen shall reimburse
EverInsight for the Cost of Goods of such units.

 

(v)            

EverInsight shall,
and hereby does, effective on such termination, assign to VistaGen
all of EverInsight’s and its Affiliates’ right, title
and interest in and to any and all Product Trademarks and other
trademarks used by EverInsight and its Affiliates in the Territory
in connection with its Development, Manufacture or
Commercialization of Licensed Product (excluding any such
trademarks that include, in whole or part, any corporate name or
logo of EverInsight or its Affiliates), including all goodwill
therein, and EverInsight shall promptly take such actions and
execute such instruments, assignments and documents as may be
necessary to effect, evidence, register and record such
assignment.

 

11.4            

Survival. Expiration or termination of
this Agreement shall not relieve any Party of any obligation
accruing prior to such expiration or termination, nor shall
expiration or any termination of this Agreement preclude either
Party from pursuing all rights and remedies it may have under this
Agreement, at law or in equity, with respect to breach of this
Agreement. In addition, the provisions of ARTICLE 1 (Definitions),
subclauses (b) through (d) of Section 5.4 (Rights of Reference),
Section 8.8 (Taxes), Section 8.9 (Financial Records and Audit),
Section

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-56-

 

 

8.10
(Audit Dispute), Section 9.1 (Ownership of Intellectual Property);
ARTICLE 10 (Confidentiality; Publicity), Section 11.3 (Effect of
Termination), this Section 11.4 (Survival), ARTICLE 13
(Indemnification; Liability), and ARTICLE 14 (General Provisions)
hereof shall survive the expiration or termination of this
Agreement. In addition, in the event that the this Agreement is
terminated by EverInsight pursuant to Section 11.2(c) (Termination
for Cause) and, pursuant to Section 11.3 (Effect of Termination),
either VistaGen does not timely request that EverInsight enter into
good faith negotiations concerning the terms of an agreement with
VistaGen granting VistaGen a license under the EverInsight
Technology and EverInsight Development Data, or if no agreement is
timely reached, then the provisions of Sections 9.2 through 9.9 of
ARTICLE 9 (Intellectual Property), solely with respect to Joint
Inventions, shall also survive the expiration or termination of
this Agreement.

 

11.5            

Termination Not Sole Remedy. Termination
is not the sole remedy under this Agreement and, whether or not
termination is effected, and notwithstanding anything contained in
this Agreement to the contrary, all other remedies will remain
available except as agreed to otherwise herein.

 

11.6            

Alternative Remedy for VistaGen’s
Breach. In the event EverInsight would be entitled to
terminate this Agreement pursuant Section 11.2(c) for
VistaGen’s uncured material breach, but if EverInsight does
not desire to exercise such termination right, then, EverInsight
may, in its sole discretion and without waiving or releasing any
right, claim or remedy for such breach, elect to maintain this
Agreement in full force and effect and reduce all future payments
due to VistaGen hereunder by [*****].

 

 

ARTICLE 12 REPRESENTATIONS AND WARRANTIES

 

12.1            

Representations and Warranties of Each
Party. Each Party represents and warrants to each other
Parties as of the Effective Date that:

 

(a)            

it has the full
right, power and authority to enter into this Agreement, to perform
its obligations hereunder;

 

(b)            

this Agreement has
been duly executed by it and is legally binding upon it,
enforceable in accordance with its terms, and does not conflict
with any agreement, instrument or understanding, oral or written,
to which it is a party or by which it may be bound, nor violate any
material law or regulation of any court, governmental body or
administrative or other agency having jurisdiction over
it;

 

(c)            

this Agreement is a
legal, valid and binding obligation of such Party enforceable
against it in accordance with its terms and conditions, subject to
the effects of bankruptcy, insolvency or other laws of general
application affecting the enforcement of creditor rights, judicial
principles affecting the availability of specific performance and
general principles of equity (whether enforceability is considered
a proceeding at law or equity);

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-57-

 

 

(d)            

it is not under any
obligation, contractual or otherwise, to any Person that conflicts
with or is inconsistent in any material respect with the terms of
this Agreement or that would impede the diligent and complete
fulfillment of its obligations hereunder; and

 

12.2            

Mutual Covenants.

 

(a)            

Employees, Consultants and Contractors.
Each Party covenants that it has obtained or will obtain written
agreements from each of its employees, consultants and contractors
who perform Development activities pursuant to this Agreement,
which agreements will obligate such persons to obligations of
confidentiality and non-use and to assign Inventions in a manner
consistent with the provisions of this Agreement.

 

(b)            

Debarment. Each Party represents,
warrants and covenants to the other Parties that it is not debarred
or disqualified under the FFDCA, as may be amended, or comparable
laws in any country or jurisdiction other than the U.S., and it has
not employed or used, does not, and will not during the Term,
employ or use the services of any person who is debarred or
disqualified, in connection with activities relating to the
Compound or any Licensed Product. In the event that any Party
becomes aware of the debarment or disqualification or threatened
debarment or disqualification of any person providing services to
such Party, including the Party itself or its Affiliates, that
directly or indirectly relate to activities contemplated by this
Agreement, such Party shall immediately notify the other Parties in
writing and such Party shall cease employing, contracting with, or
retaining any such person to perform any such
services.

 

(c)            

Compliance. Each Party covenants as
follows:

 

(1)            

In the performance
of its obligations under this Agreement, such Party shall comply
and shall cause its and its Affiliates’ employees and
contractors to comply with all Applicable Laws, including all
export control, anti-corruption and anti-bribery laws and
regulations, and shall not cause such other Party to be in
violation of any Applicable Laws.

 

(2)            

Such Party and its
and its Affiliates’ employees and contractors shall not, in
connection with the performance of their respective obligations
under this Agreement, directly or indirectly through Third Parties,
pay, promise or offer to pay, or authorize the payment of, any
money or give any promise or offer to give, or authorize the giving
of anything of value to a Public Official or Entity or other person
for purpose of obtaining or retaining business for or with, or
directing business to, any person, including, without limitation,
either Party. Each Party represents and warrants that as of the
Effective Date, such Party, and to its knowledge, its and its
Affiliates’ employees and contractors, have not directly or
indirectly promised, offered or provided any corrupt payment,
gratuity, emolument, bribe, kickback, illicit gift or hospitality
or other illegal or unethical benefit to a Public Official or
Entity or any other person in connection with the performance of
such Party’s obligations under this Agreement, and each
Party

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-58-

 

 

covenants that it
and its Affiliates’ employees and contractors shall not,
directly or indirectly, engage in any of the
foregoing.

 

(3)            

Each Party shall
have the right to suspend or terminate this Agreement in its
entirety where there is a credible finding, after a reasonable
investigation, that the other Party, in connection with performance
of such other Party’s obligations under this Agreement, has
materially violated any anti-corruption or anti-bribery laws or
regulations.

 

(4)            

Each Party shall
not, during the Term, assign, transfer, convey or otherwise
encumber its right, title and interest in (A) Licensed Technology,
in the case of VistaGen, in a manner that is inconsistent with the
exclusive license granted to EverInsight under Section 2.1
(Licenses to EverInsight) or (B) EverInsight Technology, in the
case of EverInsight, in a manner that is inconsistent with the
exclusive license granted to VistaGen under Section 2.2 (License to
VistaGen), in each case without the prior written consent of the
other Party (which consent shall not be unreasonably withheld,
conditioned or delayed)

 

(5)            

Each Party shall
not grant any right to any Third Party under the (A) Licensed
Technology (in the case of VistaGen) that would conflict with the
rights granted to EverInsight hereunder, or (B) EverInsight
Technology (in the case of EverInsight) that would conflict with
the rights granted to VistaGen hereunder.

 

12.3            

Representations and Warranties by
VistaGen. VistaGen represents and warrants to EverInsight as
of the Effective Date that:

 

(a)            

The patents and
patent applications listed on Exhibit A constitute all Licensed
Patents existing as of the Effective Date (the “Existing Licensed
Patents”);

 

(b)            

Except for
[*****],
VistaGen is the sole and exclusive owner of all Licensed
Technology, free and clear from any mortgages, pledges, liens,
security interests, conditional and installment sales agreements,
encumbrances, charges or claims of any kind, and has the right to
grant the license to EverInsight as purported to be granted under
this Agreement;

 

(c)            

The Licensed
Technology is complete, accurate, effective and capable of
achieving the Development and Manufacturing of the Compound and the
Licensed Product. The Parties hereby irrevocably agree that the
Licensed Technology shall be deemed to be complete, accurate,
effective and capable of achieving the Development and
Manufacturing of the Compound and the Licensed Product (and the
foregoing representation and warranty shall be satisfied) if, after
the completion of relevant technology transfer, EverInsight (or its
contractor) is able to produce the Compound or the Licensed
Products (as the case may be) in a manner that (1) complies with
the specifications contained in (i) the technical documents
VistaGen provided to EverInsight for evaluation and (ii) IND(s)
submitted to the applicable Regulatory Authority(ies) and (2) does
not infringe or misappropriate any intellectual property of any
Third Party.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-59-

 

 

(d)            

VistaGen has not
received any notice from a Third Party that the Development or
Manufacture of the Compound or any Licensed Product conducted by or
on behalf of VistaGen prior to the Effective Date has infringed any
Patents of any Third Party or infringed or misappropriated any
other intellectual property of any Third Party. Based on
VistaGen’s understanding as of the Effective Date of the
Compound and the Licensed Product and their intended use as
disclosed to EverInsight as of the Effective Date, the Development,
Manufacture, use or sale of any Compound or any Licensed Product
pursuant to this Agreement does not and will not, to the knowledge
of VistaGen, (y) infringe any Patents of any Third Party or (z)
infringe or misappropriate any other intellectual property of any
Third Party.

 

(e)            

To the knowledge of
VistaGen, the use of Licensed Trademark in connection with
Commercialization of the Licensed Product will not violate the
rights of any Third Party. No claim or action has been brought or,
to VistaGen’s knowledge, threatened in writing, by any
Governmental Authority or Third Party (i) that any Licensed
Trademark violates the rights of a Third Party or (ii) currently
challenging the enforceability or validity of any Licensed
Trademark;

 

(f)            

VistaGen has not as
of the Effective Date granted any right to any Third Party under
the Licensed Technology or Licensed Trademark that would conflict
with the rights granted to EverInsight hereunder;

 

(g)            

VistaGen has no
knowledge as of the Effective Date of any Third Party that is
infringing or misappropriating any of the Licensed Technology or
Licensed Trademark;

 

(h)            

no claim or action
has been brought or, to VistaGen’s knowledge, threatened in
writing by any Third Party involving any Compound, Licensed Product
and/or Licensed Technology, including any claim or action alleging
that the issued patents in the Licensed Patent Rights are invalid
or unenforceable, and any interference, opposition, cancellation or
other protest proceeding involving any Licensed Patents anywhere in
the world;

 

(i)            

to VistaGen’s
knowledge, as of the Effective Date, there is no Know-How owned or
controlled by VistaGen that is necessary for the Development of the
Compound that is not within the Licensed Know-How; and

 

(j)            

to VistaGen’s
knowledge, (x) all development works for the Compound and Licensed
Product, including clinical trials, conducted by VistaGen or its
Affiliates (including their contractors) prior to the Effective
Date have been in compliance in all material respects with all
Applicable Laws, and (y) no data or other information generated or
otherwise received from such clinical trials conducted up to the
Effective Date has, or is reasonably expected to have, any
materially negative impact on the Exploitation of any Licensed
Product in the Territory.

 

(k)            

To the knowledge of
VistaGen, VistaGen has obtained all necessary government approvals
required for the grant of the license and the transfer of the
Licensed Know-

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-60-

 

 

How to
EverInsight, including such approvals required by applicable
technology export control laws, and VistaGen will do and execute or
procure to be done and executed all such further acts, things,
agreements and other documents as may be necessary to give effect
to the terms of this Agreement, including to comply with the
applicable technology import and export laws and regulations in the
United States and the Territory;

 

(l)            

Except for the
Pherin License, there is no agreement between VistaGen or its
Affiliates and any Third Party pursuant to which VistaGen or its
Affiliates have obtained any right or license to the Compound,
Licensed Product or Licensed Technology. VistaGen has provided
EverInsight with a copy of the Pherin License that is complete with
regard to the relevant provisions of this Agreement. The Pherin
License is in full force and effect. No notice of default or
termination has been received or given under the Pherin License.
There is no act or omission by VistaGen that would provide a right
to terminate the Pherin License;

 

(m)            

During the Term of
this Agreement, VistaGen shall maintain [*****]
each In-License Agreement in full force and effect and shall not
terminate, amend, waive or otherwise modify (or consent to any of
the foregoing) its rights under [*****]
any In-License Agreement in any manner that materially diminishes
the rights or licenses granted to EverInsight hereunder, without
EverInsight’s express written consent, which shall not be
unreasonably withheld, conditioned or delayed, and VistaGen shall
provide EverInsight with a copy of all modifications to or
amendments thereto, regardless of whether EverInsight’s
consent was required with respect thereto. In the event of any
notice of breach of [*****]
any In-License Agreement by VistaGen, VistaGen shall immediately
notify EverInsight in writing, and if VistaGen fails to cure such
breach in a timely manner, EverInsight shall have the right, but
not the obligation, to cure such breach and to seek reimbursement
of or offset any reasonable amount incurred or paid by EverInsight
in connection with the cure against amount payable to VistaGen
hereunder. In the event of any notice of breach of [*****]
any In-License Agreement by the applicable Third Party in a manner
that will or is likely to materially affect EverInsight’s
rights or obligations under this Agreement, VistaGen shall
immediately notify EverInsight in writing and take such actions as
reasonably requested by EverInsight to enforce the [*****]
In-License Agreement; and

 

(n)            

All information
provided by VistaGen to EverInsight for due diligence purposes in
relation to this Agreement is complete and accurate in all material
respects. Without limiting the foregoing, VistaGen has disclosed or
made available to EverInsight for review all material non-clinical
and clinical data for the Compound and Licensed Product, and all
other material information (including relevant correspondence with
the FDA and other Regulatory Authorities) relating to the Compound
and Licensed Product, in each case that would be material for
EverInsight to assess the safety and efficacy of the Compound and
Licensed Product.

 

12.4            

Representations and Warranties by
EverInsight. EverInsight represents and warrants to VistaGen
as of the Effective Date that:

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-61-

 

 

(a)            

EverInsight has not
previously assigned, transferred, conveyed or otherwise encumbered
its right, title and interest in EverInsight Technology in a manner
that is inconsistent with the exclusive license granted to VistaGen
under Section 2.2 (License to VistaGen);

 

(b)            

EverInsight has not
as of the Effective Date, and will not during the Term, grant any
right to any Third Party under the EverInsight Technology that
would conflict with the rights granted to VistaGen
hereunder;

 

(c)            

EverInsight has no
knowledge as of the Effective Date of any Third Party that is
infringing or misappropriating any of the EverInsight
Technology;

 

(d)            

no claim or action
has been brought or, to EverInsight’s knowledge, threatened
in writing by any Third Party alleging that the EverInsight Patents
are invalid or unenforceable, and no EverInsight Patent is the
subject of any interference, opposition, cancellation or other
protest proceeding; and

 

(e)            

as of the Effective
Date, EverInsight reasonably believes it has or will have the
capability and sufficient access to the financial resources
necessary to perform its obligations under this Agreement,
including without limitation, its obligations to (i) use
Commercially Reasonable Efforts to Develop, Exploit, Commercialize
and obtain Regulatory Approval for the Compounds and each Licensed
Product in the Licensed Field in the Territory and (ii) make the
required payments to VistaGen hereunder.

 

12.5            

No Other Warranties. EXCEPT AS EXPRESSLY
SET FORTH IN THIS AGREEMENT, NO PARTY MAKES, AND EACH PARTY
EXPRESSLY DISCLAIMS, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS,
NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE
PRACTICES.

 

 

ARTICLE 13 INDEMNIFICATION; LIABILITY

 

13.1            

Indemnification by VistaGen. VistaGen
shall indemnify, defend and hold EverInsight, its Affiliates, and
their respective officers, directors, agents and employees
(“EverInsight
Indemnitees”) harmless from and against any Claims
against them to the extent arising or resulting from:

 

(a)            

the material breach
by VistaGen of this Agreement;

 

(b)            

the gross
negligence or willful misconduct on the part of VistaGen or its
Affiliates or its or their respective officers, directors, agents
or employees in performing its obligations under this Agreement;
or

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-62-

 

 

(c)            

the Exploitation by
VistaGen or any of its Affiliates or its or their sublicensees or
its or their distributors or contractors of the Compound or the
Licensed Product outside the Territory; or

 

(d)            

any Third Party
Infringement Claim that VistaGen is responsible for defending
pursuant to Section 9.5;

 

except,
in each case (a), (b) and (c) above, for those Claims for which
EverInsight has an obligation to indemnify VistaGen pursuant to
Section 13.2 (Indemnification by EverInsight) hereof or, to the
extent such Claims result from the material breach by EverInsight
of any covenant, representation, warranty or other agreement made
by EverInsight in this Agreement or the negligence or willful
misconduct of any EverInsight Indemnitee. Notwithstanding the
above, VistaGen will have no obligation to defend or indemnify
EverInsight or its Affiliates for any claim brought by a
shareholder or a class of shareholders of EverInsight or its
Affiliates including, but not limited to, securities fraud claims,
shareholder direct claims, and shareholder derivative claims,
except to the extent resulting from the gross negligence or willful
misconduct on the part of VistaGen or any Affiliate.

 

13.2            

Indemnification by EverInsight.
EverInsight shall indemnify, defend and hold VistaGen, its
Affiliates, and their respective officers, directors, agents and
employees (“VistaGen
Indemnities”) harmless from and against any Claims
arising under or related to this Agreement against them to the
extent arising or resulting from:

 

(a)            

the material breach
by EverInsight of this Agreement;

 

(b)            

the gross
negligence or willful misconduct on the part of EverInsight or its
Affiliates or its or their respective officers, directors, agents
or employees in performing its obligations under this Agreement;
or

 

(c)            

the Exploitation by
EverInsight or any of its Affiliates or its or their Sublicensees
or its or their distributors or contractors of the Compound or the
Licensed Product in the Territory;

 

except,
in each case (a), (b) and (c) above, those Claims for which
VistaGen has an obligation to indemnify EverInsight pursuant to
Section 13.1 (Indemnification by VistaGen) hereof or, to the extent
such Claims result from the material breach by VistaGen of any
covenant, representation (other than the representation set forth
in Section 12.3(d), warranty or other agreement made by VistaGen in
this Agreement or the negligence or willful misconduct of any
VistaGen Indemnitee. Notwithstanding the above, EverInsight will
have no obligation to defend or indemnify VistaGen or its
Affiliates for any claim brought by a shareholder or a class of
shareholders of VistaGen or its Affiliates including, but not
limited to, securities fraud claims, shareholder direct claims, and
shareholder derivative claims, except to the extent resulting from
the gross negligence or willful misconduct on the part of
EverInsight or any Affiliate.

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-63-

 

 

13.3            

Indemnification
Procedure.

 

(a)            

Notice of Claim. All indemnification
claims in respect of a Party, its Affiliates or their respective
directors, officers, employees and agents shall be made solely by
such Party to this Agreement (the “Indemnified Party”). The
Indemnified Party shall give the other Party (the
“Indemnifying
Party”) a prompt written notice (an
“Indemnification Claim
Notice”) of any Claims or discovery of fact upon which
such Indemnified Party intends to base a request for
indemnification under this ARTICLE 13 (Indemnification; Liability)
within [*****]
days from written receipt of such Claim or discovery of facts that
that might give rise to such Claim. Each Indemnification Claim
Notice must contain a description of the Claim and the nature and
amount of such Claim (to the extent that the nature and amount of
such Claim is known at such time).

 

(b)            

Control of Defense. The Indemnifying
Party shall have the right to assume the defense of any Claim by
giving written notice to the Indemnified Party within [*****]
days
after the Indemnifying Party’s receipt of an Indemnification
Claim Notice. The assumption of the defense of a Claim by the
Indemnifying Party shall not be construed as an acknowledgment that
the Indemnifying Party is liable to indemnify the Indemnified Party
in respect of the Claim, nor shall it constitute a waiver by the
Indemnifying Party of any defenses it may assert against the
Indemnified Party’s claim for indemnification. Upon assuming
the defense of a Claim, the Indemnifying Party may appoint as lead
counsel in the defense of the Claim any legal counsel selected by
the Indemnifying Party; provided that it obtains the prior written
consent of the Indemnified Party (which consent shall not be
unreasonably withheld, conditioned or delayed). In the event the
Indemnifying Party assumes the defense of a Claim, upon the
Indemnifying Party’s relevant notice the Indemnified Party
shall immediately deliver to the Indemnifying Party all original
notices and documents (including court papers) received by the
Indemnified Party in connection with the Claim. Should the
Indemnifying Party assume the defense of a Claim, except as
provided in Section 13.3(c) (Right to Participate in Defense), the
Indemnifying Party shall not be liable to the Indemnified Party for
any legal expenses subsequently incurred by such Indemnified Party
in connection with the analysis, defense or settlement of the Claim
unless specifically requested and approved in writing by the
Indemnifying Party. In the event that it is ultimately determined
that the Indemnifying Party is not obligated to indemnify, defend
or hold harmless the Indemnified Party from and against the Claim,
the Indemnified Party shall reimburse the Indemnifying Party for
any and all reasonable and verifiable out-of-pocket costs and
expenses (including attorneys’ fees and costs of suit)
incurred by the Indemnifying Party in accordance with this ARTICLE
13 (Indemnification; Liability) in its defense of the
Claim.

 

(c)            

Right to Participate in Defense. Any
Indemnified Party shall be entitled to participate in the defense
of such Claim and to employ counsel of its choice for such purpose;
provided, however, that such employment shall be at the Indemnified
Party’s sole cost and expense unless (i) the employment
thereof has been specifically authorized in writing in advance by
the Indemnifying Party (in which case, the defense shall be
controlled as provided in Section 13.3(b) (Control of Defense),
with such provisions applying mutatis mutandis; (ii) the
Indemnifying Party has failed to assume the defense

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-64-

 

 

and
employ counsel in accordance with Section 13.3(b) (Control of
Defense) (in which case the Indemnified Party shall control the
defense, with the reasonable out-of-pocket expense with respect
thereto borne by the Indemnifying Party); or (iii) the interests of
the indemnitee and the Indemnifying Party with respect to such
Claim are sufficiently adverse to prohibit the representation by
the same counsel of both Parties under Applicable Laws, ethical
rules or equitable principles (in which case, the Indemnified Party
shall control its defense, with the reasonable out-of-pocket
expense with respect thereto borne by the indemnifying
Party).

 

(d)            

Settlement. With respect to any Claims
relating solely to the payment of money damages in connection with
a Claim that shall not result in the applicable indemnitee(s)
becoming subject to injunctive or other relief or otherwise
adversely affect the business or interests of the Indemnified Party
in any manner and as to which the Indemnifying Party shall have
acknowledged in writing the obligation to indemnify the applicable
indemnitee hereunder, the Indemnifying Party shall have the sole
right to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Claim, on such terms as the
Indemnifying Party, in its sole discretion, shall deem appropriate.
With respect to all other Claims in connection with Claims, where
the Indemnifying Party has assumed the defense of the Claim in
accordance with Section 13.3(b) (Control of Defense), the
Indemnifying Party shall have authority to consent to the entry of
any judgment, enter into any settlement or otherwise dispose of
such Claim; provided, it obtains the prior written consent of the
Indemnified Party (which consent shall not be unreasonably
withheld, conditioned or delayed). If the Indemnifying Party does
not assume and conduct the defense of a Claim as provided above,
the Indemnified Party may defend against such Claim; provided, that
the Indemnified Party shall not settle any Claim without the prior
written consent of the Indemnifying Party (which consent shall not
be unreasonably withheld, conditioned or delayed).

 

(e)            

Cooperation. If the Indemnifying Party
chooses to defend or prosecute any Claim, the Indemnified Party
shall and shall cause each indemnitee to, cooperate in the defense
or prosecution thereof and furnish such records, information and
testimony, provide such witnesses and attend such conferences,
discovery proceedings, hearings, trials and appeals as may be
reasonably requested by the indemnifying Party in connection
therewith. Such cooperation shall include access during normal
business hours afforded to the Indemnifying Party to and reasonable
retention by the Indemnified Party of, records and information that
are reasonably relevant to such Claim and making the Indemnified
Party, the indemnitees and other employees and agents available on
a mutually convenient basis to provide additional information and
explanation of any material provided hereunder and the Indemnifying
Party shall reimburse the Indemnified Party for all of its, its
Affiliates’ and its and their sublicensees’ or their
respective directors’, officers’, employees’ and
agents’, as applicable, reasonable and verifiable
out-of-pocket expenses in connection therewith.

 

(f)            

Expenses. Except as provided above, the
costs and expenses, including fees and disbursements of counsel,
incurred by the Indemnified Party and its Affiliates and its and
their sublicensees and their respective directors, officers,
employees and agents, as

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-65-

 

 

applicable, in
connection with any Claim shall be reimbursed on a Calendar Quarter
basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified
Party’s right to indemnification and subject to refund in the
event the Indemnifying Party is ultimately held not to be obligated
to indemnify the Indemnified Party.

 

13.4            

Mitigation of Loss. Each Indemnified
Party will take and will procure that its Affiliates take all such
reasonable steps and actions as are reasonably necessary or as the
Indemnifying Party may reasonably require in order to mitigate any
Claims (or potential losses or damages) under this ARTICLE 13
(Indemnification; Liability). Nothing in this Agreement shall or
shall be deemed to relieve any Party of any common law or other
duty to mitigate any losses incurred by it.

 

13.5            

Special, Indirect and Other Losses.
EXCEPT IN THE EVENT OF A BREACH OF SECTION 2.7 (NON-DIVERSION),
SECTION 2.8 (NON-COMPETE) OR ARTICLE 10 (CONFIDENTIALITY;
PUBLICATION), NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE
OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED
HEREUNDER; provided, however, that this Section 13.5 shall not be
construed to limit either Party’s indemnification obligations
under Section 13.1 (Indemnification by VistaGen) or Section 13.2
(Indemnification by EverInsight), as applicable.

 

13.6            

Insurance. Each Party, at its own
expense, shall maintain product liability and other appropriate
insurance in an amount consistent with sound business practice and
reasonable in light of its obligations under this Agreement during
the Term. Each Party shall provide a certificate of insurance
evidencing such coverage to the other Party upon
request.

 

 

ARTICLE 14 GENERAL PROVISIONS

 

14.1            

Governing Law. This Agreement shall be
governed by and construed in accordance with the law of Hong Kong
without reference to its conflicts of laws principles.

 

14.2            

Assignment.

 

(a)            

Except as expressly
provided hereunder, neither this Agreement nor any rights or
obligations hereunder may be assigned or otherwise transferred by
either Party without the prior written consent of the other Party
(which consent shall not be unreasonably withheld); provided that
either Party may assign or otherwise transfer this Agreement and
its rights and obligations hereunder without the other
Party’s consent: (a) in connection with the transfer or sale
of all or substantially all of the business or assets of such Party
to which this Agreement relates to a Third Party, whether by
merger, consolidation, divesture, restructure, sale of stock, sale
of assets or otherwise; provided that in the event of any such
transaction (whether this Agreement is actually assigned or is
assumed by the acquiring party by operation of law (e.g., in the
context of a reverse triangular merger)),

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-66-

 

 

intellectual
property rights of the acquiring party to such transaction (if
other than one of the Parties to this Agreement) and its Affiliates
existing prior to the transaction shall not be included in the
technology licensed hereunder; or (b) to an Affiliate, provided
that the assigning Party shall remain liable and responsible to the
non-assigning Party hereto for the performance and observance of
all such duties and obligations by such Affiliate; and provided,
further, that in any such case the assigning Party shall provide
written notice to the other Party within five (5) calendar days
after such assignment or transfer. The rights and obligations of
the Parties under this Agreement shall be binding upon and inure to
the benefit of the successors and permitted assigns of the Parties,
and the name of a Party appearing herein will be deemed to include
the name of such Party’s successors and permitted assigns to
the extent necessary to carry out the intent of this section. Any
assignment not in accordance with this Section 14.2 (Assignment)
shall be null and void.

 

(b)            

The rights to
Information, materials and intellectual property, shall, in each of
cases (1) and (2) below, be automatically excluded from the rights
licensed or granted to the other Party under this
Agreement:

 

(1)            

Rights to
Information, materials and intellectual property controlled by a
Third Party permitted assignee of a Party that immediately prior to
such assignment (other than as a result of a license or other grant
of rights, covenant or assignment by such Party or its Affiliates
to, or for the benefit of, such Third Party); or

 

(2)            

Rights to
Information, materials and intellectual property controlled by an
Affiliate of a Party that becomes an Affiliate through any Change
of Control of such Party that was Controlled by such Affiliate (and
not such Party) immediately prior to such Change of Control (other
than as a result of a license or other grant of rights, covenant or
assignment by such Party or its other Affiliates to, or for the
benefit of, such Affiliate).

 

14.3            

Entire Agreement; Modification. This
Agreement is both a final expression of the Parties’
agreement and a complete and exclusive statement with respect to
all of its terms. This Agreement supersedes all prior and
contemporaneous agreements and communications, whether oral,
written or otherwise, concerning any and all matters contained
herein. No amendment, modification, release or discharge shall be
binding on the Parties unless in writing and duly executed by
authorized representatives of each of VistaGen and EverInsight;
provided that, pursuant to the definition of “Licensed
Trademarks” herein, VistaGen may designate in a writing to
EverInsight from time to time such other Trademarks, names and
logos as VistaGen may reasonably determine. In the event of any
inconsistencies between this Agreement and any schedules or other
attachments hereto, the terms of this Agreement shall
control.

 

14.4            

Relationship among the Parties. The
Parties’ relationship with one another, as established by
this Agreement, is solely that of independent contractors. This
Agreement does not create any partnership, joint venture or similar
business relationship between the Parties. Neither Party is a legal
representative of the other Party. Neither Party can assume or
create any obligation, representation, warranty or guarantee,
express or implied, on behalf of the other Party

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-67-

 

 

for any
purpose whatsoever. All persons employed by a Party shall be
employees of such Party and not of the other Party and all costs
and obligations incurred by reason of any such employment shall be
for the account and expense of such first Party.

 

14.5            

Non-Waiver. The failure of a Party to
insist upon strict performance of any provision of this Agreement
or to exercise any right arising out of this Agreement shall
neither impair that provision or right nor constitute a waiver of
that provision or right, in whole or in part, in that instance or
in any other instance. Any waiver by a Party of a particular
provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and
shall be signed by such Party. The rights and remedies provided
herein are cumulative and do not exclude any other right or remedy
provided by Applicable Law or otherwise available except as
expressly set forth herein.

 

14.6            

Force Majeure. Neither Party shall be
held liable or responsible to the other Party or be deemed to have
defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement (other than an
obligation to make payments unless the force majeure event affects
the payment process itself, such as bank closure or government
closure that affects the review and approval of the payment) when
such failure or delay is caused by or results from events beyond
the reasonable control of the non- performing Party, including
fires, floods, earthquakes, hurricanes, embargoes, shortages,
epidemics, quarantines, war, acts of war (whether war be declared
or not), terrorist acts, insurrections, riots, civil commotion,
strikes, lockouts or other labor disturbances (whether involving
the workforce of the non-performing Party or of any other Person),
acts of God or acts, omissions or delays in acting by any
governmental authority (including expropriation, seizure of works,
requisition, nationalization, exercise of march-in rights or
compulsory licensing, except to the extent such delay results from
the breach by the non-performing Party or any of its Affiliates of
any term or condition of this Agreement) and any material change in
the Applicable Laws of a Regulatory Authority that results in a
development, clinical or regulatory delay [*****].
The non-performing Party shall notify the other Party of such force
majeure within thirty (30) days after such occurrence by giving
written notice to the other Party stating the nature of the event,
its anticipated duration and any action being taken to avoid or
minimize its effect. The suspension of performance shall be of no
greater scope and no longer duration than is necessary and the
non-performing Party shall use Commercially Reasonable Efforts to
remedy its inability to perform.

 

14.7            

Export Control. This Agreement is made
subject to any restrictions concerning the export of products or
technical information from the United States or other countries
that may be imposed on the Parties from time to time. Each Party
agrees that it will not export, directly or indirectly, any
technical information acquired from the other Party under this
Agreement or any products using such technical information to a
location or in a manner that at the time of export requires an
export license or other governmental approval, without first
obtaining the written consent to do so from the appropriate agency
or other governmental entity in accordance with Applicable Laws.
VistaGen hereby undertakes to use Commercially Reasonable Efforts
to obtain necessary licenses (if required) for exporting the
Compound, the Licensed Product and the Licensed Technology from the
United States or other countries.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-68-

 

 

14.8            

Severability. If any provision of this
Agreement is held to be illegal, invalid or unenforceable under any
present or future law and if the rights or obligations of either
Party under this Agreement will not be materially and adversely
affected thereby: (a) such provision shall be fully severable; (b)
this Agreement shall be construed and enforced as if such illegal,
invalid or unenforceable provision had never comprised a part
hereof; (c) the remaining provisions of this Agreement shall remain
in full force and effect and shall not be affected by the illegal,
invalid or unenforceable provision or by its severance herefrom;
and (d) in lieu of such illegal, invalid or unenforceable
provision, there shall be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar in
terms to such illegal, invalid or unenforceable provision as may be
possible and reasonably acceptable to the Parties. To the fullest
extent permitted by Applicable Laws, each Party hereby waives any
provision of law that would render any provision hereof illegal,
invalid or unenforceable in any respect.

 

14.9            

Notices. Any notice to be given under
this Agreement must be in writing and delivered either (a) in
person or (b) by overnight courier, to the Party to be notified at
its address(es) given below for convenience, or at any address such
Party may designate by prior written notice to the other. Notice
shall be deemed sufficiently given for all purposes upon the date
of actual receipt.

 

If to
VistaGen:

 

VistaGen
Therapeutics, Inc.

343
Allerton Avenue

South
San Francisco, CA 94080

United
States of America

 

Attention:
CEO

 

with a
mandatory copy (which shall not constitute notice) to:

 

Reid
Adler, J.D.

Capital
Technology Law Group

5335
Wisconsin Ave., N.W., Suite 440

Washington, DC
20015

United
States of America

 

If to
EverInsight:

 

EverInsight
Therapeutics Inc.

Vistra
Corporate Services Centre

Wickhams
Cay II, Road Town

Tortola,
VG1110

British
Virgin Islands

ATTN:
CEO / General Counsel

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-69-

 

 

with a
mandatory copy to (which shall not constitute notice)
to:

 

Cooley
LLP

3175
Hanover Street

Palo
Alto, CA  94304-1130

ATTN: Lila Hope,
Ph.D.

 

14.10                       

Dispute Resolution.

 

(a)            

Except as provided
in Section 3.3(b)(i), (b)(ii), (c) or Excluded Claims as set forth
in subsection 14.10(g) below, if a dispute arises within the JSC
with respect to any decision under the jurisdiction of the JSC that
remains unresolved pursuant to Section 3.3 (JSC Decision-Making) or
otherwise between the Parties in connection with or relating to
this Agreement or any document or instrument delivered in
connection herewith (collectively, a “Dispute”), then either Party shall
have the right to refer such Dispute to the Executive Officers for
attempted resolution by good faith negotiations during a period of
forty-five (45) days. Any final decision mutually agreed to in
writing by the Executive Officers shall be conclusive and binding
on the Parties.

 

(b)            

The Executive
Officers shall negotiate in good faith and use reasonable efforts
to settle any Dispute arising from or related to this Agreement or
the breach thereof within such forty-five (45) day period. Subject
to Section 14.10(h) (Dispute Resolution - subsection (h)), in the
event the Executive Officers cannot fully resolve or settle such
Dispute within such period, and a Party wishes to pursue the matter
further, each such Dispute that is not an Excluded Claim (defined
in Section 14.10(g) (Dispute Resolution - subsection (g)) below)
shall be finally resolved by binding arbitration administered by
the Hong Kong International Arbitration Centre (“HKIAC”) in accordance with its
arbitration rules then in effect.

 

(c)            

The arbitration
shall be conducted by a panel of three (3) neutral arbitrators
experienced in the pharmaceutical business, none of whom shall be a
current or former employee or director, or a current stockholder,
of either Party or any of their respective Affiliates or any
Sublicensee. Within thirty (30) days after initiation of
arbitration, each Party shall select one (1) person to act as
arbitrator and the two (2) Party-selected arbitrators shall select
a third arbitrator within thirty (30) days of their appointment. If
the arbitrators selected by the Parties are unable or fail to agree
upon the third arbitrator, the third arbitrator shall be appointed
by the HKIAC (or its successor entity) in accordance with the
then-current HKIAC arbitration rules, except as modified in this
Agreement. The place of arbitration shall be in Hong Kong, and all
proceedings and communications shall be in English. The procedures
for the taking of evidence shall be governed by the HKIAC. The
decision or award rendered by the arbitrators shall be final,
binding, conclusive and non-appealable, and judgment may be entered
upon it in accordance with Applicable Laws in the Hong Kong or any
other court of competent jurisdiction.

 

(d)            

Either Party may
apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise
resolved. The arbitrators’

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-70-

 

 

authority to award
punitive or any other type of damages not measured by a
Party’s compensatory damages shall be subject to the
limitation set forth in Section 13.5 (Special, Indirect and Other
Losses). Each Party shall bear its own costs and expenses and
attorneys’ fees and an equal share of the arbitrators’
fees and any administrative fees of arbitration.

 

(e)            

Except to the
extent necessary to confirm or enforce an award or as may be
required by law, neither Party nor an arbitrator may disclose the
existence, content, or results of an arbitration without the prior
written consent of the other Party. In no event shall an
arbitration be initiated after the date when commencement of a
legal or equitable proceeding based on the dispute, controversy or
claim would be barred by the applicable Hong Kong statute of
limitations.

 

(f)            

The Parties agree
that, in the event of a dispute over the nature or quality of
performance under this Agreement, neither Party may terminate this
Agreement until final resolution of the dispute through arbitration
or other judicial determination. The Parties further agree that any
payments made pursuant to this Agreement pending resolution of the
dispute shall be refunded if an arbitrator or court determines that
such payments are not due.

 

(g)            

As used in this
Section, the term “Excluded Claim” means a dispute,
controversy or claim that concerns the construction, scope,
validity, enforceability, inventorship or infringement of a patent,
patent application, trademark or copyright.

 

(h)            

Nothing contained
in this Agreement shall deny either Party the right to seek
injunctive or other equitable relief from a court of competent
jurisdiction in the context of a bona fide emergency or prospective
irreparable harm, and such an action may be filed and maintained
notwithstanding any ongoing discussions between the Parties or any
ongoing arbitration proceeding. In addition, either Party may bring
an action in any court of competent jurisdiction to resolve
disputes pertaining to the construction, scope, validity,
enforceability, inventorship or infringement of a patent, patent
application, trademark or copyright, and no such claim shall be
subject to arbitration pursuant to subsections (b) and (c) of this
Section 14.10 (Dispute Resolution). Both Parties agree to waive any
requirement that the other (i) post a bond or other security as a
condition for obtaining any such relief; or (ii) show irreparable
harm, balancing of harms, consideration of the public interest or
inadequacy of monetary damages as a remedy.

 

14.11                       

Performance by Affiliates. Each Party
may discharge any obligations and exercise any rights hereunder
through any of its Affiliates. Each Party hereby guarantees the
performance by its Affiliates of such Party’s obligations
under this Agreement and shall cause its Affiliates to comply with
the provisions of this Agreement in connection with such
performance. Any breach by a Party’s Affiliate of any of such
Party’s obligations under this Agreement shall be deemed a
breach by such Party, and the other Party may proceed directly
against such Party without any obligation to first proceed against
such Party’s Affiliate.

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-71-

 

 

14.12                       

Headings. The captions to the several
Articles, Sections and subsections hereof are not a part of this
Agreement but are merely for convenience to assist in locating and
reading the several Articles and Sections hereof.

 

14.13                       

Waiver of Rule of Construction. Each
Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement.
Accordingly, the rule of construction that any ambiguity in this
Agreement shall be construed against the drafting Party shall not
apply.

 

14.14                       

Business Day Requirements. In the event
that any notice or other action or omission is required to be taken
by a Party under this Agreement on a day that is not a Business Day
then such notice or other action or omission shall be deemed to
require to be taken on the next occurring Business
Day.

 

14.15                       

English Language. This Agreement has
been prepared in the English language, and the English language
shall control its interpretation. In addition, all notices required
or permitted to be given hereunder, and all written, electronic,
oral or other communications between the Parties regarding this
Agreement shall be in the English language

 

14.16                       

No Benefit to Third Parties. Except as
provided in ARTICLE 13 (Indemnification; Liability), the covenants
and agreements set forth in this Agreement are for the sole benefit
of the Parties hereto and their successors and permitted assigns
and they shall not be construed as conferring any rights on any
other Persons.

 

14.17                       

Further Assurances. Each Party shall
duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done
such further acts and things, including the filing of such
assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the
provisions and purposes hereof or to better assure and confirm unto
such other Party its rights and remedies under this
Agreement.

 

14.18                       

Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the
same instrument.

 

IN WITNESS WHEREOF, the Parties intending to be bound have
caused this License Agreement to be executed by their duly
authorized representatives.

 

	
EverInsight
Therapeutics Inc.   

	
VistaGen
Therapeutics, Inc.

	
 

	
 

	
 By: /s/ Wei
Fu 

	
By: /s/ Shawn K. Singh

	
 Name: Wei
Fu 

	Name: Shawn K.
Singh, J.D.
	
 Title: Director of
EverInsight Therapeutics Inc.  

	Title: Chief Executive
Officer 
	
 

	

 

 

 

                                                                                    

 

                                                                          

                                                                                                                                

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-72-

 

 

 

 LIST
OF EXHIBITS

 

Exhibit
A:

Licensed Patents
Existing as of the Effective Date

 

Exhibit
B:

Licensed
Trademarks

 

Exhibit
C:

PH94B Chemical
Structure

 

Exhibit
D:

Initial Development
Plan

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-73-

 

 

 

Exhibit
A: Licensed Patents in the
Territory as of the Effective Date

 

 

[*****]

 

 

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-74-

 

 

 

Exhibit
B: Licensed Trademarks as
of the Effective Date

 

 

VISTAGEN®,
United States Registration # 2787886 and international counterparts
in the Territory to be obtained in due course

 

 

 

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-75-

 

 

 

Exhibit
C: PH94B Chemical
Structure

 

 

 

(3b)-androsta-4,16-dien-3-ol

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-76-

 

 

Exhibit
D

Initial
Development Plan for Acute Treatment of SAD in the
Territory

 

[*****]

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [*****], HAS BEEN OMITTED BECAUSE VISTAGEN THERAPEUTICS, INC.
HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM TO SUPER LEAGUE GAMING,
INC. IF PUBLICLY DISCLOSED.

 

 

-77-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]